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CHAPTER I 
INTRODUCTION AND BACKGROUND 
Scope of Thesis Study 
Numerous structure-activity relationships (SAR's) for 1,4-dihydropyridine 
(DHP) derivatives are available in the literature. However, the influence of the 
alkoxy groups at the C3 and C5 ester positions on the conformation of the rest of 
the molecule and, thus, on the activity is still somewhat unclear. A further 
understanding of 1) the effect of increasing the length and bulk of the ester alkyl 
groups on the . overall conformation of 1,4-DHP compounds and 2) the 
conformational changes associated with DHP decomposition to the nitro-pyridine 
form and the potential effects on the calcium antagonistic activity of these 
changes was the focus of this study. The nine new compounds prepared and the 
four prepared using literature preparations have C3 and C5 ester alkyl groups 
that range from a two carbon to an eight carbon chain (compounds V, VII, VIV, 
XIII, XVII, XVIV, and XX). In order to observe the conformational dependence 
upon increased bulk of these side chains; isopropyl, isobutyl; tertiary butyl, 
isopentyl, and benzyl groups were also included (compounds VIII, X, XII, XIV, 
and XXII). The decomposition products studied were those of nifedipine (I and 
II), dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
(IV), 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (Ill), 
diethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (VI), 
di-isobutyl 2,6-dimethyl-4-(3-nitrophenyl}-1,4-dihydropyridine-3,5-dicarboxylate 
(XI}, di-isopentyl 2,6-dimethyl-4-(3-nitrophenyl}-1,4-dihydropyridine-3,5-




dropyridine-3,5-dicarboxylate (XVIII), and nitrendipine(XXIII). To investigate the 
effect of inserting an oxygen in the side chain di-2-methoxyethyl 2,6-dimethyl-4-
(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (XXI) was synthesized. 
These compounds are tabulated in TABLE 4. Compounds V, VII, VIII, and XXI, 
which had been prepared previously, but had not been examined by single 
crystal studies. 
Calcium in biological processes . 
Calcium is the most abundant metal ion in the body. Over 90% is in the 
form of hydroxyapatite, which occurs in the bones and teeth. The rest is in the 
form of the soluble calcium ion, Ca2+ 1• This ion is involved in numerous func-
tions in the cell acting as a intercellular messenger and also as a trigger for cell 
death. 
Cells normally maintain a very low concentration of Ca2+ (- 1 o-a M), but 
this value can rise transiently during cell excitation. Calcium is involved in the 
regulation of excitation-contraction and stimulus-secretion coupling. The cellular 
mechanism that links surface membrane excitation with an increase in 
intracellular calcium, and thus with the initiation of contraction, is termed 
excitation-contraction coupling. In smooth, cardiac, and skeletal muscle 
cytoplasmic calcium ions regulate contractile protein activation and the 
generation of tension of the ce111. The sarcoplasmic reticulum (S. R.) is an 
intracellular organelle that acts as a reservoir for calcium ions within muscle cells. 
Following membrane excitation, calcium is released from the S.R. which 
activates the contractile proteins2• Ca2+ can thus be regarded as a cellular 
trigger which interacts with calcium-binding proteins such as troponin C and 
calmodulin2. This interaction, in turn, initiates the stimulus-response coupling of 
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the cell. A constant elevation of the calcium ion concentration within the cell may 
also serve as a lethal cell signal, the rise being caused by excessive cell 
stimulation, cell damage, or disease3• 
Events mediated by Ca2+ actions at extracellular sites, including blood 
clotting, cell adhesion, and membrane stabilization, are low affinity processes 
operating at the millimolar concentrations of Ca2+ found in the serum3. The 
intracellular Ca2+ mediated processes, such as the major categories of 
excitation-contraction and stimulus-secretion coupling, are high affinity processes 
occurring at the micromolar concentrations of ionized Ca2+ achieved in excitable 
cells3. 
Ion Channels 
Cells normally maintain an asymmetric distribution of ions across the cell 
membrane, maintained by the selective permeability of the cell membrane itself 
and by the operation of metabolically driven pumps. Since the cell membrane is 
made up of a lipid bilayer, impermeable to ions, ion channels are used to 
transport ions from the intracellular space to the extracellular space (Figure 1 }. 
These channels are proteins that span the membrane and form aqueous pores 
through which ions can travel4• The movement of ions, subsequent to cell 
stimulation, serves to carry current and allows certain ions to act as cellular 
messengers3. The possible functions of a channel may be defined by the 
location on the cell, the voltage range over which a given type of channel opens, 
and the duration of that opening. 
Ion channels are a regulated species and can be considered as allosteric 
enzymes. As part of the membrane, ion channels respond to chemical and 
electrical signals (hence regulation} and allow ion flow and membrane potential 
change. Ion channels are regulated by a variety of receptor initiated stimuli and 
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by various organic and inorganic ligands. They possess specific drug binding 
sites and are regulated by various drugs. They may also possess a multitude of 
ligand binding sites, for example, the voltage-gated Na+ channel possesses at 
least five5• 
Figure 1 : A generic ion channel, shown as a protein molecule that spans the 
lipid bilayer (m). (A) Selectivity filter determining which ions may 
pass; (B) Channel gate(s); (C) Sensor that determines the position 
of the gate.4 
Ion channels can be classified according to many different criteria, such as 
ion selectivity, voltage sensitivity, and pharmacological sensitivities3,5. There are 
two basic classes of ion channels that are involved in the generation of electrical 
signals: ligand gated and voltage sensitive. Voltage sensitive channels mediate 
rapid, voltage-gated changes in membrane ion permeability during action 
potentials (the change of electrical conductance of the cell) in excitable cells and 
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also modulate membrane potential6. Ligand gated channels play a role more akin 
to a receptor. These ligand gated ion channels include the nicotinic acetylcholine 
receptor, y-aminobutyric acid (GABA) receptor, and the glycine receptor. These 
channels also mediate local increases in ion conductance at chemical synapses6. 
Ion channels exist in different states of activation, which may alter their 
affinity for various ligands. Therefore, different points of view must be considered 
in the analysis of these channels as sites for drug regulation. For example, 
different states may have different affinities for certain drug molecules, certain 
ligands may stabilize different channel states, and the structure-activity 
relationships of a class of compounds may change depending upon which state 
of the channel with which they are interacting. 
Ion channels also have certain gating characteristics. Normally there are 
three gating processes, a) activation, b) deactivation, and c) inactivation4. These 
gating characteristics dictate the availability of an ion channel to regulation by the 
binding of ligands. 
Calcium Channels 
The type, location, density and function of calcium channels varies with 
different kinds of cells7. The calcium channel is highly selective for calcium, as 
opposed to Na+ or Mg2+, which may arise from high affinity Ca2+ binding sites in 
the ion conducting pore7. 
The physiology of these channels include a wide variety of functions such 
as excitation-contraction coupling, control of secretion, excitability, conduction 
and pacemaker activity8• It has also been shown that three different modes of 
channel gating exist for the calcium channel9. 
Voltage-sensitive Ca2+ channels play many essential roles in the cell. 
They are an important part of all excitable cells in that they convert electrical 
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signals into biochemical events10• They constitute the link between transient 
changes in membrane potential and are involved in a variety of cellular 
responses such as secretion of neurotransmitters and hormones, initiation of 
contraction in cardiac and smooth muscle, and activation of second messenger 
responses in many types of cells 11 • In cardiac and smooth muscle, voltage-
dependent calcium channels are important in controlling the supply of calcium 
that is directly or indirectly used in the contractile process2,12. 
Calcium channels are usually classified as receptor operated (ROC) or 
potential dependent channels (PDC). Receptor operated channels are far less 
well characterized than the potential dependent channels, and less is known 
about their function. 
The potential dependent channels have been much more susceptible to 
pharmacologic and electrophysiological definition, thus, a variety of subclasses 
have emerged. At least 3 classes of voltage sensitive calcium channels that 
require a large amount of depolarization before they are activated (high-
threshold), have been observed, and one class of the low-threshold type3,8,13• 
1) L channels ---- This type plays a key role in excitation-contraction 
coupling in smooth and cardiac muscle. They may also be involved in 
modulating membrane excitability and the release of some hormones and 
neurotransmitters. They are sensitive to the class of compounds known 
as the 1,4-dihydropyridines (DHP). The highest conc.entration of DHP 
sensitive L channels is in skeletal muscle, where they mediate slowly 
activated, long lasting Ca2+ currents. The evidence of the essential role of 
these channels in the heart is the observation that channel blockade with 
DHP's or phenylalkylamines results in decreased force of cardiac 
contraction and can result in total suppression of cardiac activity2. 
2) N channels --- These are found mainly in neuronal cells and play a 
major role in neurotransmitter release2. They are DHP insensitive. 
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3) P channels -- These are insensitive to DHP's, but sensitive to certain 
spider toxins2. 
4) T channels (transient) -- These are low threshold, that is they are 
activated with small amounts of depolarization and inactivate rapidly2. 
They are most abundant in sinoatrial and purkinje cells, the pacemaker 
cells of the atria and ventricles, respectively, and are insensitive to DH P's. 
Subtypes of the above channels also exist in different cell and tissue types. 
The greatest advances in elucidation of the structure and composition of a 
calcium channel has been made for the L-type calcium channel of skeletal 
musc1e2. This is a result of the abundance in skeletal muscle t-tubules of L-type 
calcium channels with high-affinity binding sites for the dihydropyridine class of 
compounds and of the availability of a variety of DHP ligands to which these 
channels are sensitive. 
The primary amino acid (AA) sequence for the DHP receptor from rabbit 
skeletal and cardiac muscle has been deduced7•14• There is a 66% degree of AA 
sequence homology between the cardiac and the skeletal muscle DHP receptor 
(calcium channel). The skeletal muscle DHP receptor AA sequence is 
homologous to that of the sodium channel. The general similarity in biochemical 
properties of Na+ channel subunits and Ca2+ channel subunits has its basis in 
this substantial similarity of AA sequence. 
Sodium and calcium channels consist of a principal transmembrane 
subunit, which forms the ion-conducting pore (Figure 1)15• The subunits of K+, 
Ca2+, and Na+ channels are members of an homologous gene family, therefore 
they are all formed from a similar encoded gene and hence show similar 
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structure. It is now generally believed that the Ca2+ channel of skeletal muscle is 
composed of several subunits, termed a1, a2, p, 'Y and 66. The overall structure 
of Ca2+ channels consists of a single principal subunit expressed in association 
with a variable number of other polypeptides. Only the a1-subunit, which is the 
central component of the protein complex, binds calcium channel antagonist 
compounds (DHP's)16. Hofmann et al illustrated this by radiolabeling a DHP 
molecule, letting it bind to its receptor in the channel, and then isolating the 
portion that was labeled (Figure 2)10 . 
... . 
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Figure 2: The Subunit Organization of the Calcium Channel.15 
Since the a 1-subunit is the observed receptor in these channels, its 
membrane organization is important. Different models have been proposed for 
the transmembrane organization of the a1-suhunit7,14,15. Given the homology 
between the Na and Ca channels, there will obviously be a similarity in 
secondary structure. 
The sodium channel consists of four homologous domains14. It has been 
proposed that each of these domains contains six regions of probable a-helical 
structure long enough to span the membrane, which are designated S1-S6. It 
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was suggested that S1 and S2, which are hydrophobic with occasional 
hydrophilic residues, and the S5 and S6 segments, which are uniformly 
hydrophobic, formed the transmembrane structure of the protein, whereas 
segments S3 which has more numerous charged residues, and S4, which are 
both hydrophobic and positively charged, project from the cytoplasmic surface of 
the protein 15,17(Figure 3). This initial description of the S4 segments as probable 
a-helices with both hydrophobic and positively charged characteristics led to 
specific models of the voltage dependent gating in which these segments had a 
transmembrane organization. 
The substantial AA sequence similarity of the calcium channel to the 
sodium channel led to a proposal of an analogous transmembrane structure. 
The proposed model by Tanabe et al indicates the presence of four internal 
repeats that exhibit sequence homology as stated above7 . Each of the four 
repeats consists of six membrane spanning a-helical sequences. The S4 regions 
of each repeat, which consists of alternating charged and uncharged residues, 
likely characterizes the voltage sensor region of the channel (Figure 3). 
I II w 1V 
Figure 3: Schematic representation of the predicted structural organization 
of the voltage-dependent calcium channel a1-subunit.18 
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The pharmacology of calcium channels differs depending on where the 
channel is located and its function. The major ligand classes active in the L-type 
voltage-dependent Ca2+ channel, which has been the best characterized, are the 
phenylalkylamines (Verapamil), 1,4-Dihydropyridine's (Nifedipine), and the 
benzothiazepines (Diltiazem) (Figure 4). There is substantial evidence that these 
three classes define three allosterically linked sites on a component of the protein 












Figure 4: General structure of the DHPs, Phenylalkylamines and 
Benzothiazepines. 
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Calcium Antagonists - The 1,4-Dihydropyridlnes 
A wide variety of chemical compounds exhibit calcium antagonistic 
properties. These range from simple metal ions to highly complex organic 
molecules8•19• 
Calcium channel antagonists inhibit the flow of calcium into the cell by 
blockage of certain membrane channels. Therefore, they mimic the effect of 
Ca2+ withdrawal on the heart and hence block contraction. These compounds 
produce a negative inotropic effect in heart muscle, a marked relaxation of 
smooth muscle, decreased vasocohstriction, and a decrease in cardiac 
arrhythmias. Calcium antagonists reduce the flow of calcium across the 
sarcolemma during the twitch of the heart muscle. Evidence implies that they do 
this by blocking calcium flow through slow calcium channels or by affecting the 
kinetics of the gating process20. These agents are clinically used for the 
treatment of angina, hypertension, peripheral vascular disorders, and some types 
of cardiac arrhythmias8•21 • Calcium activators, or agonists, display the opposite 
effect. They promote the transport of Ca2+ through the calcium channels. 
The 1,4-dihydropyridine (DHP) class of calcium antagonists has been very 
useful therapeutically, and also as a biochemical tool with which to analyze and 
probe the structure and function of the DHP sensitive type L calcium channel 
(Figure 5). This has been facilitated by the availability of large numbers of DHP 
derivatives (TABLE 1) and the existence of DHP compounds of similar structure 
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2-F, 6-CI ~CH3 CQ:!CH3 CH3 CH3 H 29,38 
2-Cl,3-CF3 ~CH3 C~H2CH3 CH3 NH2 H 39 
2-CI, 5-NQ:! ~CH3 ~CH3 CH3 CH3 H 29 
2-CF3 CQ:!CH3 CQ:!CH3 CH3 CH3 H 22,29,42,43, 79,8 
0 
2-CF3 CQ:!CH~H3 ~H2CH3 CH3 CH3 H 22 
2-CF3 C02C(CH3)3 ~(CH3)3 CH3 CH3 H 22 
3-CF3 ~CH~H3 ~H2CH3 CH3 CH3 H 22 
4-CF3 ~CH~H3 C~H2CH3 CH3 CH3 H 22 -0\ 
2-CF3 C<>2CH~H3 C<>2CH2CH3 CH3 CH3 CH3 22 
2-CF3 C<>2CH~H3 C<>2CH2CH3 CH3 CH3 C<>2CH2CH3 22 
2-CF3 C<>2CH~H3 C<>2CH2CH3 CH3 CH3 C5H5 22 
2-CF3 C<>2CH~H3 ~CH2CH3 H H H 22 
2-CF3 C<>2CH~H3 C<>2CH2CH3 CH2CH3 CH2CH3 H 22 
2-CF3 C(O)CH3 C(O)CH3 CH3 CH3 H 22 
2-CF3 C<>2CH~H3 C<>2CH2CH3 CH3 CH3 Aromatic 22 
2-CF3 C~CH3 C<>2CH3 CH3 CH3 H 23 
3-CF3 C<>2CH3 C~CH3 CH3 CH3 H 23,29 
2-CF3 N~ C~CH3 CH3 CH3 H .· 43,80,81 
2-CF3 C~CH3 CO~H~H(CH3)2 CH3 CH3 H 27 
3-CF3 C~CH3 CO~H~H(CH3)2 CH3 CH3 H 27 
2-CN C~CH3 C<>2CH3 CH3 CH3 H 23,29,38 
3-CN C<>2CH3 C<>2CH3 CH3 CH3 H 25,29,38 
4-CN C<>2CH3 ~CH3 CH3 CH3 H 29 
3-CN C~CH3 C<>2CH~H(CH3)2 CH3 CH3 H 27 
2-C<>2CH3 C<>2CH~H3 C<>2CH2CH3 CH3 CH3 H 22 
4-C~H C<>2CH~H3 C<>2CH2CH3 CH3 CH3 H 22 
2-CH..CH2 C<>2CH3 C<>2CH3 CH3 CH3 H 29,79 
2-CH..CHC<>2- C<>2CH~H3 C~H2CH3 CH3 CH3 H 82 
C(CH3)3 
2-CH2CH3 C<>2CH3 ~CH3 CH3 CH3 H 29 
2-F ~CH3 ~CH3 CH3 CH3 H 29,37,38 
.... ..., 
2-F ~CH3 C~H2CH3 CH3 CH2<)(CH2)2N3 H 39 
2-F ~CH3 C~H2CH3 CH3 CH2<)(CH2)2NH2 H 39 
2,3,4,5,6-F5 ~CH3 C~CH3 CH3 CH3 H 25,29,38,43,79 
3-F C02CH3 C~CH3 CH3 CH3 H 29,38 
4-F C02CH3 C~CH3 CH3 CH3 H 29,38 
4-F C02CH3 CO~H2CH(CH3)2 CH3 CH3 H 27 
H ~CH3 ~H2CH3 CH3 CH~(CH2)2NH2 H 39 
H <Xl2CH3 C~H2CH3 CH3 CH2<)(CH2)2N3 H 39 
H ~CH3 ~CH~H(CH3)2 CH3 CH3 H 29 
H C02CH2CH3 C~H2CH3 CH3 CH3 H 22,58 
H C02C(CH3)3 C~C(CH3)3 CH3 CH3 H 22 
H ~CH~H3 C~H2CH3 CH3 CH3 CH3 22 
H C~CH~H3 C~H2CH3 CH3 CH3 CO~H2CH3 22 
H ~CH2CH3 ~H2CH3 CH3 CH3 CsHs 22 
H C02CH2CH3 C~H2CH3 H H H 22 
H C02CH~H3 ~CH2CH3 C02CH2CH3 CO~H2CH3 H 22 
H CN CN CH3 CH3 H 22 
H C(O)CH3 C(O)CH3 CH3 CH3 H 22 
H C(O)NHPh C(O)NHPh CH3 CH3 H 22 
H ~CH~H3 C~H2CH3 CH3 CH3 Aromatic 22 
H ~CH3 ~CH3 CH3 CH3 H 21,23,29,38 
2-1 ~CH3 ~CH3 CH3 CH3 H 29,37 
..... 
00 
3-1 C<>2CH3 C<>2CH3 CH3 CH3 H 29 
4-1 C<>2CH3 C<>2CH3 CH3 CH3 H 29 
2-CH3 C<>2CH~H3 C<>2CH2CH3 CH3 CH3 H 22 
2-CH3 C<>2CH3 C<>2CH3 CH3 CH3 H 23,29 
2-CH3 C<>2CH3 C<>2CH2CH3 CH3 CH~CH2)2NHCH3 H 39 
2.~CH3)2 C<>2CH3 C02CH3 CH3 CH3 H 29 
2,4, 6-(CH3)3 C<>2CH~H3 C02CH2CH3 CH3 CH3 H 22 
3-CH3 C<>2CH3 C<>2CH3. CH3 CH3 H 21 
3-CH3 C02CH3 C02CH3 CH3 CH3 H 29,38 
4-CH3 C~CH3 C~CH3 CH3 CH3 H 23,38 
4-CH3 C<>2CH3 C<>2CH3 CH3 CH3 H 21,29 
2-N<>2 C<>2CH3 C<>2CH3 CH3 CH3 H 22-24,83 
2-N02 C02C"3 C<>2CH3 CH3 CH3 H 24,25,38,43,83 
Nifedipine 
2-N02 C02CH2CH3 C~CH2CH3 CH3 CH3 H 24 
2-N<>2 0<>2CH(CH3)2 C<>2CH(CH3)2 CH3 CH3 H 24 
2-N~ C02C(CH3)3 C02C(CH3)3 CH3 CH3 H 24 
2-N02 C<>2CH~H~H3 C02CH2CH:PCH3 CH3 CH3 H 24 
2-N<>2 C<>2(CH2):!-0CH2CH3 C<>2(CH2):!-0CH~H3 CH3 CH3 H 24 
2-N02 CH2CH~H CH2CH~H CH3 CH3 H 24 
2-N<>2 CH2CH=CH2 CH~H=CH2 CH3 CH3 H 24 
2-N~ CH2CH CH CH2CH CH CH3 CH3 H 24 
2-N~. 4-0CH3 C<>2CH3 C<>2CH3 CH3 CH3 H 24 -'° 
2-N~. 4-0CH3 C02CH~H3 CO~H2CH3 CH3 CH3 H 24 
2-N~, 5-0CH3 C02CH2CH3 C~CH2CH3 CH3 CH3 H 24 
2-N02, 5-0H C02CH2CH3 C02CH2CH3 CH3 CH3 H 24 
2,4-(N02)2 C02CH3 C~CH3 CH3 CH3 H 21 
2-N02 C02CH3 C02CH2CH(CH3)2 CH3 CH3 H Nisoldipine 27,38 
2-N02 ~CH3 C02CH2-2-Furyl CH3 CH3 H Fumidipine 84 
3-N02 ~CH2)2 C~CH3 
N(CH3)CH2C5H5 
CH3 CH3 H Nicardipine 35 
3-N~ ~CH3 C~CH3 CH3 CH3 H 21,23,24,38,83 
3-N02 C02CH2CH2')CH2CH2CH3 C02(CH2)20 (CH2)2CH3 CH3 CH3 H Niludipine 23,24,26 
3-N02 ~CH2CH3 C02CH(CH3)2 CH3 CH3 H 23 
3-N02 C02CH3 C~CH2CH3 CH3 CH3 H Nitrendipine 23,26,38,43,80 
3-N~ C~CH(CH3)2 C~CH2CH2')CH3 CH3 CH3 H Nimodipine 23,26,38,44 
3-N02 C02CH2CH3 C02CH2CH3 CH3 CH3 H 24,26 
3-N~ C~H(CH3)2 C02CH(CH3)2 CH3 CH3 H 24,26 
3-N02 C~CH~H2')CH3 CO~H2CH~H3 CH3 CH3 H 24,26 
3-N~ C~(CH2)2')CH2CH3 C02(CH2)20CH2CH3 CH3 CH3 H 24,26 
3-N02 CH2-2-Pryidiyl CH2-2-Pryidiyl CH3 CH3 H 24 
3-N02 CH2-2-Pryidiyl CH2-2-Pryidiyl CH3 CH3 H 24 
3-N~ CH2CH=CH2 CH~H=CH2 CH3 CH3 H 24,26 
3-N~. 4'-0CH3 C~CH3 C~CH3 CH3 CH3 H 24 
3-N~. 4-N(CH3)2 ~CH3 C~CH3 CH3 CH3 H 24 
3-N~. 6-SCH3 ~CH3 C~CH3 CH3 CH3 H 24 
N 
0 
3-N~,4-0H C02CH2CH3 C~CH2CH3 CH3 CH3 H 24 
3-N~. 6-SOaH C~CH2CH3 C~CH2CH3 CH3 CH3 H 24 
3-N~. 4-N(CH3)2 C02CH2CH2')CH3 C02CH2CH~H3 CH3 CH3 H 24 
3-N02 C02C(CH3)3 C02CH3 CH3 CH3 H 83 
3-N02 C~C(CH3)3 C~CH3 CH3 CH3 H 83 
3-N02 C~C(CH3)3 C~CH3 CH3 CH3 H 83 
3-N02 C02C(CH3)3 C~H2CH3 CH3 CH3 H 83 
3-N02 C~C(CH3)3 C~CH2CH3 CH3 CH3 H 83 
3-N02 C02C(CH3)3 C~CH2CH3 CH3 CH3 H 83 
3-N02 C02CH3 C02CH(CH3)2 CH3 CH3 H 26,38,51 
3-N02 C~CH3 ~CH2CH3 CH3 CH2-0-(CH2)2-NCH3 H 39 
3-N02 C~CH3 ~CH2CH(CH3)2 CH3 CH3 H 27 
3-N02 C~CH2CH~CH3 C~CH2CH~N~ CH3 CH3 H 47,56 
3-N02 C02CH3 C02CH2CH~N~ CH3 CH3 H 56,85 
3-N02 C02CH3 C02CH2CH2Br CH3 CH3 H 56 
3-N~ C02CH3 C02CH2CH2NHCH3 CH3 CH3 H 67 
3-N~ ~CH3 C~H2CH2N(Bz)CH3 CH3 CH3 Aromalic 67 
3-N~ C~H2CH2CH3 C~CH2CH2CH3 CH3 CH3 H 26 
3-N02 C02CH2CH3 C02CH2CH~H3 CH3 CH3 H 26 
3-N~ ~CH~H(CH3)2 ~CH~H(CH3)2 CH3 CH3 H 26 
3-N~ ~CH3 C02CH2CH(CH3)2 CH3 CH3 H 26 
3-N~ C02CH2CH3 C02CH2CH=CH2 CH3 CH3 H 26 
N ..... 
3-N~ C02<}H2C(CH3)3 C02CH2C(CH3)3 CH3 CH3 H 41 
3-N~ C~(CH2)2')CH2CH3 C02<}H2CH3 CH3 CH3 H 26 
4-N~ C~CH3 ~CH3 CH3 CH3 H 23,38 
4-N~ C02CH3 C02CH3 CH3 CH3 H 24 
4-N02 C02CH2CH3 C02CH2CH3 CH3 CH3 H 24 
4-N02 C02<}H(CH3)2 .. C~CH(CH3)2 CH3 CH3 H 24 
4-~ C~C(CH3)3 C02<}(CH3)3 CH3 CH3 H 24 
4-N02 C~CH2)30CH3 C02(CH2)30CH3 CH3 CH3 H 24 
4-N02 C02(CH2)30H C~(CH2)30H CH3 CH3 H 24 
4-N~ C02(CH2)2CH=CH2 C02(CH2)2<}H:1CH2 CH3 CH3 H 24 
4-N02 ~CH3 C~CH3 CH3 CH3 H 21,29 
2-0H,5-N~ C02CH3 ~CH3 CH3 CH3 H 29 
4-N(CH3)2 C02CH2CH3 C02CH2CH3 CH3 CH3 H 22 
3-N3 ~CH3 C02CH3 CH3 CH3 H 23,38 
3-N(CH3)3+ C~CH3 C02CH3 CH3 CH3 H 29,38 
2-NH2 C~CH3 C02CH2CH3 CH3 CH3 H 49 
3-N(CH3)2 C~CH3 C~CH3 CH3 CH3 H 29 
3-NH2 C02CH3 C~CH3 CH3 CH3 H 29 
4-N(CH3)2 C~CH3 C02CH3 CH3 CH3 H 29 
3-N3 C~CH3 ~CH3 CH3 CH3 H 29 
3-NH2 C02CH3 C02(CH2)2N(Bz)CH3 CH3 CH3 H 67 
3-NH2 ~CH3 C02(CH2)2NHCH3 CH3 CH3 H 67 
~ 
3-NH2 <Xl2CH3 C02(CH2)2NHCH3 
2-0CH3 <Xl2CH2CH3 C0:!CH2CH3 
4-0H ~CH2CH3 CO:!CH2CH3 
2-0CH3 CO:!CH3 C02CH3 
3-0CH3 <Xl2CH3 CO:!CH3 
4-0CH3 CO:!CH3 C02CH3 
2-0CH3 <Xl2CH3 C02CH2CH3 
2-0CH2CH3 <Xl2CH3 C02CH3 
3-0H C0:!CH3 C02CH3 
2,4,5-(0CH3)3 ~CH3 .co2cH3 
3-0CH3 CO:!CH3 CO:!CH2CH(CH3)2 
2-SCH3 C0:!CH3 . C02CH3 
CH3 CH3 Aromatic 
CH3 CH3 H 
CH3 CH3 H 
CH3 CH3 H 
CH3 CH3 H 
CH3 CH3 H 
CH3 CH2'>(CH2)2NHCH3 H 
CH3 CH3 H 
CH3 CH3 H 
CH3 CH3 H 
CH3 CH3 H 
















The structure activity relationships (SAR's) of the 1,4-DHP's have been the 
most studied, because of the ease of synthesis of this class of compounds and 
also because of the therapeutic interest in sin,ilar chemical structure with both 
antagonist and activator properties. Numerous structure-activity studies are 
available for the DHP antagonists, but few SAR studies have been performed on 
the DHP activators21 •36• Calcium antagonistic activity of the 1,4-dihydropyridine 
family is influenced by a number of factors. The active conformation of these 
compounds normally includes the presence of the 1,4-dihydropyridine moiety with 
the DHP ring in a flattened boat configuration and the 4-phenyl substituent in a 
pseudoaxial conformation. Early SAR studies revealed some basic structural 
requirements for activity22 • The activity of these compounds is defined as the 
compounds ability to block calcium entry into the cell. 
i) Antagonist activity increases according to the C4 substituent on the 
DHP ring in the order: H < CH3 < cycloalkyl < heterocyclic < phenyl and 
substituted phenyl. 
ii) The position of the substituent on the 4-phenyl ring has an effect. 
Activity increases as the substituent is moved from para << meta < ortho. 
The presence of an electron withdrawing group in the ortho position is 
optimum. 
iii) The DHP ring is essential, oxidation to pyridine greatly diminishes 
activity. 
iv) The presence of an N1 hydrogen atom is essential, alkyl substitution 
at this position decreases activity. 
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v) Ester groups at C3 and CS of the DHP ring are optimum, replacement 
by other electron withdrawing groups such as CN and C(=O)CH3 reduces 
activity. 
These original structural parameters have been largely confirmed in a 
variety of SAR studies using in vitro methods8. Subsequent SAR studies, 
summarized below, have led to further conclusions concerning the structural 
requirements of this class of compounds. 
As stated previously, variation of the phenyl substituent led to the 
conclusion that ortho substituted derivatives are most active, meta being less 
active, and para being very inactive. The activity appears to be generally 
independent of the electronegativity of the phenyl substituent since those with 
electron withdrawing groups and electron-donating groups possess activity22. It 
has also been observed that the ortho N02 group present in the parent 
compound nifedipine is not essential and that an ortho CF3 group is more 
effective23. 
The size of the phenyl substituent appears to have an influence21 •23• In a 
series of halogen substituted ortho--phenyl derivatives, as the size of the halogen 
increased, activity also increased37. 
Analysis of a series of nisoldipine derivatives (Figure 5) led to the 
conclusion that the effects of the ester groups and the phenyl ring substituent are 
expressed independently27. Therefore, in all SAR studies performed, the rank 
order of activity for the phenyl ring substituents always is the same, o > m >> p, 
despite the changes in the ester R group 1• 
Variation of the C3 and CS ester substituents has led to conflicting 
evidence. In an early investigation, it was concluded that an increase in the bulk 
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of the ester side chain led to an increase in activity22,38. However, in a series of 
meta-nitro phenyl derivatives, activity appeared to decrease with an increase in 
the bulk of the ester side chains23,35. To complicate things further, another 
investigation reported that for ortho substituted phenyl derivatives, activity 
decreased as ester bulk increased; for meta-phenyl derivatives, activity increased 
as bulk increased; and for para-phenyl derivatives, activity was always observed 
to be low24• 
In all the above mentioned derivatives, the C3 and C5 ester groups were 
the same, therefore, they were symmetrical. However, when the ester groups 
are different from each other, the C4 carbon becomes chiral. It has been shown 
that unsymmetrically substituted derivatives tend to show higher activity26 and 
stereoselectivity, one enantiomer being much more potent than the other2S,39,40. 
Also, it appears that unsymmetrical derivatives tend to exhibit higher activity 
overall28. 
Although the C3, C5 ester substituents and the phenyl ring substitution 
have been frequently studied with respect to structure-activity relationships, the 
effects of the 2, 6 substitution pattern have not been ignored1• An amino 
substituent has been substituted in the 2-position26 leading to maintenance of 
antihypertensive activity. Furthermore, it was shown that 2-dialkylamino-3,4-
DHP's (hydrogens at C3 and C4 instead of N1 and C4) also exhibited 
antihypertensive activity comparable to that of the 2-amino derivatives. 
Therefore, it appears that the N1-H may not be as important as was originally 
· thought. 
From a series of 6-methyl 3-carbomethoxy-5-carboethoxy-4-(2-
chlorophenyl)-1,4-DHP's containing 2-aminoalkoxy-methyl substituents, it was 
observed that the derivative bearing a 2-dimethylaminoethoxymethyl substituent 
(amlodipine) (Figure 5) possessed activity comparable to that of nifedipine, the 
27 
parent compound of the 1,4-DHP calcium antagonists39• Of considerable interest 
was the fact that the S-(--) - enantiomer of amlodipine was approximately 1000x 
more potent than the R-(+) enantiomer4°, suggesting an unsymmetrical binding 
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The conformational requirements for calcium channel activity of the 1,4-
DHP's have been studied by solid-state and solution studies, the synthesis of 
rigid and semi-rigid analogs, and using theoretical calculations21.2s.21.2s.37,39-s9. 
Numerous DHP compounds have been studied in the solid-state by X-ray 
diffraction (TABLE 2). These diffraction studies show that the two rings of these 
compounds (phenyl and DHP) are not oriented coplanar with respect to each 
other. The 1,4-DHP ring exists as a boat-shaped structure with the C4 phenyl 
ring in a pseudoaxial position (Figure 7), oriented perpendicular to the plane of 
the base of the DHP boat. 
Figure 7: X-Ray Structure of Nifedipine Illustrating General Conformation 
TABLE2 
1,4-Dihydropyridine Derivatives Studied by X-Ray Crystallography 
' 
X Bl 82 m .M 85 Reference 
H C02CH2CH3 C02<}H2CH3 CH3 CH3 H 58 
2-CF3 C02<}H3 C02CH3 CH3 CH3 H 42 
2-CI C02<}H3 CO~H3 CH3 CH3 .H 55 
H C02<}H3 .co~Ha CH3 CH3 H 21 
3-N<l2 ~H3 CO~H3 CH3 CH3 H 21 
3-N<l2 ~H(CH3)2 C~CH2CH~H3 CH3 CH3 H 28,44 
Nimodplne 
2-N~ C02<}H3 C02<}H3 CH3 CH3 H 25 
Nifedipine 
3-CH3 C02<}H3 C02<}H3 CH3 CH3 H 21 
t,..) 
'° 
4-CH3 CO~H3 C~CH3 CH3 CH3 H 21 
4-N02 ~H3 ~CH3 CH3 CH3 H 21 
3-CN ~CH3 ~CH3 CH3 CH3 H 25 
2,4-(N02)2 C~H3 C~H3 CH3 CH3 H 21 
2,3,4,5,6-F5 ~CH3 C02CH3 CH3 CH3 H 25 
2-N~ ~H3 C02CH2CH2CH(CH3)2 CH3 CH3 H 27 
Nisoldipine 
2-CF3 N02 C02CH3 CH3 CH3 H 43 
3-N02 C02CH3 C02(C5H7N)-CH2C5H5 CH3 CH3 H 52 
2-NH2 C02CH3 C02CH2CH3 CH3 CH3 H 49 
2,3-Cl2 C02CH2CH3 C02CH2CH2CH(CH3)2 CH3 CH3 H 50 
Felodipine 
H CO~H3 C~CH2CH2CH(CH3)2 CH3 CH3 H 27 
3-N02 ~H3 C~CH2CH2CH(CH3)2 CH3 CH3 H 27 
3-CN ~H3 C02CH2CH2CH(CH3)2 CH3 CH3 H 27 
3-0CH3 ~H3 C02CH2CH2CH(CH3)2 CH3 CH3 H 27 
4-F C~H3 C02CH2CH2CH(CH3)2 CH3 CH3 H 27 
2-CF3 C~H3 C02CH2CH2CH(CH3)2 CH3 CH3 H 27 
2,4-Cl2 C(O)N(CH2CH3)2 C(O)N(CH~H3)2 CH3 CH3 H 46 
l..ll 
0 
3-N~ C<>2CH2CH~H3 CO~H2CH~N02 
3-N02 CO~H3 . CO~H2CH~N02 
3-N02 ~H3 C02CH2CH3 
4-CI CO~H3 ·· ~CH2CH2CH(CH3)2 
3-CF3 ~H3 ~CH2CH2CH(CH3)2 
4-N(CH3)2 ~H3 C~CH3 
3-N~ ~CH~(CH3)3 C~CH2C(CH3)3 
3-N02 ~H(CH3)2 C~CH3 
2-Cl,3-N~ CO~H3 CO~H3 
2-Cl,4-N~ C~H3 ~H3 
2-Cl,5-N02 ~H3 CO~H3 
CH3 CH3 H 
CH3 CH3 H 
CH3 CH3 H 
Nitrendiplne 
CH3 ···cH3 H 
CH3 CH3 H 
CH3 CH3 H 
CH3 CH3 H 
CN CH3 H 
Nilvadipine 
CH3 CH3 H 
CH3 CH3 H 














In this conformation, rotation of the phenyl ring is sterically.hindered and the ring 
is therefore forced to lie close to the vertical plane passing through N1 and C4 
and perpendicular to the base of the DHP boat3. As the phenyl ring approaches 
a perfect orthogonal position, activity increases. Synthesis and testing of rigid 
analogs also support this theory60• 
The conformation of the ortho or meta substituents on the phenyl may be 
oriented in the sp (away from the DHP) or ap (toward the DHP) conformation 
(Figure 8). In the solid state, the sp conformation appears to be the preferred 
orientation, two exceptions being the 3-CN (ap ) and the 2-CI, which adopts both 
the sp and ap conformations21 •55• Theoreti~al calculations support the favored 
stability of the sp conformation. Where some solution studies have indicated a 
bias toward the sp conformation, others indicate the opposite3•55,61 • This would 
be consistent with the observation that meta,meta'-disubstituted phenyl 
derivatives are also potent antagonists 1 •29• Hence, the evidence seems to 
indicate a lack of bias towards the sp or ap conformation at the receptor site. 
However, Rovnyak et al suggest there is a preferred conformation because rigid 
analogs in which the phenyl substituent is held in the sp conformation have 
higher activities than those in which the phenyl substituent is held in the ap 
conformation55• 
The receptor apparently distinguishes between ortho, meta-disubstituted 
and ortho, meta'-disubstituted derivatives55• Hence, it is suggested that there is 
an asymmetric preference in the binding site for the phenyl substituents and is 
indicative of a preferred sp conformation for both substituents in the ortho, meta-
disubstituted derivative (Figure 8). 
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sp-Rotamer ap-Rotamer 
Figure 8: Illustration of the s,p and a,p Conformations of the Phenyl Substituents. 
The DHP ring adopts a flattened boat conformation in all compounds 
studied thus far. It has been proposed that a direct correlation exists between 
the flatness of this ring and activity. Flatness is not a sufficient condition for 
activity, because many inactive compounds have very flat DHP rings. However, 
it may be the corresponding change in the position of the phenyl ring that alters 
the activity (Figure 9). 
Figure 9: Illustration of the Change in Conformation of the Phenyl Ring as the 
DHP Ring Becomes Flatter in the Active Pentafluorophenyl 
Derivative. 3 
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Compounds with different ester substituents appear to have the same degree of 
ring flattening. Hence, the identity of the ester substituent does not appear to 
affect this parameter. 
The ester substituents can adopt one of three different conformations. sp, 
sp {cis, cis}, ap, ap {trans, trans}, or sp, ap {cis, trans} (Figure 10). The ester 
carbonyl groups are always found to be nearly coplanar with the nearest double 
bond in the DHP ring, with the carbonyl group oriented either cis {sp} or trans 
{ap} to the neighboring carbon carbon double bond of the DHP ring. 
Figure 1 
Figure 1 O: Illustration of the s,p and a,p Conformation of the Ester Substituents. 
It appears that in the solid state, ortho-substituted derivatives have a 
preference for sp, sp geometry, whereas the non-ortho-substituted derivatives 
prefer sp, ap geometry. These ratios are consistent with the thesis of non-
equivalent environments adjacent to the DHP binding site, and the probability of 
the ester groups being oppositely oriented at the receptor site is high. 
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The preference for coplanar groups at the receptor is supported by the greater 
activity of rigid DHP analogs which favor this conformation. These 
conformational characteristics are summarized in Figure 11. 
sp vs ap - ester groups 
sp vs ap - phenyl subs 
R 
0 
Figure 11 : General Conformational Details Consistent with High Activity of the 
1,4-Dihydropyridine Derivatives. 
DHP Receptor Characteristics 
· The actual receptor that the 1,4-DHP's bind to is unknown. However, 
based on the amino acid sequence(AA) of the a 1-subunit of the voltage 
dependent calcium channel isolated from rabbit skeletal muscle transverse tubule 
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membranes, a receptor model has been proposed28. This isolated AA sequence 
(receptor) has been shown to restore excitation-contraction coupling and restore 
slow calcium current when reconstituted into membrane bilayers 14• 
Characteristics of the voltage-sensing unit28 
Based on the AA sequences of the channel forming a-subunits of voltage-
gated channels, several models have been proposed to describe how the a-
subunits (a-helical segments) are arranged in the lipid bilayer15•17•62. These ion 
channel sequences are characterized by four homologous repeating domains 
which are organized around an ion selective channel. Each of the four domains 
of the protein sequence contain eight a-helices, and the fourth helix in each 
domain, termed the S4 helix, has a regular pattern of five or six positively 
charged arginine (Arg) or lysine (Lys) residues spaced ever; third AA apart28. 
In an a-helix, each residue is displaced by a 100° right hand rotation from 
its preceding N-terminal residue. Therefore, there will be 300° right hand, or a 
60° left hand helical displacement for each three residue separation. A pattern of 
five or six Arg and Lys residues, spaced three apart, would form a left handed 
spiral staircase of positive charges on the outside of the S4 helix. This staircase 
of charged Lys and Arg side chains has been proposed to H-bond the S4 helix to 
a matching h~lical pattern of H-bond accepting groups provided by the outer 
surrounding collar of a-helices in each voltage sensing bundle. It has also been 
proposed that the S4 helix is able to slide up or down in this semi-rigid collar of 
the sensing unit in response to changes in the membrane potential15,28. 
Calcium channel blocking drugs are thought to interfere with the voltage-
induced movements of the S4 subunit2B. The DHP amine function should 
interact with proton accepting functional side chains of such AA's as aspartic acid 
(Asp), asparigine (Asn), glutamic acid (Glu), glutamine (Gin), serine (Ser), and 
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threonine (Thr), while the ester carbonyl oxygens should form H-bonds with such 
proton donor as Arg, Lys, and histidine (His). Since Lys, Arg, and His residues 
were scarce on other transmembrane helices, it appeared logical to investigate 
whether or not a 1,4-DHP molecule could satisfy its H-bonding requirements by 
interacting with the S4 a.-helix. The optimum docking site is proposed to be in 
between the side chains of two arginine residues lying parallel to each other on 
successive turns of the helix2s. While there are a number of these sequences 
present, modeling studies show that the peptide sequence Arg-Leu-Leu-Arg-Leu-
Phe-Lys-lle, offers the best fit of highly active members of the 1,4-DHP class. , 
Therefore, this portion of the sequence has been used to explore docking 
efficiency. This was modeled by Langs et al, docking the drug molecule with the 
phenyl ring between two Arg side chains on the S4 helix (Figure 12)2s. 
Figure 12: Stereodiagram of nimodipine bound to the proposed 
· receptor surface2S 
The unsubstituted para position of the phenyl ring is seen to have tight van der 
Waals interactions with the S4 helix core. Thus, this may explain why para 
substituted derivatives are much less active. The two Arg side chains flank 
opposite sides of the phenyl ring and also form H-bonds with the carbonyl oxygen 
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atoms of the drug molecule. When the drug molecule is positioned as shown in 
Figure 12, the N1-H bond is approximately perpendicular to and directed away 
from the axis of the S4 helix, supposedly towards a H-bond acceptor, presumably 
located on an adjacent helical strand in the voltage sensing bundle 28 . The 
amount of ring pucker affects the projection of the N1-H bond, hence affecting 
the H-bonding capacity. Those with large ring puckers may not be able to form 
these H-bonds as well. 
Based on the modeling results of Langs et al, it appears that the major 
recognition surfaces of the receptor lie in helical grooves on the S4 strand, or 
voltage-sensing a-helix that is positioned in the center of the bundle of 
transmembrane helices that define each of the four calcium channel domains. 
Multiple binding clefts defined by Arg-X-X-Arg reading frames exist on the S4 
strand. 
The tissue selectivity of certain derivatives may also be the result of the 
differences in lipophilic character, shape and volume of the ester groups. In this 
model, the ester groups slide under the aliphatic connecting arms of the Arg side 
chains and rest against the side chain residues of amino acids exposed in the 
next turn of the helix. 
The above model given by Langs et al is merely an hypothesis. The cleft 
used is only one of many where the DHP may bind. However, it may be a 
starting point. The degree to which this model may be correct has not yet been 
established. 
Decomposition of the 1,4-Dihydropyrldines 
1,4-Dihydropyridine derivatives undergo a photodecomposition sequence 
forming nitroso-pyridine derivatives and finally nitro-pyridine derivatives63-ss. 
Nifedipine decomposition has been reported to be extremely wavelength 
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sensitive. The two decomposition products have been identified by 
spectroscopic methods (Figure 13). Exposure to UV radiation appears to cause 
the aromatization of the dihydropyridine ring and reduction of the nitre group to a 
nitroso moiety (Figure 13b). Daylight and air oxidation lead to reoxidation of the 
nitroso group to a nitro function. (Figure 13c). The existence of these 
decomposition products has led to concern about shelf life, packaging and 
potency of the pharmaceutica165•66• 
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Figure 13: Decomposition Scheme for 1,4-Dihydropyridine Compounds 
Oxidation of the 1,4-dihydropyridine ring to pyridine is reported to diminish 
activity significantly in some cases22• The nitro-pyridine decomposition product 
has been identified as one of the major metabolites of the parent 1,4-
dihydropyridine compound67 and has been reported to be as much as 1 OOOx less 
active68• However, some of the oxidized derivatives do display some activity22• 
Even though the SAR's of the dihydropyridine type compounds seemed 
highly developed, there appeared to be a lack of understanding concerning the 
effect of the C3, CS ester alkyl groups on the activity. For example, there was 
really no systematic study of increasing the chain length of the ester alkyl groups 
and how this affected the overall conformation of the compounds. Also, the 
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effect of decomposition on the conformation of the parent 1,4-DHP's was barely 
investigated at all. 
Therefore, this thesis study set out to accomplish a further understanding 
of 1) the effect of increasing the length (bulk) of the ester alkyl groups on the 
overall conformation of these compounds and 2) the conformational changes 
associated upon decomposition to the nitre-pyridine derivatives and the potential 
effects of this on the calcium antagonistic activity of these compounds. 
Furthermore, a study of the calcium blocking efficiency of the parent compounds 
and their oxidized derivatives can lead to an understanding of the activity factors 





The main objective of X-Ray crystallography is the acquisition of a detailed 
model of the three-dimensional contents of a crystal at the molecular level. A 
wealth of information is available from the positions of the individual atoms; bond 
lengths and angles, intermolecular interactions, molecular packing, conformation, 
and hydrogen bonding. Although this method can only be applied to crystalline 
materials, it can be adapted to a wide range of different temperatures, pressures 
and environments. 
In the crystalline state, there exists a very high degree of internal order 
and symmetry. The molecules, atoms, or ions in the crystal are arranged in a 
precise regular way, a motif which is repeated over and over in all directions. It is 
this property of crystals that allows the diffraction of X-rays and the subsequent 
solution of a crystal structure. Most crystals are very regular in shape with sharp 
faces and edges, but this characteristic is not sufficient to define a crystal. They 
must have a repeating pattern in three dimensions, which defines the crystal 
lattice. 
The basic "building block" in a crystal is the unit cell. The unit cell is 
characterized by its cell edges {a, b, and c) and angles (a., f3, and y). The crystal 
system to which a unit cell belongs is defined by the relationship between these 
edges and angles. There are seven possible crystal systems {TABLE 3). 
TABLE 3 









Unit cell shape 
a * b * c, a * ~ * 'Y * 90° 
a* b* c, a= 'Y= 90°,~ * 90° 
a * b * c, a = ~ = 'Y = 90° 
a = b * c, a = ~ = 'Y= 90° 
a =b = c, a = ~ = 'Y * 90° 
a = b * c, a = ~ = 90°, 'Y = 120° 
a = b= c, a = ~ = 'Y = 90° 
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The unit cell of a crystal also may contain a variety of symmetry elements 
relating atoms or molecules to each other. These can include: 
Mirror Plane: A plane of reflection which must be perpendicular to an 
axis and parallel to one of the crystal faces. 
Rotation Axis: An n-fold rotation axis in which the rotation through 
27t/n (n=1, 2, 3 or 4) leaves the appearance of the motif unchanged. 
Glide Plane: The combination of a mirror reflection and a translation. 
Screw axjs: The combination of a rotation and a translation. 
loversjon axes: The combination of a rotation axis with a center of 
symmetry. 
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The crystal lattice can be classified as primitive, P, or face centered (A, B, 
or F) or body centered, I. Fourteen Bravais lattices result when the crystal 
system is combined with these lattice types. The combination of the fourteen 
Bravais lattices with the space symmetry elements gives rise to a total of 230 
possible space groups. Each crystal crystallizes in a specific space group that 
characterizes that crystalline structure69. 
Since crystals have the highly ordered structure described above, they are 
capable of diffracting radiation similar to an optical grating. The diffraction 
pattern of a crystal is much more complicated because a crystal exhibits three-
dimensional periodicity and gives rise to diffraction in all directions of space70• 
When crystals diffract X-rays, it is the core electrons that possess the diffracting 
power. The core electrons act as secondary point sources and diffract the X-ray 
beam. The diffraction of an X-ray by a crystal obeys a mathematical relationship 
called Bragg's Law: 
nA= 2dsin0 (1) 
where 1'. is the incident radiation wavelength, d is the interplanar spacing or 
distance between the regularly oriented layers of a set of (hkl)-planes, 0 is the 
angle of incidence and the angle of diffraction of the X-ray beam. Bragg's law, 
thus, describes the relationship between the wavelength of the incident radiation, 
the distance between the parallel planes of the crystal, and the _angles at which 
specific diffracted beams will be observed. Bragg's law must be satisfied in order 
for diffraction to occur. 
The diffraction pattern of a crystal is characteristic of the unit cell and the 
distribution of the atoms present. The intensities of the diffracted reflections are 
determined by the types of atoms present and the relative positions of these 
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atoms within the unit cell. Different types of elements have different abilities to 
scatter X-rays, which is dependent on the number of core electrons of that 
specific element. The "heavier" the atom, the greater the ability it possess to 
scatter the X-ray beam. Each crystal has its own diffraction pattern characteristic 
of its structure. 
The intensity data collected from a crystal supplies all the information 
necessary to solve the molecular structure of that crystal. However, the 
intensities of these reflections are influenced by numerous other factors which 
must be taken into account. The raw intensity data (lmeas) must be corrected for 
these various effects before it can be used to solve the structure. This is termed 
data reduction. These corrections include i) background, ii) polarization, iii) 
Lorentz effect, iv) absorption factor, and v) decomposition. 
i) Background - When a reflection intensity is measured, it is usually 
accompanied by a certain amount of scattered (background) radiation which 
must be eliminated to obtain the true intensity of a reflection71 • The correction for 
the left and right background is calculated as follows: 
where: 
where: 
hnt = (lmeas-Lbg-Rbg) x Scan speed 
lint -- Integrated Intensity 
lmeas -- Measured Intensity 
The error in this intensity measurement is given by: 
(2) 
olint = (lmeas + Lbg - Rbg)112 x Scan speed (3) 
olint -- The standard deviation of lint 
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ii) Polarization factor-The polarization factor is a function of 29. As the 
data is collected, 0 is varied. In so doing, the nature of the X-ray beam and the 
efficiency in which diffraction occurs also varies. A normal X-ray beam is 
unpolarized and contains two limiting components, one parallel to the reflecting 
plane (Ill) and one perpendicular to the reflecting plane (I.L), These components 
of the X-ray beam are diffracted by the crystal monochromator with different 
efficiencies and the ratio of these differences changes with the 20 angle. At 
lower 20, the 111 and IJ. components are diffracted with approxi!llately equal 
efficiency. At higher 20 the efficiency of diffraction of the IJ. component 
decreases dramatically, causing the diffracted beam to become partially 
polarized. Thus, diffraction measured at high 20 appears to be less. 
The polarization factor, P. is a function of 20 and is independent of 
the geometry of data collection .. ft is calculated by the following e>,epression. 
P = ( 1 + cos2 20)/2 (5) 
iii) Lorentz factor-The Lorentz correction (L) is necessary because when 
the crystal is rotated at a constant speed, some reflections pass through the 
Bragg position at a faster rate than others. Reflections with low 20 are positioned 
in optimum diffraction geometry for a longer period than those with high 20. The 
Lorentz factor corrects for this effect and is given by: 
L = (sin 20 )-1 (6) 
The combination of the Lorentz and polarization factors results in what is known 
as the Lorentz-polarization factor (LP): 
LP = ( 1 + cos220 )/2sin20 (7) 
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iv) Absorption factor- As the data is collected, some of the intensity of 
the radiation is absorbed by the crystal. This absorption is dependent on the 
nature of the elements present in the compound being studied, the path length of 
the beam through the crystal, and the wavelength of the incident X-ray beam. 
Inorganic crystals containing heavy atoms absorb more strongly than purely 
organic molecules containing only C, H, N, 0, or S. The absorption factor (A) is 
defined by the following mathematical expression: 
A = ( 1 I V) f e·µl dv (8) 
where µ is the linear absorption coefficient which is defined as absorption per mm 
of material passed through, L is the path length through the crystal, and V is the 
volume of the crystal. 
v) Decomposition - Many crystals exhibit a steady decrease in diffraction 
intensity during the process of data collection. This effect appears to be a result 
of radiation damage to the crystal from the incident X-ray beam and can be 
observed by the remeasurement of certain high-intensity standard reflections at 
regular intervals. The correction for this effect is given by: 
D = long / lave (9) 
where: 
long -- starting intensity of a standard reflection 
lave -- average current intensity of the standard reflection 
Once all of the above corrections have been taken into account (data 
reduced), the total corrected intensity may be calculated by: 
lcorr = lint X (LP)-1 x A-1 x 0 (10) 
where: 
lint - the integrated intensity (from background corrections) 
lcorr -- the overall corrected intensity · 
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The reflection is considered to be observed if lint ~ 2cr(lint) and is used in 
the solution of the crystal structure. 
where: 
lint is related to the structure factor (F) by: 
I Fhkl I= (Klhkl I Lp)112 
p -- polarization factor 
L -- Lorentz factor 
(4) 
K -- constant, based on crystal size, beam intensity and machine 
constants 
The structure factor can be calculated, theoretically, once the positions of 
the atoms are known. Also, this factor is used in the calculation of electron 
density maps from which the position of the atoms can be determined. The 
relationship between F and I depends on the corrections listed above and must 
be taken into account in order to convert IFI into IFobsl which is used in the 
subsequent structure solution. 
The X-rays scattered by a single unit cell of a structure in any direction in 
which there is a diffraction maximum has a particular combination of amplitude 
and phase which is termed the structure factor ( F ). The structure factor may be 
calculated from the positions of the atoms in the cell, their ability to scatter X-
rays, and the phase angle, <lhkl (i.e. the difference in period, expressed as an 
angle, between the wave resulting from a specific set of planes and a wave 
resulting from scattering at the origin). 
where: 
I Fhkl I = { ( Ahkl )2 + ( Bhkl )2} 112 
Ahkl = L fj cos 21t (hXj + kyj+ IZj ) 
Bhkl = l: fj sin 2x (hxj + kyj+ lzj) 
exhkl = tan-1 (Bhkl I Ahkl) 
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where fj is the individual atomic scattering factors and Xj, Yj, Zj are the positional 
parameters in the unit cell of atom j. 
In order to acquire a three dimensional picture of the scattering matter (the 
electron distribution), a three dimensional Fourier synthesis must be performed. 
The number of electrons per unit volume or the electron density at any point X, V, 
Z, represented by p(XVZ) is given by: 
where: 
p(XVZ) = (1Nc) l:l:l: I Fhkl I cos {21t (hX +kV+ 12) - ex} 
h,k,I . 
Ve -- the volume of the unit cell 
Fhkl -- structure factor for the particular set of indices h,k,I 
ex -- phase angle 
(13) 
Therefore, if I F I and ex were known, p could be computed for all values of X, V, 
and Zand these values could be plotted to obtain a three-dimensional electron 
density map. However, only the structure factor can be obtained experimentally, 
not the phase angle. This value must be derived from the values of A and B from 
previously known structures or by purely analytical methods. This is what is 
known as the "phase problem" in X-ray crystallography. In order to solve a 
structure, a certain number of the phase angles must be determined 
approximately in order to compute an initial model from which to complete the 
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structure. This problem has been solved mainly by two mathematical 
approaches: The Patterson method and direct methods. 
The Patterson method is based on the idea that the phase angle is 
dominated by the presence of the heavy atoms. This method is only successful 
for structures containing elements with a higher molecular weight than sulfur. 
This method is based on the following equation 
P(u, v, w) = (1 I Ve) LLL I F 12 cos21t (hu+ kv + lw) (14) 
where only the indices and the I F 12 value of each diffracted beam are needed 
and which are derivable from the primary experimental quantities. No phase 
information is required because no origin for the unit cell is implied, only the 
relative positions of the atoms. The peaks in this map occur at points whose 
distances from the origin correspond in magnitude and direction to distances 
between atoms in the crystal. 
The Patterson function ( P(u, v, w)) is always centrosymmetric (has a 
center of symmetry at the origin), therefore interatomic distances can be plotted 
assuming one atom is at the origin. A peak in the Patterson map, called a vector 
at (u,v,w) implies that there are two atoms in a crystal structure at {x1, Y1, z1) 
and (x2, Y2, z2) such that (x2-x1 =U, y2-y1 =V, z2-z1 =W). Thus, the Patterson map 
gives the orientation and length of every interatomic vector. Depending on the 
space group in effect, certain spatial relationships can be used to help locate 
atoms. For example, if a space group contains a mirror plane perpendicular to 
the b axis, for every atom with coordinates x, y, z, there is another atom with 
coordinates x , -y, z. Thus the vectors between these atoms all have the 
coordinates 0, y, O. This represents what is known as a Harker line71. If only one 
value is fixed, a Harker plane results (eg. 0, v, w from a rotation axis parallel to 
a). 
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The heights of the peaks in the Patterson map are proportional to the 
values of ZiZj, where Zi is the atomic number of the atom at one end of the vector 
and Zj is the atomic number of the atom at the other end of the vector. The 
vectors formed between those atoms of high atomic number are much more 
visible than those formed between lighter atoms. Thus, the positions of the 
heavy atoms are determined from the map by analysis of the stronger Patterson 
vectors, Harker lines and planes and the use of the general equivalent positions 
of the space group of that crystal. In this way a starting trial model is obtained. 
The second approach most commonly used to obtain the positional 
parameters of a structure is called direct methods and is applicable to both light 
and heavy atom structures. Direct methods is a way of determining the phase(s) 
based on relationships among the intensities of the reflections themselves. The 
practical objective of direct methods is to phase enough reflections to provide an 
identifiable representation of the molecule. The first step in this solution requires 
the conversion of the observed intensities into normalized structure factors by the 
following equation: 
I Ehkl 12 = I Fhkl 12 I r fi2 (15) 
where: 
IEhkll = normalized structure factor 
fi = the scattering factor of the ith atom 
This equation is applied in shells of 10°0. Once the structure factors are 
normalized, the effects of the decline in atomic scattering power with increasing 
20 are eliminated. 
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The phases of a subset may be derived directly from the magnitudes of 
Ehkl, This value will allow the calculation of an electron density map from which 
one can derive a suitable structure. 
In defining the electron density it will be recalled that the following 
equation holds: 
p(XYZ) = (1Nc) l:l:l: I Fhkl I cos {21t (hX +kV+ IZ) - a} (16) 
h,k,I 
where: 
Ve -- the volume of the unit cell 
Fhkl -- structure factor for the particular set of indices h,k,I 
a -- phase· angle 
In a centrosymmetric cell, this equation simplifies to: 
p(XYZ) = (1/ Ve) l:l:l: ±1 Fhkl I cos 21t (hX +kV+ IZ) (17) 
h,k,I 
The phase angle has simplified because in a centrosymmetric cell, with each 
atom at x, y, z, there is an equivalent atom at -x, -y, -z, therefore the phase angle 
can only be O O or 180 ° (hence the ± sign in front of the structure factor). Thus, 
the electron density map can be constructed from equation (17), if the signs of a 
significant number of structure factors are known. 
Phases can be initially assigned by the use of what is known as Harker-
Kasper inequalities. These inequalities provided the first method of determining 
the phase of one reflection in terms of its magnitude and those of others. The 
inequalities that were derived are given below: 
where: 
u2hkl .S. 1/2 + 1/2 U2h,2k,21 
u2hkl .s. 112 (± 1,21u2h,2k,21 I) 




These equations are significant because the only unknown is the phase 
(or sign) of u2h,2k,21· The quantity u2hkl must be positive. For example, if u2hkl is 
equal to 0.60 and I u2h,2k,21 I is equal to 0.20, then it follows that the sign of 
u2h,2k,21 must be positive. Only then will equation (19) be satisfied. 
Once a few initial phases are determined, it is possible to define relations 
among the them. These relationships are based on the fact that the electron 
density can never be negative and that electron density consists of discrete 
spherically symmetric atoms. · For centrosymmetric structures, it can be shown 
that for any structure factor Fhkl, the phase is determined by the products of all of 
the phases of the pairs of structure factors whose indices add to give (hkl). Thus 
F213 depends on the products of the phases of F322 and F-1-11, F604 and F-
41 -1 , and so on. This relationship is described in the following equation 
introduced by Sayre: 
s(Fh1k111) • s(Fh2k212) ::= s(Fh1 + h2, k1 + k2, 11 + 12) (20) 
This is known as the triplet product sign relationship, wheres means" sign or 
and ::= means "is probably equal to". s(h, k, I) may be considered as ±1, and 
(h1k1l1), (h2k2l2) and (h1 + h2 k1 + k2 l1+ 12). are strong reflections with high IE I 
values. The triplet product sign relationship is used to expand the number of 
known phases. Therefore, if two of the signs in the equation are known, the third 
can be deduced. However, only a limited number of phases can be determined 
from the triplet relationship. A method termed symbolic addition is used to 
expand the number of phases known. 
In symbolic addition, one starts with a limited number of phases and uses 
them in connection with equation (20) to build a large enough set of known 
phases in order to produce a recognizable electron density representation of the 
structure. The preliminary step in symbolic addition is the calculation of the E 
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values for the entire data set as given in equation (15). For all the E values that 
are greater than a chosen minimum, a list is compiled of all the triples of 
reflections belonging to this set for which the indices sum to zero. The list of 
strongest relationships is used to select those reflections that are most often and 
most reliably interconnected, and appropriate ones of these are chosen for origin 
determination. In the centrosymmetric case, the origin is placed on one of the 
· centers of symmetry in the unit cell. In any primitive, centrosymmetric space 
group in the triclinic, monoclinic, or orthorhombic systems, arbitrary signs can be 
allocated to three reflections in order to specify the origin. These form a basic set 
from which more phases can be defined by using the triplet product relationships. 
For example, if the signs of 601 and 133 are +1, then 734 is generated by the 
combination of these and its sign will be positive: 
s(734)::::: s(601) • s(133) = +1 • +1 = +1 
Many times these starting reflections will combine to relate to two new ones and 
imply their phases by equation (20). The next step then involves the assignment 
of a new, strong reflection as a variable, a, b, or c. This variable stands for a 
general phase in the non-centrosymmetric case or a sign in the centrosymmetric 
case. These variables are then used to determine other phases exactly or in 
terms of one or more variables. This series is continued until a sufficient number 
of reflections have been phased to provide an initial structural model. 
When enough phases have been determined, an electron density map (E-
map) is calculated with the IE I values instead of the IF I values. 
p(XYZ) = (1Nc) I.I.I. ±1 Ehkl I cos 21t (hX +kV+ 12) (21) 
h,k,I 
A trial model is derived from the E-map. 
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When the initial model is defined, the phased structure factors (Fcalc) can 
be calculated and their magnitudes compared with those that have been 
measured (Fobs). This is performed by a least squares refinement method 
(refinement). Least-squares refinement modifies the atomic positional 
parameters of the calculated structure to improve the least-squares fit. This 
procedure then identifies any missing atoms (using the difference Fourier I 
(IFobsl) - (IFcalcl) I). The correctness of the model is given by the 'Residual 
Factor', Rf, defined as: 
Rf = ( L I (IFobsl> - (IFca1c1) I) I ( l: I Fobs I ) (22) 
Once this initial R factor is determined, refinement of the total set of atom 
positions in the crystal structure is performed using the least-squares method. 
As the model approaches completion, the difference between Fobs and Fcalc is 
reflected in a lower Rt value. 
The atom positions are first refined using isotropic temperature 
parameters. Each atom has an associated temperature parameter. This value, a 
measure of the thermal vibration of the atom, effectively spreads the electron 
cloud over a larger volume. This factor"'·,:eflects the decrease in the atomic 
scattering factors as 20 increases. The sc~ttering factor for an atom at rest is 
given by the following equation: 
exp { -Biso (sin20) / 12} . (23) 
where Biso is the isotropic thermal parameter, which is equal to 81t2 <U2>, where 
<u2> is the mean square displacement of the atom from its equilibrium position. 
However, the atomic scattering behavior is more accurately defined by an 
anisotropic thermal parameter given by: 
55 
where bij is the individual anisotropic thermal parameter of the atom. The 
refinement is continued using the anisotropic form of the temperature parameter 
which provides more accurate positional parameters and hence a better Rf for 
the structure. These anisotropic thermal parameters describe an ellipsoidal 
electron distribution of the electron density. 
Hydrogen atom positions are normally calculated using idealized 
geometry, unless the intensity data is sufficiently good to allow them to be 
located from the difference Fourier map. When all atoms have been located, an 
appropriate weighting scheme and e~inction correction can be applied. The 
structural refinement is considered complete when the Rf factor reaches a value 
of between 3 - 6% and all atom bond lengths and angles are reasonable. 
Tables of crystal information (cell dimensions), data collection conditions, 
anisotropic thermal parameters, positional parameters and bond distances and 
angles are now prepared: A table of final Fobs and Fcalc structure factors is 
printed. Three dimensional drawings of the molecule and/or the unit cell are 
prepared to show the atoms as ellipsoids of 50% probability. From these data, 
structural . characteristics can be interpreted such as bond type, H-bonding 




Introduction to Molecular Modeling 
Molecular modeling (MM) is a computer-based method of predicting three 
dimensional details (bond lengths, bond angles, conformation, torsion angles, 
etc.) of a chemical structure from minimum energy evaluations. The results 
obtained can .. be compared to experimental values or used to predict the 
properties or reactivity of a molecule. Use of thi·s method in biological research 
areas has grown extensively during the past decades due to advances in 
computer hardware and software, which has in turn brought high-performance 
computing and graphics within the capacity of many industrial and academic 
laboratories. 
Molecular modeling (MM) systems supply the tools necessary to visualize, 
build, analyze, and store models of complex molecules without the necessity of 
synthesis. Most MM systems work in approximately the same fashion; the two-
dimensional structure of the molecule is entered and a corresponding 3-D model 
is calculated. Using an empirical, parameterized force field, the computer 
calculates a total energy value for the model. Subsequently, the model is 
subjected to small perturbations to reduce its energy until a local minimum is 
achieved (minimization). This conformation is then considered to be a stable 
conformer relative to other conformations which may have higher energy values 
in the gas phase (one molecule only). Conclusions may then be drawn about 
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structure-activity relationships, binding-site conformations, and reactivity of this 
conformer. MM can also be used to design new structures with specific 
biological properties (QSAR). This capacity has made MM an important tool for 
design of novel drugs because it can eliminate or speed up many processes that 
are normally very time consuming, i.e., the trial and error method of synthesizing 
and testing the new compounds. MM helps make this process more efficient by 
"testing" various 3-D characteristics of the new molecule to ascertain if 
synthesis and testing are warranted. 
The two most common approaches used in drug design are the "direct" 
and "indirect" methods. Direct drug design utilizes the 3-D features of a known 
receptor site. The new drug is then designed to conform to this model. For 
example, if the 3-D structure of a certain protease or enzyme is known, the 
actual dimensions of the receptor site can be visualized and a molecule can be 
designed that will act as a key to fit the receptor site and which will inhibit or alter 
the function of the substrate. The indirect method is based on a known structure, 
with the desired biological activity, termed a lead compound. Analogs of this 
compound are designed and MM is used analyze the ability of the analog to 
mimic the 3-D structure of the lead compound. This is normally a good indication 
of the biological activity of the analog. Frequently, a number of derivatives have 
already been synthesized and tested, therefore these structure-activity 
relationships can be kept in mind during the design process. Direct and indirect 
methods can also be used together. For example, the indirect method may be 
used to assess the 3-D properties of various active and inactive molecules. The 
information gathered from the indirect method can be used to construct a 
"blueprint" of the receptor site. The selection of new molecules for MM studies, 
thus, becomes more rational. The 3-D structure of the lead compound can be 
determined by X-ray crystallography or NMR analysis. X-ray crystallography can 
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determine the precise 3-D structure of a compound in the solid state, but it 
requires preparation of a high-quality crystal. If a crystal structure is determined 
for one member of a class of compounds, there is no need to determine others 
since the MM system is able to give reasonable 3-D structures based on the data 
from the initial compound. NMR can also supply 3-D information about the lead 
compound. Two-dimensional NMR techniques have become highly advanced 
and can determine the 3-D structure of a molecule in solution using NOE and 
coupling constant analysis. This is advantageous because the structure of a 
molecule changes in response to its environment; i.e. solvation interactions may 
make the minimum energy conformation in solution different from that in the 
crystal. The application of MM techniques without any initial structural data is 
very difficult, requiring ab initio methods and quantum mechanical calculations. 
This is normally unrealistic because the computer time required is so extensive 
even for moderate sized molecules. However, if 3-0 data is already known for a 
compound with similar structure, the MM system can use it as a starting point in 
determination of the structure of the unknown molecule and thus reduce the 
computer time required. 
Many commercial MM programs are available. Each offers specific 
advantages, but most include a basic set of capabilities: manipulation and 
visualization of the 3-D structure of a molecule; structure building, rotating bonds, 
molecular mechanics and dynamics, conformational analysis, molecular surface 
displays, electronic properties, docking algorithms and calculation of various 
physical properties of the molecule. The two major MM packages available are 
SYBYL® and Discover®. The Discover® program was used in this research and 
its capabilities are described below. 
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The Discover® Program72 
The Discover® program enables the user to perform molecular simulations 
such as molecular mechanics, dynamics, energy minimizations and template 
forcing (forcing the conformation of one molecule to be similar to that of a 
template structure), calculation of interaction energies and vibrational 
frequencies. Using Discover®, one can also evaluate docking interactions, such 
as enzyme-substrate, receptor-ligand, or polymer-polymer. Discover® can also 
evaluate the multitude of conformations available to a drug, catalyst, or polymer 
and energy refine a model-built structure. 
Minimization 
Discover® uses different algorithms for the energy minimization process. 
However, the final structure reached represents one of the low energy 
conformations. In order to find other low energy conformations, molecular 
dynamics can be used to search the conformational space and hence find other 
minima. 
Minimization with solvent attempts to take into account the interactions of 
solvent molecules with the substrate. This is done by placing either a layer or 
sphere of solvent around the substrate. The whole system is then minimized. 
This will tend to alter the minima acquired versus that found with minimization in 
the gas phase. This new minima may provi,de insight into how the substrate 
conformation changes with a solvent environment and hence what the true 
conformation is in biological systems. 
Docking 
The Docking Module is used to evaluate the non-bond energy between 
two molecules. This energy is frequently used as a guide to the preferred 
orientation of one molecule relative to another. As in the minimization process 
60 
described above, the parameters used in this calculation are stored in a force 
field file which calculates values for the van der Waals non-bond potential. The 
van der Waals interaction energy is calculated by summing the energy 
contributions between all atoms of the two molecules. Hydrogen bonding is also 
used as an indicator of a positive interaction. This is especially important in the 
interaction between a ligand and its receptor. (i. e. it is favorable to form more 
hydrogen bonds which will aid in the binding process). The primary objective of a 
docking calculation is to evaluate the interaction energies of many orientations of 
one molecule relative to another, while searching for the orientations that result in 
low interaction energies. The lowest energy value obtainable is used to describe 




Materials. All chemicals were reagent grade materials and were used without 
further purification. 
1,4-Dlhydropyridlne Synthesis 
The synthetic procedure used to prepare the compounds of this study is 
known as the Hantzsch dihydropyridine synthesis73, a " one pot" synthesis in 
which all the reactants are mixed in an alcohol solvent (CH30H, CH3CH20H) 
and refluxed for 4-6 hours {scheme A). The product usually crystallizes out of the 
mother liquor, otherwise, evaporation of the alcohol solvent and replacement with 
another solvent usually CH3CN, enhanced precipitation. 
2 
+ QN0_2_R.....;O;..;.H __ ---1~R02 
cone. NH40H 
0 
Scheme A: General Hantzsch Synthesis of Dlalkyl 2,6-Dimethyl-4-(3-
nitrophenyl)-1,4-Dihydropyridines. 
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Decomposition was carried out by oxidation with nitric acid (HN03), potassium 
permanganate (KMn04) (Scheme B), or (compound I), by placing the sample 






Scheme B: Decomposition of 1.4-Dihydropyridines 
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Dimethyl 2,6-dimethyl-4-(2-nitrosophenyl}-pyridine-3,5-dicarboxylate (I) 
Nifedipine (50 mg, 0.1445 mmol) (2,6-dimethyl-3,5-dicarbomethoxy-4-(2-
nitrophenyl)-1.4-dihydropyridine in an ethanol solution was exposed to normal 
sunlight. After approximately two days, light green crystals formed. A crystal 
with appropriate dimensions (< 0.5 x 0.5 x 0.5 mm) was mounted on a glass fiber 
for use in X-ray diffraction studies. (mp=93-95 °C)64. 
Bis(2,6-dimethyl-3,5-dicarbomethoxy-4-(2-nitrophenyl)pyrldlne)dlchloro-
copper(II) (II) 
A mixture of 20 mg (0.0578 mmol) of nifedipine and 9.8 mg (0.07334 
mmol) copper(II) chloride in· 10 ml of ethanol was allowed to sit in an open 
container on the bench top. Dark purple crystals were produced after several 
weeks. 
2,6-Dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-pyridine • N03 • H20 (Ill) 
Di-tert-butyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-di-
carboxylate-(2 g ,4.65 mmol) was mixed with 30 ml of 2 N HN03. The resulting 
solutio,n was extracted with CHCl3. The organic layer was washed twice with 
water and once with 5% NaHC03. The aqueous layer yielded transparent, 
colorless crystals. 
Dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate (IV) 
A mixture of 6 g of 2,6-dimethyl-3,5-dicarbomethoxy-4-(3-nitrophenyl)-1.4 
dihydropyridine was warmed with 5 M (11 O ml) nitric acid to approximately 80°C. 
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The reaction mixture was stirred for 30 minutes and then extracted with 
methylene chloride(CH2Cl2). The extract was washed with water, 5% aqueous. 
NaHC03, again with water, and then dried over Na2S04. Large crystals 
precipitated out of the organic layer (mp =121-124 °C). 
Diethyl 2,6-dlmethyl-4-(3-nitrophenyl)·1,4-dihydropyrldlne-3,5-cHcarboxy_late 
(V) 
A solution of 5g (0.0331 mole) of 3-nitrobenzaldehyde, 8.61 g (0.06618 
mole) ethyl acetoacetate, and 4.56 g (0.065moles) ammonium hydroxide ·was 
refluxed for approximately 4 hours. The product precipitated out of the reaction 
mixture, was filtered, and recrystallized from a methanoVwater mixture (mp=205-
207 °C). 
Diethyl 2,6-dimethyl-4-(3-nltrophenyl)-pyrldlne-3,5-dlcarboxylate (VI) -
A mixture of 4g of 2,6-dimethyl-3,5-dicarboethoxy-4-(3-nitrophenyl)-1,4 
dihydropyridine was warmed with 5 M nitric acid (100 ml) to approximately 80°C. 
The mixture was. stirred at this temperature for approximately 30 minutes and 
extracted with CHCl3. The organic layer was washed with water twice. The 




A solution of propyl acetoacetate (14.417 g, 0.1 mole), 3-nitro-
benzaldehyde (7.556 g, 0.05 mole), and concentrated ammonium hydroxide (0.1 
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mole) was refluxed for 5-6 hours in 30 ml of ethanol. Yellow plate-like crystals 
precipitated out of the mother liquor upon cooling (mp =144-147 °C). 
Di-isopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxylate(VIII) 
A solution of isopropyl acetoacetate (14.417 g, 0.1 mole), 3-nitro-
benzaldehyde (7.556 g, 0.05 mole), and concentrated ammonium hydroxide (0.1 
mole) was refluxed for 5-6 hours in 30 ml of ethanol. Yellow plate-like crystals 
precipitated out of the mother liquor upon cooling (mp =107-113 °C). 
Dibutyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
(IX) 
A solution of n-butyl acetoacetate(15.82 g, 0.1 mole), 3-nitrobenzaldehyde 
(7.556 g, 0.05 mole), and concentrated ammonium hydroxide(3.85 g, 0.1 mole) 
was refluxed in ethanol for approximately 4 hours. The ethanol was removed and 
the resulting oil dissolved in acetonitrile. Large yellow crystals formed upon slow 
evaporation of the acetonitrile solution (mp = 89-94 °C). 
Di-isobutyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dlhydropyridine-3,5-
dicarboxylate (X) 
· A solution of 7.556 g (0.05 mole) of 3-nitrobenzaldehyde, 17.402 g (0.11 
mole) isobutyl acetoacetate, and 3.85 g (0.11 mole) concentrated ammonium 
hydroxide was refluxed in ethanol for 7 hours. The product precipitated out of the 
reaction mixture, was filtered, and recrystallized from ethanol (mp=139-143 °C). 
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Di-isobutyl 2,6-dimethyl-4-(3-nitrophenyl)-pyridlne-3,5-dicarboxylate {XI) 
A mixture of 4 g of di-isobutyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-
dihydropyridine-3,5-dicarboxylate (compound X) was warmed with 5N nitric acid 
(100ml) to approximately 80°C. The mixture was stirred for approximately 30 
minutes and extracted with CHCl3. The organic layer was washed twice with 




A solution of 3-nitroberizaldehyde (7.556 g, 0.05 mole), tert-butyl 
acetoacetate (17.402 g, 0.11 mole), and ammonium hydroxide (3.85 g, 0.11 
mole) was refluxed in methanol for 7 hours. The methanol was removed under 
reduced pressure and the solid dissolved in acetonitrile (CH3CN). Bright yellow 




A solution of n-pentyl acetoacetate (17.20 g, 0.1 mole), 3-nitro-
benzaldehyde (7.556 g, 0.05 mole), and concentrated ammonium hydroxide 
(3.85 g, 0.1 mole) were refluxed in ethanol for approximately 4 hours. Large 




A solution of di-isopentyl acetoacetate(17.20 g, 0.1 mole), 3-
nitrobenzaldehyde (7.556 g, 0.05 mole), and concentrated ammonium hydroxide 
(3.85 g, 0.1 mole) were refluxed in ethanol for approximately 4 hours. Large 
yellow crystals formed upon slow evaporation of the ethanol solution 
(mp= 115-117 °C). 
Di-isopentyl 2,6-dimethyl-4-(3-nitrophenyl)pyridlne-3,5-dlcarboxylate (XV) 
A solution of di-isopentyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-
dihydropyridine-3,5-dicarboxylate (4.59g, 0.01 mole}, potassium permanganate 
(1.58g, 0.01 mole}, and montmorillonite KSF (3.42g) was refluxed in 60 ml 
benzene for 24 hours. The reaction mixture was filtered and subsequently 
solidified. The solid was recrystallized from methanol. 
Di-neopentyl 2,6-dimethyl-4-(3-nitrophenyl}-pyridine-3,5-dicarboxylate (XVI) 
A mixture of 4 g of di-neopentyl 2,6-dimethyl-4-{3-nitrophenyl)-1,4 
dihydropyridine 3,5-dicarboxylate was warmed with SM nitric acid (100 ml) to 
approximately 80°C. The mixture was stirred for approximately 30 minutes and 
extracted with CHCl3. The organic layer was washed twice with water. The 





A solution of n-hexyl acetoacetate (18.60 g, 0.1 mole), 3-nitro-
benzaldehyde (7.556 g, 0.05 mole), and concentrated ammonium hydroxide 
(3.85 g, 0.1 mole) was refluxed in methanol for approximately 4 hours. The 
ethanol was removed under reduced pressure and the resulting oil dissolved in 
acetonitrile. Large yellow crystals formed upon slow evaporation of the 
acetonitrile solution (mp = 75-78 °C). 
Dlhexyl 2,6-dimethyl-4-(3-nltrophenyl)-pyridlne-3,5-dlcarboxylate(XVIII) 
A solution of dihexyl 2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-
dicarboxylate (0.01 mole, 5.0 g), potassium permanganate (0.01 mole, 1.58 g), 
montmorillonite KSF (3.42 g), and 60 ml benzene was refluxed for 24 hours. After 
the benzene was removed, the resulting oil was dissolved in hexane which 
yielded clear transparent crystals upon slow evaporation. 
(Diheptyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dlhydropyrldlne-3,5-
dicarboxylate) • CH3CN (XIX) 
A solution of n-heptyl acetoacetate (20.02 g, 0.1 mole), 3-
nitrobenzaldehyde (7.556 g, 0.05 mole), and concentrated ammonium hydroxide 
(3.85 g, 0.1 mole) were refluxed in methanol for approximately 4 hours. 
Acetonitrile was added to the original mixture causing compound XIX to 





A solution of n-octyl acetoacetate (21.40 g, 0.1 mole), 3-nitrobenzaldehyde 
(7.556 g, 0.05 mole), and concentrated ammonium hydroxide (3.85 g, 0.1 mole) 
was refluxed in methanol for approximately 4 hours. Acetonitrile was added to the 
original mixture causing compound XX to precipitate. Large yellow crystals 
formed upon slow evaporation of the acetonitrile solution (mp = 58-67 °C). 
Di-(2-Methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboylate(XXI) 
A solution of 3-nitrobenzaldehyde (4.53 g,0.03 mole), 2-methoxyethyl 
acetoacetate (10.4 g, 0.065 mole), and ammonium hydroxide(2.275 g, 0.065 
mole) was refluxed in ethanol for seven hours. The product precipitated out of the 
reaction mixture, was collected by filtration, and recrystallized from ethanol 
(mp=125-129 °C). 
(Dibenzyl 2,6-dimethyl-4-(3-nltrophenyl)-1,4-dihydropyridine-3,5-
dlcarboxylate) • 0.5 CH3CN (XXII) 
A solution of benzyl acetoacetate (0.1 mole), 3-nitro-benzaldehyde (0.05 
mole), concentrated ammonium hydroxide (0.1 mole) was refluxed in 30 ml 
ethanol for approximately 5-6 hours. The product crystallized from the mother 
liquor as a yellow precipitate. The precipitate was dissolved in acetonitrile which 




A solution of 2 g (5.55 mmole) of 2,6-dimethyl-4-(3-nitrophenyl)-3-
carbomethoxy-5-carboethoxy-1.4-dihydropyridine and 2 M HN03 (100 ml) was 
refluxed for 4 hrs. The resulting solution was extracted with methylene chloride 
(CH2Cl2). The organic layer was washed twice with water, dried with Na2S04 
and the CH2Cl2 removed under reduced pressure. The resulting oil was 
dissolved in ethyl acetate and upon slow evaporation, yielded clear crystals 
suitable for X-ray diffraction. 
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CRYSTALLOGRAPHY 
Crystals with the appropriate dimensions (<0.2 mm in all three 
dimensions) of each compouhd were chosen for X-ray diffraction. A single 
crystal of good quality was mounted on a glass fiber held in a brass support. The 
brass pin was placed in a goniometer head and mounted on a Siemens P4 
automated four-circle diffractometer equipped with a PC-486DX computer (Figure 
14). The crystals were irradiated with molybdenum radiation at an average 
wavelength of 0. 71073 A (a weighted average of ka 1 and ka2). Unit cell 
dimensions were determined using the centered angles from 25 - 50 independent 
strong reflections which were refined by least-squares methods using the 
automated procedure irt XSCANS74. The intensity data were collected at room 
temperature using a variable scan rate, a 0-20 scan mode and a scan range of 
0.6° below ka1 and 0.6° above ka2 to a maximum 20 value (normally 50.0° or 
the observed diffraction of the crystal). Backgrounds were measured at the ends 
of the scan range for a combined time equal to the total scan time. The 
intensities of three standard reflections were remeasured after every 97 
reflections to monitor crystal decomposition. , The raw intensity data collected 
were corrected for Lorentz, polarization, absorption, decomposition, centering 
and background effects, after which redundant and space group forbidden data 
were removed. 
Observed reflections (F>4.0 oF) were used to arrive at the non-hydrogen 
atom positions by direct methods75•77• Refinement of the scale factor, positional 
. and anisotropic thermal parameters for all atoms was carried out using either 
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.·.······················· ········· ················. :· :-:· :-:· :-:· ;,:• :-:· ;,:• ;,:• :-:· :-:· ;,:• ;,:• :-:· ;,:• ;,:• ;,:• ... 
-~~~~~~~~~~~ ~ ~~~~ 
.· ...... · ... ..................... ... ............ . . ................................... .............. 
- ~~~~~~~~~~~~~~~~ 
,',•,',•,',•,',•,',•,',•,',•,',•,',•,',•,' ,•,'.•, ',•,".•,',•, ' ,• 
tr~·~·==:~:J 
... :~f:7:7:?.?. :!:1: ....................... . 111 ......... .. ~.___. ... ~.................. ~.~-~-. ..... ...... ...... ......... . . 
. ........ ...... ......... .... . ..................... ...... .. 
. ........................... . . ........... ......... ....... . ...... ...... ................. 
,•,'.•,',•,',•,',•,'.•,',•,',•,',•, ' ,• 
Figure 14. Siemens P4 automated 4-circle diffractometer with 
PC-486DX computer and printer 
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XLS (refinement on F) or SHELXL78 (refinement on F2) to convergence. 
Scattering factors were taken from the International Tables for Crystallography. 
Hydrogen atom positions were calculated using idealized geometry. The profile 
fitting technique for data reduction was employed. A weighting scheme 
( w = 2 1 I I 2 J and extinction correction were applied at the last stages of a (F)+ gF 
refinement. Final refinement led to the final agreement factor, Rw. 
73 
MOLECULAR MODELING 
The molecular modeling performed in this study were done on a Silicon 
Graphics IRIS® Workstation, which was graciously provided by the Department 
of Biochemistry and Molecular Biology at Oklahoma State University.. The 
program used for the minimization in the gas phase and in solution was 
Discover72• The coordinates of the X-ray crystal structure were introduced using 
FOAT file format. Minimizations. were performed using these initial coordinates. 
The docking calculations were performed using the program Docking®72• The 
a1-subunit coordinates were obtained from Dr. David A. Langs at the Department 
of Molecular Biophysics, Medical Foundation of Buffalo, Inc. , Buffalo, New York. 
The molecules of this study as seen in their single crystal X-ray conformations 
were docked into the proposed receptor site and the Van der Waals interaction-
energy calculated. 
Biological Evaluation 
The biological testing procedures for the six compounds evaluated in this 
study were done by David J. Triggle using the method of Bolger3B et. al. at the 
school of pharmacy at the University of Buffalo, State University of New York, 
C126 Cooke-Hochstetter Complex, Box 601200, Buffalo, NY, 14260-1200. The 
method used measured the displacement of 6.1 x 10-11 M [3H]-(+)-PN200-110 
binding in rat brain membranes. Membrane protein was incubated in Tris buffer 
with the labeled compound and the drug under inspection. The total assay 
volume was 2.5 ml in Tris buffer at a pH of 7 .2 at 25°C. The tested compounds 
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were incubated with the membrane protein and bound [3H]-(+)-PN200-110 for 
four hours. The amount of [3H]-(+)-PN200-11 O that was displaced was 
measured using liquid scintillation counting. This gave a binding value which 
described the affinity of the compound being tested with respect to the labeled 
DHP derivative, [3H]-(+)-PN200-110. 
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CHAPTERV 
RESULTS AND DISCUSSION 
Numerous structure-activity relationships (SAR's) for 1,4-dihydropyridine 
(DHP) derivatives are available in the literature1. However, the influence of the 
alkoxy groups at the C3 and CS ester positions on the conformation of the rest of 
the molecule, and thus on the activity, is still somewhat unclear. A further 
understanding of 1) the effect of increasing the length and bulk of the ester alkyl 
groups on the overall conformation of 1,4-DHP compounds and 2) the 
conformational changes associated with DHP decomposition to the nitre-pyridine 
form and the potential effects on the calcium antagonistic activity of these 
changes was the focus of this study. The nine new compounds prepared, and 
the four prepared using literature preparations, (TABLE 4) have C3 and CS ester 
alkyl groups that range from a two carbon to an eight carbon chain (compounds 
V, VII, VIV, XIII, XVII, XVIV, and XX). In order to observe the conformational 
dependence upon increased bulk of these side chains, isopropyl, isobutyl, tertiary 
butyl, isopentyl, and benzyl groups were also included (compounds VIII, X, XII, 
XIV, and XXII). The decomposition products studied were those of nifedipine (I 
and II), dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxylate (IV), 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxylate (Ill), diethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-








Q2msmuod X. B1 B2. 12ecomsm11ll'2D 
erm:1ue1 (Bal 
I 2-NO CD2CH3 CD2CH3 yes 
II 2-N02 CD2CH3 CD2CH3 yes 
Ill ~~N02 C02H C02H yes 
IV 3-N02 C02CH3 CD2CH3 yes 
v2a 3-N02 C02CH2CH3 CD2CH2CH3 no 
VI 3-N02 CO~H~H3 · CD2CH~H3 yes 
v112s 3-N02 C02CH2CH2CH3 C02CH2CH2CH3 no 
v1112s 3-N02 C02CH(CH3)2 CD2CH(CH3)2 no 
VIV 3-N02 C02(CH2)3CH3 C02(CH2)3CH3 no 
X 3-N02 CD2CH2CH(CH3)2 CD2CH2CH(CH3)2 no 
XI 3-N02 CD2CH2CH(CH3)2 CD2CH2CH(CH3)2 yes 
XII 3-N02 C02C(CH3)3 C02C(CH3)3 no 
XIII 3-N02 C02(CH2)4CH3 C02(CH2)4CH3 no 
XIV 3-N02 CD2(CH2)2CH(CH3)2 C02(CH2)2CH(CH3)2 no 
xv 3-N02 CD2(CH2)2CH(CH3)2 CD2(CH2)2CH(CH3)2 yes 
XVI 3-N02 C02(CH2)C(CH3)3 C02(CH2)C(CH3)3 yes 
XVII 3-ND2 C02(CH2)sCH3 C02(CH2)5CH3 no 
XVIII 3-N02 C02(CH2)sCH3 C02(CH2)sCH3 yes 
XVIV 3-N02 C02(CH2)aCH3 C02(CH2)aCH3 no 
xx 3-N02 C02(CH2)7CH3 C02(CH2)7CH3 no 
xx126 3-N02 C02CH2CH20CH3 C02CH2CH20CH3 no 
XXII 3-N02 C02CH2CaHs CD2CH2CaHs no 





3,5-dicarboxylate (XVIII), and nitrendipine(XXIII). To investigate the effect of 
inserting an oxygen in the side chain di(2-methoxyethyl) 2,6-dimethyl-4-(3-
nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (XXI) was synthesized. These 
compounds are tabulated in TABLE 4. Compounds V, VII, VIII, and XX, which 
had been prepared previously, but had not been examined by single crystal 
studies. 
All of the nifedipine derivatives previously examined by single crystal X-ray 
diffraction3,46 exhibit a flattened boat conformation of the 1,4-dihydropyridine ring 
with the nitrogen atom at the prow and the phenyl ring in pseudo-axial position at 
the bow. In orde.r to quantify the effect of changes in bulk and length of the ester 
alkyl groups on the general conformation ofthe compounds in this study, specific 
structural parameters were defined. ·. The parameters used were 1) the 
configuration of the ester carbonyl groups as sp or ap and of the phenyl 
substituent as ap or sp, 2) the sum of the internal torsion angles of the DHP ring 
to describe its planarity (SUM), 3) the deviation from orthogonality of the phenyl 
ring with respect to the base of the DHP boat, and 4) the cone angle of the ester 
groups to quantify the space occupied by the alkyl groups. The questions that I 
set out to answer were 1) How does the identity of the ester alkyl groups affect 
the deviation value of the phenyl ring, the planarity of the DHP ring, the 
conformation of the ester groups (ap vs sp) and that of the phenyl substituent (ap 
vs sp) and 2) based on these parameters, how does the identity of the ester alkyl 
group affect the activity? The X-ray parameters determined in this study are 

























Selected X-Ray Parameters for Compounds 1-XXIII 
Conformation of 
C3,C5 Esters a 
ap,sp 
sp,sp 
Conformation of # Carbons In 
Phenyl Ring Ester Alkyl 






























(Viti) Di-isopropyl 2,6-dimethyl-4- ap,sp sp 3 97.2 8.4 48.3 
(3-nitrophenyl)-1,4-dihydro-
pyridine-3,5-dicarboxylate 
(VIV) Dibutyl 2,6-dimethyl-4-(3- ap,sp sp 4 103.4 14.8 52.7 
nitrophenyl)-1,4-dihydro-
pyridine-3,5-dicarboxylate 
(X) Di-isobutyl 2,6-dimethyl-4-(3- sp,sp sp 4 100.97 8.88 56.2 
nitrophenyl)-1,4-dihydro-
pyridine-3,5-dicarboxylate 
(Xl)Dl-lsobutyl 2,6-dimethyl-4-(3- - - 4 24.87 17.19 
nitrophenyl)pyridine-3,5-
dicarboxylate 
(XII) Di-tert-butyl 2,6-dimethyl-4- sp,ap sp 4 73.99 33.71 48.4 
(3-nitrophenyl)-1,4-dihydro-
pyridine-3,5-dicarboxylate 
(XIII) Dipentyl 2,6-dimethyl-4-(3- sp,sp sp 5 90 10.1 70;3 
nitrophenyl)-1,4-dihydro-
pyridine-3,5-dicarboxylate 
(XIV) Di-isopentyl 2,6-dimethyl-4- sp,sp sp 5 102.02 14.035 63.5 
(3-nitrophenyl)-1 ,4-dihydro-
pyridine-3,5-dicarboxylate 
(XV) Di-isopentyl 2,6-dimethyl-4- - - 5 6.33 21.08 
(3-nitrophenyl)pyridine-3,5- . 
dicarboxylate 
























• 0.5 CH3CN 
(XXIII) Ethyl Methyl 2,6-climethyl-
4-(3-nitrophenyl)pyridine-
3,5-dicarboxylate • N03 
sp,ap sp 6 
6 
sp,sp sp 7 
sp,ap sp 8 
sp,sp sp 3 
sp,sp sp 7 
1,2 
99 16.9 60.5 
14.7 21.1 
68.2 5.9 44.2 
103.2 21.8 64.7 
66.2 4.6 61.1 
99.6 8.0 50.0 
6.86 39.07 
a. The ester carbonyl groups of the decomposition products are no longer conjugated with the double bonds of the 
pyridine ring, therefore, they cannot be classified as sp or ap. 
b. The conformation of the phenyl ring substituent is in reference to the hydrogen atom on the DHP ring. In the 
decomposition products, this atom is missing, therefore, this classification can not be made 
c. The sum of the absolute values of the internal torsion angles of the DHP or pyridine ring. 
d. The deviation from orthogonality of the phenyl ring with respect to the base of the DHP boat or pyridine ring. 
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The ester groups can adopt 1 of 4 different conformations, sp,sp; ap,sp; 
sp,ap; or ap,ap. Of the thirteen parent compounds in TABLE 4, three adopt the 
ap,sp conformation, 7 adopt the sp,sp conformation, and 3 adopt the sp,ap 
conformation. It appears that the sp,sp conformation is favored (7/13) in the solid 
state. However, there appears to be no correlation between the size or length of 
the ester groups and their conformation in the X-ray structures. 
The planarity of the DHP ring is described by the sum of the absolute 
values of th~ internal torsion angles of the DHP ring (SUM). As the number of 
carbon atoms increases, the SUM value also increases, i.e. the DHP ring 
becomes less planar. This is a general trend and is not very well obeyed by 
compounds dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxylate (a), VIV (n-butyl)* and XVIV (n-t,eptyl) (Figure 15a). A better 
correlation results if these compounds are not considered (Figure 15b). 
The deviation of the phenyl ring from a perpendicular orientation to the 
base of the DHP ring is described using the C3-C4-C7-C8 torsion angle. The 
. ideal value for this angle of the unoxidized parent compound is 60°. To arrive at 
the deviation value, the absolute value of the C3-C4-C7-C8 angle is subtracted 
from 60. The identity of the ester group appears to have an effect on this 
parameter. As. the number of carbons in the ester alkyl chain increases, the 
deviation value also increases. This is represented graphically in Figure 16. This 
appears to be a general trend, which is not obeyed by compound XVIV, which 
contains a heptyl alkoxy group. This may be explained by the fact that the 
conformation of the ester groups are sp,sp. In the crystal lattice, the phenyl ring 
is flanked on both sides by heptyl chains from another molecule. Therefore, the 
phenyl ring would be forced to lie closer to the plane of bisection. In Figure 16a, 
all compounds in this study are represented. However, a better correlation exists 
* The phrase in parentheses denotes the identity of the ester alkyl chain throughout text. 
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if only linear chain alkoxy groups are considered (Figure 16b). Again, this is not 
well obeyed by the n-heptyl compound. 
The conformation of the ester groups appears to have an effect on the 
deviation value. In the sp conformation the alkyl esterification group is extended 
towards and parallel to the phenyl ring. When both ester groups are oriented 
sp,sp, the phenyl ring is more constricted, and therefore will have a smaller 
deviation value. The deviation values for compounds having the sp,sp 
orientation range from 4.6 to 14.035°, those with one group ap, and one group 
sp, range from 8.4 to 14.8. Thus, the sp,ap conformation seems to cause an 
increase in the deviation value. 
SUM versus Number of carbons (linear chain) 
SUM versus Number of carbons (linear chain) 
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Figure 15: Plots of the SUM value versus the number of carbons in the ester groups. 

















a: Dimethyl 2,6-dimethyl-4-(3-nitroph~nyl)-1,4-dihydropyricine-3,5-dicarboxylate 
b: Dineopentyl 2,6-dimelhyl-4-(3-nitrophenyl)-1,4-clihyctopyridine-3,5-dicarboxylate 
{a) 
Number of Carbons VS Deviation of Phenyl Ring {linear chain) 
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Figure 16: Plots of the deviation value versus the number of carbons in the ester 
alkyl group 
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A parameter that can be used to describe the space occupied by an ester 
alkyl group is the cone angleB6. This is the angle swept out by the extent of the 
van der Waals radii of the group attached to the carboxy oxygen, assuming free 
rotation about the C3-C3' or C5-C5' bonds. These angle are given in TABLE 5. 
The number of carbons in the ester groups (branched and linear chain alike) 
appears to cause an increase in the cone angle parameter. Again, this trend is 
not followed as well by compound XVIV (n-heptyl). This is represented 
graphically in Figure 17. 
Cone Angle versus the Number of Carbons in the ester alkyl chain 
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# of Carbons 
a: Dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-l,4-dihydropyridine-3,5-dicarboxylate 
b. Dineopentyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
Figure 17 : Graph of the Cone Angle versus the number of 
carbons in the ester alkyl group 
The effect of the magnitude of the cone angle on the deviation and SUM 
values was also investigated. The initial hypothesis was that as the cone angle 
increased, the deviation value would decrease. This was a logical conclusion 
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because the phenyl ring should be more restricted as the space occupied by the 
ester alkyl groups increased. This hypothesis was tested by plotting the cone 
angle against the deviation value (Figure 18a). The effect of the cone angle on 
the deviation value is exactly the opposite of that expected. As the cone angle 
increases, the deviation value also increases. However, three compounds do not 
obey this trend well, XIII (n-pentyl), XXI (2-methoxy ethyl) and XII (t-butyl-not 
shown). 
The SUM value was plotted against the cone angle (Figure 18b). There is 
no correlation between these two values, hence, it does not appear that the cone 
angle affects the SUM value in any way. 
Since SAR analysis indicates that as the SUM value increases, activity 
decreases, it would appear that as the number of carbons increases, activity 
should decrease. Similarlyi as the number of carbons increases, the deviation 
value increases, and thus activtiy should decrease. Finally, since the deviation 
value appears to increase.with an increase.in cone angle, it would be logical to 
assume that compounds with large cone angles would display generally lower 
activities. 
Cone Angle versus the Deviation value 
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Cone angle(0 ) 
a: Dimethyl 2,6-climethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-clicarboxylate 
b: Dineopentyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-clihydropyridine-3,5-clicarboxylate 
(a) 
Cone Angle versus the SUM value 
y = 0.967x + 37 .247 
v,v. 






















Structure-activity studies have demonstrated that flattening of the DHP 
boat conformation correlates with increased activity, presumably due to the 
concurrent change in position of the phenyl ring (Figure 9). As previously stated , 
the sum of the internal torsion angles is a measure of the planarity of the DHP 
ring. Published SAR's have indic,ated that as the SUM value decreases, calcium 
















y = 164818.486 * 10 -0.042x 
3• 
4• 
SUM (0 ) 
c::, 
c::, - c::, -- c::, N -
1: Dimethyl 2,6-<fimethyl-4-(2,3,4,5,6-pentaftuorophenyl)-1,4-dihydropyridine 3,5-dcarboxylale 
2: Nifecipine 
3: Dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine 3,5-dicarboxylate 
4: Dimethyl 2,6-dimethyl-4-(3-melhylphenyl)-1,4-dihydropyridine 3,5-dicarboxylate 
5: Dimethyl 2,6-dimelhyl-4-phenyl-1,4-dihydropyridine 3,5-dicarboxylate 
6: Dimethyl 2,6-dimethyl-4-(3-cyanophenyl)-1,4-dihydropyridine 3,5-dicarboxylalB 
Figure 19: Graph of the Activity versus the SUM value 21 
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This information may be used to predict the relative activity of compounds 
in which the activity has not been measured, i.e., compounds with higher SUM 
values should have lower activities. 
The activities of the new compounds prepared in this study were 
estimated using this approach. Using the equation of the line (Figure 19), their 
activities were calculated and then plotted on the same graph (Figure 20). It was 
concluded that compounds V (ethyl), VII (n-propyl), XII (t-butyl), XVIV (n-heptyl), 
and XXI (2-methoxy ethyl) should be relatively active with activity values of; V 
(232), VII (120), XII (129), XVIV (225), and XXI (273). The SUM versus activity 
model predicted that compound VII (isopropyl) should have an activity value of 
13.6, compound XVII (n-hexyl), 11.45, compound XII (t-butyl), 129, and 
compound XX (n-octyl), 7.6. These values· are relative to the activity of 
nifedipine, which is assigned a value of 100. It also appears from this model that 
the identity of the ester group has no effect on activity. 
In order to test these values, four new compounds were submitted for 
activity testing using the method of Bolger et al3B, actual results: VIII (isopropyl 
side chain; 80.6), XII (t-butyl; 3.7), XVII (n-hexyl; 16), and XX (n-octyl; 3.6). 
These values do not correspond with the values predicted from the above model. 
One may also compare the order of activity of the four tested compounds. 
This order is VIII (isopropyl) > XVII (n-hexyl) > XII (t-butyl) - XX (n-octyl). Using 
the above analysis, the order calculated is XII (t-butyl) > VIII (isopropyl} - XVII (n-
hexyl} > XX (n-octyl}. The order is correct except for compound XII (t-butyl}. A 
possible reason for this failure could be that the model was constructed using 
compounds having only methyl alkyl groups on the ester substituents while the 
substituent on the phenyl ring was varied. 
000 Relative Activity versus the SUM value 1 I zo,,;;.: I 
y = 165142.598 * 10 -O.o42x 
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SUM(") 
1: Dtmethyt 2,6-dlmelhyl-4-(2,3,4,5,6-pentafluorophenyl)-1,4-dlhydropyrldlne 3,5-dlcarboxylate 4: Dimethyl 2,6-dlmelhyl-4-(3-melhylphenyl)-1,4-dlhydropyrldlne 3,5-dlcarboxylate 
2: Nlledlplne 5: Dtmethyl 2,6-dlmelhyl-4-phenyl-1,4-dlhydropyrldlne 3,5-dlcarboxylate 
3: Dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine 3,5-dicarboxylate s: Dimethyl 2,6-dlmethyl-4-(3-cyanopheny~-1,4-dlhydropyrldlne 3,5-dlcarboxylate 
Figure 20: Graph of the Relative Activity versus the SUM value of six known 
compounds and the thirteen unoxidized parent compounds of this study 
~ 
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Known SAR's have indicated that as the deviation value decreases, 
activity increases. Therefore, a plot of relative activity versus the deviation value 
was prepared for the same compounds considered in Figure 17 (Figure 21 ). 









x = -8.864LOG(y) + 26.456 
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1: Dimethyl 2,6-<limethyl-4-(2,3,4,5,6-pentaftuorophenyl)-1,4-dihydropyridine 3,S-dicarboxylate 
2: Nifedipine 
3: Dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine 3,5-di(:arboxylate 
4: Dimethyl 2;6-<limethyl-4-(3-methylphehyl)-1.4-dihydropyridine 3,5-dicarboxylate 
5: Dimethyl 2,6-dimethyl-4-phenyl-1,4-dihydropyridine 3,5-dicarboxylate 
6: Dimethyl 2,6-dimethyl-4-(3-<;yanophenyl)-1.4-dihydropyridine 3,5-dicarboxylate 
Figure 21: Graph of Deviation vs Activity of known compounds 
The correlation resulting was not as good as that using SUM value versus 
relative activity. Nevertheless, the graph was used to predict the relative 
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c:, ~ s ~ ~ ~ g ~ i 
Deviation (0 ) 
1: Dimethyl 2,6-dimelhyl-4-(2,3,4,5,6-pentafluorophenyl)-1,4-dihydropyrldine 3,5-dicarboxylat~: Dlrnelhyl 2,8-dlmelhyl-4-(3-methylphenyl)-1,4-dlhydropyrldlne 3,5-dlcarboxylate 
2: Nifedipine 5: Dimethyl 2,6-dimethyl-4-phenyl-1,4-dlhydropyrldlne 3,5-dlcarboxylate 
3: Dimethyl 2,8-dlmelhyl-4·(3-nllrophenyl)-1,4-dlhydropyrldlne 3,5-dlcarboxylate 6: Dimethyl 2,6-dlrnelhyl-4-(3-cyanophenyl)-1,4-dihydropyrldine 3,5-dlcarboxylate 
Figure 22: Graph of the relative activity versus the deviation of the phenyl ring of six 
known compounds and thirteen unoxidized parent compounds from this study. .s 
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activities of the unoxidized compounds in this study (Figure 22). Based on this 
analysis, compounds V (ethyl, 80), VII (n-propyl, 134), VIII (isopropyl, 108.9), 
X (isobutyl, 96.13), XIII (n-pentyl, 70), XVIV (n-heptyl, 208.5), XXI (2-methoxy 
ethyl, 292.2), and XXII (benzyl, 121) should be active. Again, this hypothesis 
was tested using the compounds submitted for activity data. This model 
predicted that compound VIII (isopropyl) should have an activity of 109, however, 
the actual tests show a value of -80. Also, it is known that compounds V (ethyl) 
and XXI (2-methoxy ethyl) have a relative activity of· 80, but the activity versus 
deviation model predicts activities to be 79. 73 and 292~2 respectively. 
The order analysis as above, gives VIII (isopropyl) > XVII (n-hexyl) > XX 
(n-octyl) ... XII (t-butyl), a much more consistent result. Therefore, this model may 
lead to a better order analysis, but not to absolute activity value predictions. 
It appears that the activity is affected by the identity of the ester groups, 
since as the identity of the ester alkyl group increases in the number of carbon 
atoms in the four tested compounds, activity decreases. 
It was concluded that a different combination of these two parameters 
would give a better model, since using each parameter by itself did not appear 
very satisfactory. If the SUM and deviation values are added together, the 
resulting sum describes both the deviation of the phenyl ring and the planarity of 
the DHP ring. This parameter will be termed SUM+Deviation (S+D). If one plots 
the S+D value of the known compounds listed below in Figure 23 against relative 
activity, a different correlation is obtained. 
Sum value plus the Deviation value VS Relative Activities 
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VI - VI r--
1 : Dimethyl 2,6-dimethyl-4-(2,3,4,5,6-pentafluorcphenyl)-1,4-dhydropyridne 3,5-dicarboxylate 
2: Nifedipine 
3: Dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine 3,5-dicarboxylate 
4: Dimethyl 2,6-dimethyl-4-(3-methylphenyl)-t,4-dihydropyridine 3,5-dicarboxylate 
5: Dimethyl 2,6-0methyl-4-phenyl-1,4-dhydrcpyridine 3,5-dicarboxylate 
6: Dimethyl 2,6-dimethyl-4-(3-cyanophenyl)-1,4-dihydropyridine 3,5-dicarboxylate 
7: Dimethyl 2,6-dimethyl-4-(3-bifluorcmethylphenyl)-1,4-dhydropyridine 3,5-dicarboxylate 
8: Dimethyl 2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihycropyricine 3,5-dicarboxylate 
9: Dimethyl 2,6-dimethyl-4-(4-dimethylamino-phenyl)-1,4-dihydropyridine 3,5-dicarboxylate 
Figure 23: Graph of the SUM value + the Deviation value versus the relative 
activities of known compounds 
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Using this new parameter and compounds of known activities, the activity 
of the compounds in this study were calculated. This is represented graphically 
in Figure 24. This model predicted the most active compounds to be XXI (2-
methoxy ethyl), XVIV (n-heptyl), V (ethyl}, and VII (n-propyl). The order analysis 
gave VIII (isopropyl) > XU (t-butyl} > XVII (n-hexyl} > XX(n-octyl). This order is 
correct except for the position of the tertiary butyl derivative. However, testing 
this model with the known compound dimethyl 2,6-dimethyl-4-(2-chlorophenyl}-
1,4-dihydropyridine-3,5-dicarboxylate gave more encouraging results. 
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~ ~ 8 - SUM + Deviation (0 ) 
1 : Dlmelhyl 2,6-dme~(2,3,4,5,6-pentafluorophenyl)-1,4-dhydrOP'fridine 3,&<iccnloxylate 2: Nlfedipine 
~ - c:, 11"1 -
3: Dimethyl 2,6-dimelhyl-4-(3-ni.-ophenyl)-1,4-dihydropyridine 3,5-dicarboxylate 4: Dimethyl 2,6-dmetlyl-4-(3-melhylphenyl)-1,4-dihydropyridine 3,5-dcarbo,cylate 
5: Dlmelhyl 2,6-dimethyl-4-phenyl-1,4-dhydropyridine 3,5-dcarboxylate 6: Dimethyl 2,6-<imef,yl-4-(3-<:yanophenyl)-1,4-dhydropyridine 3,5-dicarboxylale 
7: Dimethyl 2,6-dimelhyl-4-{3-billuoromelhylphenyl)-1,4-dihydropyridine 3,5-dicarboxylate 8: Dimethyl 2,6-dmelhyl-4-{4-nitrophenyl)-1,4-dihydropyridine 3,5-dcarboxylate 
9: DlmMelhyl 2,6-dmelhyl-4-(4-dimef,ylami~phenyl)-1,4-dihydropyridine 3,5-dcarboxylate 
Figure 24: Graph of ,the SUM+Deviation value versus the 
Relative activity of thirteen known compounds and the 
thirteen parent compounds of this work '° VI 
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This compound displays an activity of -150, while the model calculates a 
theoretical activity of 145, very close to the true value. 
The effect of the cone angle on activity was also investigated. A plot of 
the cone angle versus activity of six known compounds (including the four 
compounds in which activity was tested) was graphed (Figure 25). From this 
model it appears that the cone angle does not have a direct effect on activity, 
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1: Dimethyl 2.~methyl-4-(2,3,4,5,6-pentaftuorophenyl)-1,4-dihydropyric:line 3,5-dicarboxylate 
2: Nifecipine 
3: Dimethyl 2,6-dimethyl-4-{3-nilrophenyl)-1,4-dihydropyridine 3,5-dicarboxylate 
4: Dimethyl 2,6-dunethyl-4-(3-melhylphenyl)-1,4-dihydropyridine 3,5-dicarboxylale 
5: Dimethyl 2,6-dmelhyl-4-phenyl-1,4-dihydropyric:line 3,5-dicarboxylale 
6: Dimethyl 2,6-dimelhyl-4-(3-cyanophenyQ-1,4-dihydropyric:line 3,5-clicarboxylate 




In any crystal structure, the molecule under study is affected by the 
packing of neighboring molecules in the crystal lattice. Therefore, it seemed 
logical to assume that the various parameters used in this study(the deviation 
value and SUM) would be affected by the packing of the molecules in the crystal 
lattice. 
One of the continuing arguments in structural biochemistry concerns the 
use of X-ray structures in structure activity relationships, i. e. whether or not the 
X-ray structure reflects the actual conformation in vivo. 
In order to address this issue, the molecular modeling program Discover 
was used to perform energy minimizations on the crystal structures of the thirteen 
parent compounds in the gas and aqueous phases. This program uses the 
expected values for bond lengths and angles to calculate a theoretical 
conformation of lowest energy. All thirteen parent compounds show a SUM 
value of approximately 50 degrees and a deviation value of approximately 60 
degrees in the gas and aqueous phases. Hence, no differences were observed 
to correlate activity with variations in structure. Therefore, the X-ray structures 
were used in all subsequent analyses. 
This has been approached historically by synthesizing rigid analogs which 
hold the structure in a predefined conformation and then examining the activity. 
Conformationally restrained analogs of the 1,4-DHP calcium antagonists60 were 
studied in this way. Baldwin et al synthesized conformationally restricted analogs 
of the 1,4-DHP's where the phenyl ring was held in different positions, which then 
gave different deviation valuesso. Those compounds that exhibited the smallest 
deviation value showed the highest activtiy. Hence, Baldwin et. al. illustrated that 
at least one of the active conformations is that of the X-ray structure. 
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Decomposition Products 
The decomposition products examined in this study are listed in TABLE 4. 
They display many differences when compared to their parent, unoxidized forms. 
The DHP ring has been oxidized to a pyridine ring, which has changed the 
overall conformation (Figure 31 ). Since the pyridine ring is planar, the 4-phenyl 
ring is not in a pseudoaxial position. The C7 and C1 O carbon atoms of the 
phenyl ring are now coplanar with the C4 and N1 atoms of the pyridine ring and 
the phenyl ring is approximately perpendicular to the pyridine ring. Aromatization 
of the 1,4-dihydropyridine ring results in the loss of the hydrogen atom at N1, 
removing any possible hydrogen bonding interaction with the receptor site. 
However, the rotation of the 3,5 ester groups out of conjugation with the pi bonds 
of the ring may permit increased hydrogen bonding to these groups. 
The conformation of the ester groups is changed significantly. In the 
majority of the more than 30 crystal structures of members of the nifedipine 
family, the ester groups are found to be nearly coplanar with the nearest double 
bond in the DHP ring, with the carbonyl group oriented either cis (sp, 
synperiplanar) or trans (ap, antiperiplanar) to that bond3. In nifedipine itself, the 
carbonyls of the ester groups are ap and sp and thus point in opposite directions. 
It is thought that only the sp conformation of the ester group permits hydrogen 
bonding to the carbonyl oxygen atom as an acceptor atom when the drug binds 
to its receptor site25,28. In the decomposition products, the carbonyl groups of 
the esters are no longer coplanar with any double bond in the pyridine ring. This 
could move the ester oxygens out of reach or within reach of possible H-bonding 
with the receptor site. 
In order to observe how these conformational differences between the 
parent compounds and their decomposition products affected the activity, two 
decomposition products were submitted for activity testing. These were 
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compounds I and XXIII, which are decomposition products of nifedipine and 
nitrendipine respectively. These two compounds exhibited no activity. 
Therefore, it could be concluded that the conformational changes arising upon 
decomposition abolish the calcium antagonistic properties of the 1,4-DHP's, and 
that the ester position has significant interaction with the receptor site. 
Receptor Docking Analysis 
Since all drug molecules have specific interactions with their receptors, 
one of the goals of molecular modeling is to elucidate this interaction spatially 
using 3-dimensional models of the receptor and the ligand, and evaluating the 
affinity of the ligand for its receptor. This type of analysis can give insight into the 
different interactions occurring in the receptor-ligand model. The 3-D atomic 
coordinates of the receptor site proposed by Langs et al was used (Figure 12)28. 
The receptor cleft is that between the two Arginine side chains in which the 
phenyl ring is docked. Van der Waals interaction energy was used as a measure 
of the compounds affinity for the receptor site and the number of H- bonds was 
maximized allowing only reasonable H-Bond distances (1.9 - 2.8 A). 
Initially, compounds of known activities were docked at the receptor site to 
ascertain a favorable conformation. This was done using nifedipine, dimethyl 
2, 6-dimethyl-4-(2,3, 4, 5, 6-pe ntaflou rophenyl)-1 ,4-di hyd ropyridi ne-3,5-dicarbox-
ylate (5-F), nitrendipine, nisoldipine, dimethyl 2,6-dimethyl-4-(2-triflouromethyl-
phenyl)-1,4-dihydropyridine-3,5-dicarboxylate (2-CF3), felodipine, dimethyl 2,6-
dimethyl-4-(3-cyanophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (3-CN), and 
dimethyl 2,6-dimethyl-4-( 4-nitrophenyl)-1 ,4-dihydropyridine-3,5-dicarboxylate ( 4-
N02). Each molecule was brought slowly into contact with the receptor cavity as 
in Figure 12. Van der Waals interaction energy was minimized as much as 
possible by altering the position of the molecule. This was continued until a 
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minimum was found which maximized H-bonding of reasonable distances. The 
energy value that results can only be used as a guide to the relative activity, not 
as an indicator of the absolute value. 
The six high activity compounds examined in the docking procedure gave 
interaction energy values in the range of 250 to 3000. This range was then 
considered as favorable. All of these compounds fit into the receptor cavity 
without difficulty, and with no great energy barrier (i.e. did not bump into anything 
before entering the receptor cavity). The number of H-bonds formed ranged from 
1 to 5. The 3-CN compound, which is known to have a low activity, did not fit into 
the receptor without causing a very large increase in interaction energy (106). 
This was due to the large deviation value (36.28°), which caused the cyano group 
on the phenyl ring to bump into one of the arginine side chains protruding from 
the receptor cavity. The 4-N02 compound, also of low activity, could not fit into 
the receptor cavity because of negative interactions with the para-N02 group on 
the phenyl ring. The para-N02 group could not get past side chains extending 
from the receptor without a great increase in energy, therefore, the likelihood of 
this compound binding in the same manner as the high activity compounds 
above was low. This modeling provided information about the possible reasons 
for high or low activity. 
Each of the compounds prepared in this study was modeled in the same 
way. These results are given in TABLE 6 below, which may be compared with 
modeling results of the known compounds. Conclusions were drawn about the 
relative binding affinities of all the compounds in this study. 
The decomposition products displayed interaction energies in the range of 
4.3 x 1 o4 to 1 x 1 O 14. These energies were very high and therefore were not 
considered as indicative of a favorable interaction between the decomposition 
products and the receptor. The number of H-bonds varied for these compounds 
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(0 to 5). The decomposition product that displayed the lowest interaction energy 
was compound Ill. This compound contains carboxylic acid side chains, and 
hence encountered less resistance to binding than the others. All of the other 
decomposition products encountered much more resistance to binding. This 
could be explained from the fact that since the boat shaped DHP moiety is no 
longer present, the position of the ester side chains interfered much more. 
Figure 26 illustrates the binding conformation of the nitroso decomposition 
product of nifedipine, indicated by an arrow. When one compares this to Figure 
12, it can easily be seen how structural changes on decomposition has adversely 
affected the binding process. 
The thirteen parent compounds modeled in this way produced varying 
results. The main goal of this study was to elucidate the effect of the length and 
bulk of the ester side chains, therefore, the modeling was geared towards 
observing the interaction between the different ester side chains and the 
proposed receptor site. 
Compound V, which contains ethyl alkyl groups, showed difficulty in 
binding because the ester group that was in the sp orientation bumped into the 
receptor core. This caused a great increase in interaction energy (6 x 1 o3). 
Compound VII, with sp,sp propyl ester side chains, also displayed the same 
problem. The propyl groups tended to bump into the receptor core. This 
bumping interaction impedes the binding of ooth of these compounds. Other 
compounds with straight chain ester groups, compounds VIV (n-butyl), XIII (n-
pentyl), XVII (n-hexyl), XVIV (n-heptyl) and XX (n-octyl) also display this problem. 
This adverse interaction appeared to be associated with the orientation of the 
ester groups. The ester orientation that seemed the most favorable for H-
bonding interactions is sp, which allowed the most H-bonding to the arginine side 
chains from the keto oxygens. However, as the alkyl chain length increases, this 
102 
orientation becomes disadvantageous, because the ester groups hit the receptor 
core before binding can occur. Therefore, it would seem logical to conclude that 
the methyl side chains are optimum, if both esters contain the same alkyl group. 
It has been reported in the literature that unsymmetrically substituted 1,4-
DHP's are more active. This was observed in the modeling of the known 
compounds given in TABLE 6. Compounds 5-F and 2-CF3 are symmetrically 
substituted with methyl ester groups, only the phenyl substituents were varied. In 
the docking of these two compounds, there was no interference from the ester 
side chains. One H-bond was formed with each compound to the arginine side 
chain of the receptor, both times. to the sp oriented ester. Nitrendipine, which 
contains an ethyl ester and a methyl ester, had a higher energy, but formed more 
H-bonds, involving both of its ester groups. Nisoldipine, which contains an 
isobutyl and a methyl ester, displayed one of the lowest binding energies. This 
was attributed to the fact that the isobi.Jtyl ester group was oriented ap, and 
therefore did not interfere with the binding process. The methyl ester was sp, 
which formed a H-bond from its keto oxygen to one of the arginine side chains. 
The effect on the binding process of branching the ester alkyl groups was 
investigated. Compound VIII (isopropyl), had a much lower interaction energy 
than its straight chain counterpart. In the docking of this compound, branching in 
the isopropyl group did appear to be advantageous. As this compound was 
brought towards the receptor site, the isopropyl groups did not interfere, and 
once the compound was in its optimal binding position, an H-bond was formed 
between its sp ester and one of the arginine side chains. This favorable 
interaction suggests that this compound should have a relatively high activity 
(interaction energy : -1500). Compound X (isobutyl) did not display such 
favorable interactions. Both ester groups are oriented sp, which caused the 
102 
orientation becomes disadvantageous, because the ester groups hit the receptor 
core before binding can occur. Therefore, it would seem logical to conclude that 
the methyl side chains are optimum, if both esters contain the same alkyl group. 
It has been reported in the literature that unsymmetrically substituted 1,4-
DHP's are more active. This was observed in the modeling of the known 
compounds given in TABLE 6. Compounds 5-F and 2-CF3 are symmetrically 
substituted with methyl ester groups, only the phenyl substituents were varied. In 
the docking of these two compounds, there was no interference from the ester 
side chains. One H-bond was formed with each compound to the arginine side 
chain of the receptor, both times to the· sp oriented ester. Nitrendipine, which 
contains an ethyl ester and a methyl ester, had a higher energy, but formed more 
H-bonds, involving both of its ester. groups. Nisoldipine, which contains an 
isobutyl and a methyl e~ter, displayed one of the lowest binding energies. This 
was attributed to the fact that the isobutyl ester group was oriented ap, and 
therefore did not interfere with the binding process. The methyl ester was sp, 
which formed a H-bond from its keto oxygen to one of the arginine side chains. 
The effect on the binding process of branching the ester alkyl groups was 
investigated. Compound VIII (isopropyl), had a much lower .interaction energy 
than its straight chain counterpart. In the docking of this compound, branching in 
the isopropyl group did appear to be advantageous. As this compound was 
brought towards the receptor site, the isopropyl groups did not interfere, and 
once the compound was in its optimal binding position, an H-bond was formed 
between its sp ester and one of the arginine side chains. This favorable 
interaction suggests that this compound should have a relatively high activity 
(interaction energy : -1500). Compound X (isobutyl) did not display such 
favorable interactions. Both ester groups are oriented sp, which caused the 
Figure 26: Nitroso Decomposition Product of Methyl 2,6-dimethyl-4-(2-
nitrophenyl)-1 ,4-dihydropyridine-3,5-dicarboxylate (Nifedipine) 
docked in Proposed Receptor Site 
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interaction energy (1010) to be great. The position of both side chains impeded 
the approach of the molecule and hence precluded the formation of any H-bonds. 
Thus, compound X should not display a very high affinity for the receptor. 
Compound XII (t-butyl), encountered a different kind of problem on docking. Its 
106 
large deviation value (33. 71 °) impeded its approach to the receptor site and 
caused a high interaction energy (1 o4). Therefore, this may explain why the 
deviation of the phenyl ring is important, i.e. lack of orthogonality interferes with 
the approach of the molecule to the receptor site. Compound XIV (isopentyl) 
encountered the same problem as the isobutyl derivative (X}. Since both ester 
groups were oriented sp, approach to the receptor site was practically impossible 
without hitting the extending arginine side chains. The interaction energy was far 
too great to suspect any activity for this compound. Therefore, it can be 
concluded that branching of the side chains normally has a adverse effect on the 
binding process. However, this conclusion is dependent on the orientation of the 
ester groups. Interaction energy is less if one of the ester groups is oriented sp, 
and the other ap. When both esters are sp, approach to the receptor site is 
greatly impeded. 
The ability of this model to predict relative activities was also tested using 
the four compounds submitted for activity analysis. The order given from the 
activity study was isopropyl >> n-hexyl >> t-butyl -n-octyl; Based on the 
interaction energies obtained from the modeling study described above, the order 
is also isopropyl (1534) >> n-hexyl (23256) >> t-butyl (107) -n-octyl (1010) 
(TABLE 6). This order can be explained by the docking interactions encountered 
for each individual compound. 
Compound VIII, which contains isopropyl ester groups is seen to slide 
easily underneath the two arginine side chains (Figure 27). Also, the low 
deviation value (nearly ideal bisection of the DHP ring) allows this compound to 
enter the receptor site without any great energy barrier. The interaction energy 
for this compound is 1534. 
Compound XVII, which contains n-hexyl ester substituents has an 
interaction energy of 23256. This high interaction energy arises from the " 
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bumping" of the hexyl side chain into the receptor core. This adverse interaction 
occurs only for the side chain that is oriented sp (Figure 28). The ap ester group 
does not interfere with the binding of this molecule. The high interaction energy 
precludes great activity on this compounds part. Compound XX, with the octyl 
ester alkyl groups is known to have a lower activity than that of the n-hexyl 
derivative. The n-octyl derivative has two more carbon atoms in its alkyl side 
chain that interfere to a greater extent than that of the n-hexyl alkyl side chains 
(Figure 29). This is indicated by the much greater interaction energy observed 
for this compound (1010). 
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Figure 27- Di-isopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxylate(VIII) docked in proposed receptor site 
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Figure 28 - Dihexyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxylate(VIII) docked in proposed receptor site 
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Figure 29- Dioctyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxylate(VIII) docked in proposed receptor site 
Figure 30 - Di-tert-butyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-




The questions to be addressed in this thesis were 1 ) How does the identity 
of the ester alkyl group affect the deviation of the phenyl ring, the planarity of the 
DHP ring, and the conformation of the esters (ap vs sp) and 2) based on these 
parameters, how does the identity of the ester alkyl group affect activity? 
Moreover, the conformational changes associated with decomposition to the 
nitro-pyridine derivatives and their potential effects on the calcium antagonistic 
activity of these compounds was investigated. 
It appears the identity of the ester alkyl group has an effect on most of the 
significant parameters. The deviation value increases with the number of carbon 
atoms. It has been shown that as the number of carbon atoms in the chain 
increases, activity decreases. The SUM value is affected in the same manner by 
the length of the carbon chain. It has been shown that as the length of the ester 
group increases, the SUM increases and activity decreases. The cone angle, 
which is a reflection of the primary, secondary or tertiary character of the 
esterification group demonstrates the opposite effect of that expected. The initial 
hypothesis was that as the cone angle increased, the deviation value would 
decrease, due to increased bulk of neighboring groups. However, most bulky 
esterification groups exhibit ap, sp conformation of the ester groups and the 
phenyl ring tilts away from the bulk of the sp ester group, and thus the deviation 
value increases. This conclusion agrees with the fact that as the ester alkyl 
groups size increases, the deviation value increases and activity c.fecreases. 
Based on the molecular modeling analysis of the receptor-ligand complex, 
the general trend is that increasing the alkyl chain length causes a decrease in 
binding affinity due to increased repulsive interactions. Branching in the ester 
alkyl group decreases this repulsion, but only if the number of carbons is below 
three. One of the compounds prepared in this study, di-isopropyl 2,6-dimethyl-4-
113 
(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (VIII), exhibited an activity 
value comparable to the high activity compound nitrendipine . 
-Figure 31: Projection view of Methyl 2,6-dimethyl-4-(2-nitrosophenyl)-pyridine-3,5-dicarboxylate(I) -~ 
TABLE 7 
CRYSTAL DATA FOR 
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Dimethyl 2,6-dimethyl-4-(2-nitrosophenyl)-pyridine-3,5-dicarboxylate (I) 
-----------------------------------------------------------------------------------------------------------
Formula C17H15N205' 
M.W. 328.3 g mole-1 
.s 18.171(4) A 
12 7.157(1) A 
' 26.165(5) A a 90.0° 
13 90.2 (1)0 
'Y 90.0° 
V 3402.6(13) A3 
F(OOO) 1376 
µMo Ka 11.28 cm-1 
A.Mo Ka o.71069 A 
Deale 1.282 g/cm3 
z 8 
Meas refl 7522 




Space Group P21/c 
Octants meas -1 sh s 19, -1 s ks 8, -31 s Is 31 
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TABLE 8 
POSITIONAL PARAMETERS FOR 
Dimethyl 2,6-dimethyl-4-(2-nitrosophenyl)-pyridine-3,5-dicarboxylate (I) 
------------------------------------------------------------------------------------------------------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 0.2852(3) -0.1787(8) 0.0848(2) 
C2 0.3300(3) -0.0918(10) 0.0523(2) 
C2' 0.3326(3) -0.1806(9) 0.0005(2) 
C3 0.3726(3) 0.0585(10) 0.0668(2) 
C3' 0.4241(4) 0.1545(10) 0.0296(3) 
03' 0.4883(2) 0.1801 (8) 0.03731 (15) 
03" 0.3876(2) 0.2127(8) -0.0108(2) 
C3" 0.4316(4) 0.2938(11) -0.0510(2) 
C4 0.3715(3) 0.1225(9) o.11n(2) 
cs 0.3225(3) 0.0309(9). 0.1508(2) 
CS' 0.3181 (3) 0.0904(11) 0.2059(3) 
CS" 0.2796(3) 0.3342(9) 0.2607(2) 
05' 0.3384(3) -0.0012(8) 0.2409(2) 
05" 0.2867(2) 0.2539(7) 0.2100(2) 
C6 0.2818(3) -0.1207(10) 0.1329(3) 
C6' 0.2298(3) -0.2199(9) 0.1683(2) 
C7 0.4183(3) 0.2808(10) 0.1360(2) 
ca 0.3990(3) 0.4600(10) 0.1288(2) 
cs 0.4400(4) 0.6035(10) 0.1489(2) 
C10 0.5028(4) 0.5665(10) 0.1773(3) 
C11 0.5239(3) 0.3854(10) 0.1846(2) 
C12 0.4830(3) 0.2433(10) 0.1639(2) 
N2 0.5020(3) 0.0504(9) 0.1690(2) 
01A 0;5649(17) 0.0186(33) 0.1865(14) 
018 0.5550(22) 0.0264(41) 0.1929(15) . 
N91 0.0632(4) 0.2394(8) -0.0383(2) 
C92 0.0034(4) 0.3288(10) -0.0554(2) . 
C92' -0.0674(3) 0.2501 (9) -0.0354(2) 
C93 0.0064(3) 0.4696(10) -0.0901 (2) 
C93' -0.0625(4) 0.5461 (12) -0.1138(3) 
C93" -0.1711 (14) . 0.7197(44) -0.1023(9) 
C93X -0.1492(19) 0.7960(49) -0.1132(12) 
093' -0.0845(2) 0.5016(7) -0.1544(2) 
093" -0.0903(33) 0.6592(75) -0.0784(15) 
093X -0.1004(29) 0.6788(61) -0.0900(14) 
C94 0.0739(4) 0.5358(10) -0.1080(2) 
C95 0.1370(4) 0.4472(10) -0.0896(2) 
------------------------------------------------------------------------------------------------------------
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TABLE 8 {Continued) 
------------------------------------------------------------------------------------------------------------
C95' 0.2129{5) 0.4977(14) -0.1100(3) 
C95" 0.2871 (4) 0.7447(12) -0.1359(2) 
095' 0.2583(3) 0.3847(10) -0.1222(2) 
095" 0.2208(3) 0.6802(9) -0.1111 (2) 
C96 0.1295(4) 0.2991 (11) -0.0556(2) 
C96' 0.1932(4) 0.1850(12) -0.0359(2) 
C97 0.0749(3) 0.6917(10) -0.1452(2) 
C98 0.0605(4) 0.8694(11) -0.1304(3) 
C99 0.0592{4) 1.0135(10) -0.1652(3) 
C910 0.0735(3) 0.9826(10) -0.2163(3) 
C911 0.0855(3) 0.8038(10) -0.2323(2) 
C912 0.0881 (3) o.65n(10) -0.1976(2) 
N92 0.1012(3) 0.4688(9) -0.2111 (2) 
091 0.1145(3) 0.4430(7) -0.2563(2) 
H2'A 0.2992(3) -0.2845(9) -0.0009(2) 
H2'B 0.3184(3) -0.0894(9) -0.0246(2) 
H2'C 0.3816(3) -0.2232(9) -0.0065(2) 
H3"A 0.4013(4) 0.3286(11) -0.0796(2) 
H3"B 0.4534(4) 0.4038(11) -0.0364(2) 
H3"C 0.4698(4) 0.2108(11) -0.0623(2) 
H5"A 0.2565(3) 0.4549(9) 0.2607(2) 
H5"B 0.2509(3) 0.2492(9) 0.2809(2) 
H5"C 0.3282(3) 0.3442(9) 0.2749(2) 
H6'A 0.2309(3) -0.1661 (9) 0.2019(2) 
H6'B 0.1810(3) -0.2104(9) 0.1544(2) 
H6'C 0.2439(3) -0.3490(9) 0;1702(2) 
H8A 0.3566(3) 0.4898(10) 0.1084(2) 
H9A 0.4253(4) 0.7314(10) 0.1444(2) 
H10A 0.5324(4) 0.6652(10) 0.1913(3) 
H11A 0.5666(3) 0.3580(10) 0.2050(2) 
H92'D -0.0593(3) 0.1506(9) -0.0114(2) 
H92'E -0.0941 (3) 0.3491 (9) -0.0190(2) 
H92'F -0.0955(3) 0.2041 (9) -0.0639(2) 
H93"D -0.1942(14) 0.8002(44) -0.0778(9) 
H93"E -0.1573(14) 0.7912(44) -0.1318(9) 
H93"F -0.2049(14) 0.6232(44) -0.1123(9) 
H93A -0.1680(19) 0.8804(49) -0.0879(12) 
H93B -0.1310(19) 0.8659(49) -0.1418(12) 
H93C -0.1879(19) 0.7142(49) -0.1245(12) 
H95"A · 0.2873(4) 0.8787(12) -0.1375(2) 
H95"B 0.3288(4) 0.7027(12) -0.1164(2) 
H95"C 0.2898(4) 0.6946(12) -0.1699(2) 
H96'H 0.1732{4) 0.0877(12) -0.0149(2) 
H96'1 0.2207(4) 0.1304(12) -0.0635(2) 
H96'J 0.2252(4) 0.2626(12) -0.0158(2) 


















ANISOTROPIC THERMAL PARAMETERS FOR 
Methyl 2,6-dimethyl-4-(2-nitrosophenyl)-pyridine-3,5-dicarboxylate(I) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U23 U13 U12 
----------------------------------------------------------------
N1 38(3) 68(4) 78(4) -9(4) -4(3) -1 (3) 
C2 34(4) 53(5) 70(5) -13(4) -12(4) 10(4) 
C2' 62(4). 111(7) n(S) · -19(5) -17(4) 10(5) 
C3 35(4) 62(5) 63(4) 4(4) -5(3) 6(4) 
C3' 67(5) 78(6) 53(4) -1(4) 12(4) 14(5) 
03' 50(3) 139(5) 74(3) 0(3) 5(3) -7(4) 
03" 68(3) 147(5) 74(3) 34(4) 1(3) 8(4) 
C3" 99(6) 181(10) 88(5) 17(7) 2(5) 10(7) 
C4 36(4) 68(5) 62(4) 4(4) -11 (3) 9(4) 
cs 40(4) 48(5) 54(4) 1(4) -7(3) 7(4) 
cs· 35(4) 64(6) 62(5) -1(5) 0(3) 2(4) 
CS" 98(6) 102(7) 86(5). -38(5) 12(4) -5(5) 
05' 133(4) .138(6) 74(3) 32(4) -10(3) 58(4) 
05" 81(3)· 67(4) 63(3) -7(3) -1 (3) 10(3) 
C6 41(4) 51(5) 73(5) 14(4) 7(4) 5(4) 
C6' n(S) 91(6) 106(5) 13(5) 3(4) -18(5) 
C7 33(4) 50(5) 59(4) -2(4) -1 (3) 5(4) 
CB 41(4) 50(5) · 83(5) 0(4) -12(3) 4(4) 
C9 61(5) 53(5) 111 (6) -8(5) -2(4) 9(5) 
C10 55(5) 55(6) 101 (5) -14(5) 0(4) -9(5) 
C11 . 47(4) 55(5) 87(5) -2(4) -11 (4) -3(4) 
C12 . 50(4) 43(5) 67(4) 3(4) · 1 (3) 3(4) 
N2 65(5) 63(5) 113(5) 8(4) -34(4) 13(4) 
01A 54(12) 46(12) 244(28) -26(14) -92(13) 8(9) 
018 113(23) 146(23) 208(25) 85(18) -81 (18) 33(16) 
N91 92(5) .70(5) 51(3) 16(3) 2(4) 7(4) 
C92 80(5) 61(5) 40(4) 3(4) 10(4) 0(5) 
C92' 92(5) 100(7) 67(4) 23(5) 2(4) -9(5) 
C93 58(4) 63(5) 34(3) 7(4) 3(3) 4(4) 
C93' 60(5) n(6) 48(5) -3(5) -2(4) -14(5) 
C93" 89(18) 120(25) 79(15) -11 (16) -49(15) 59(18) 
C93X 139(25) 130(31) 156(22) 43(18) 48(18) 10(20) 
093' "63(3) 140(5) 63(3) -24(3) -13(2) 2(3) 
093" 95(12) 186(24) 91(27) -37(20) -41 (20) 93(13) 
-------------------------------------------------------------------------------------------------------
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TABLE 9 (Continued) 
--------------------~---------------- .. -----------------------
093X 139(33) 100(15) 31(7) -28(8) -59(11) 55(16) 
C94 65(5) 59(5) 37(4) -4(4) 2(4) 9(4) 
C95 66(5) 73(6) 37(4) 9(4) 5(4) 0(5) 
C95' n(7) 94(8) 57(5) 14(6) -15(5) -5(7) 
C95" 98(6) 221 (12) 95(6) 40(7) -4(5) -41(8) 
095' 91(4) 171 (7) 117(4) 0(4) 26(3) 48(4) 
095" 54(3) · 123(5) 91(4) 7(4) 8(3) -12(4) 
C96 78(5) 77(6) 49(4) 14(4) -9(4) 30(5) 
C96' 102(6) 209(11) 88(5) 55(6) 5(5) 50(7) 
C97 48(4) 50(5) 52(4) 4(4) 2(3) 1 (4) 
C98 101 (6) 66(6) 56(4) 7(5) 0(4) 9(5) 
C99 110(6) 62(6) 69(5) -9(5) 12(5) 6(5) 
C910 82(5) 54(6) 68(5) 14(4) -2(4) -6(5) 
C911 68(5) 61(5) 53(4) 14(4) -3(4) -11 (5) 
C912 47(4) 48(5) 58(4) -1 (4) -3(3) 4(4) 
N92 86(4) 70(5) 55(3) 1 (4) 8(3) 7(4) 
091 39(4) 96(4) 60(3) -11 (3) 23(3) 8(4) 
----------------------------------------------------------------------------------------------------------
The anisotropic displacement exponent takes the form: 
-2x2(h2a•2u11 + ... + 2hka*b*U12) 
TABLE 10 
BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 


































































































































































































































































TORSION ANGLES (0 ) FOR 







































































































































































































Figure 32: Projection view of Bis(2,6-dimethyl-3,5-dicarbomethoxy-4-(2-nitrophenyl)-pyridine)dichloro-copper(JI)(II) -"" VI 
TABLE 12 





Formula C34 H32 Cl2 Cu N4 012 
M.W. 823.1 g mole·1 
a 13.184(3) A 
.t2 7.768(2) A 
~ 17.736(4) A 
(X 90.0 ° 
J3 91.5 (3)0 
y 90.0 ° 
V 1815.5(7) A3 
F(OOO) 846 
µMo Ka 11.28 cm·1 
A.Mo Ka o.71069 A 
Deale 1.506 g/cm3 
z 2 
Meas refl 4231 




Space Group P211n 
Octants meas -1 s; h S15, -1 s; ks; 9, -21 s; Is; 21 
TABLE 13 





























































































































































TABLE 13 (Continued) 
03' -0.0697(6) - -0.191 (1) -0.3368(4) 
C3' -0.1103(8) -0.094(1) -0.2959(5) 
C3" -0.2676(8) -0.15(1) -0.3562(7) 
H3"A · -0.3375 -0.1159 -0.3540 
H3"B -0.2429 -0.1266 -0.4056 
H3"C -0.2618 -0.2708 -0.3458 
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TABLE 14 




ATOM U11 U22 U33 U23 U13 U12 
------------------------------------------------------------------------------------------------------------
N1 38(3),. 68(4) 78(4) -9(4) -4(3) -1(3) 
Cu1 41 (1) 56(1) 25(1) 1 (1) 0(1) 2(1) 
Cl1 55(2) 94(2) 49(1) 24(1) 2(1 4(1) 
N1 26(3) 56(5) 35(4) 0(3) -1 (3) -9(4) 
C2 39(4) 42(7) 39(5) 9(4) 12(4) -2(4) 
C2' 65(6) 64(7) 32(5) · -20(5) 3(4) 0(5) 
C3 43(4) 43(5) 32(4) 0(5) 6(3) -4(5) 
C4 46(5) 56(7) 33(5) 6(5) 6(4) 4(5) 
cs 44(5) 36(6) 32(5) -1(4) 2(4) 4(4) 
CS' 68(7) 49(7) 39(6) 4(5) 5(5) -3(5) 
CS" 121(10) 116(11) 83(10) -68(9) 15(8) 7(8) 
05' 42(8) 65(5) 79(6) 2(5) 31 (5) 5(5) 
05" 73(5) 82(5) 63(5) -21 (4) 22(4) 3(4) 
cs 36(5) 58(6) 32(5) 2(5) 0(4) -4(5) 
C6' 72(7) 63(7) 44(6) -7(6) -7(5) 1(5) 
C7 61(6) 59(7) 25(5) -18(5) 15(4) -1 (5) 
CB 78(8) 76(8) 48(7) -14(7) -18(5) 23(6) 
C9 87(9) 90(10) 83(10 -5(8) -28(7) 32(8) 
C10 151(13) 112(12) 33(7) -49(11) -1 (8) 6(8) 
C11 122(11) . 83(9) 40(7) -23(9) 16(6) -14(6) 
C12 66(7) 75(8) 38(6) -3(6) -4(5) 6(6) 
N2 161 (17) 133(16) 94(13). -37(12) -34(12) 20(11) 
01 150(12) 171 (13) 215(19) 3(11) 50(14) -9(15) 
02 142(9) 241 (15) 168(13) 29(10) 63(9) -64(11) 
03" 58(4) 98(6) 63(5) -14(4) -9(4) -27(4) 
03' 95(6) 104(6) 63(5) 12(5) --11(4) -41(5) 
C3' 52(6) 66(7) 32(6) -13(6) 1 (4) -2(5) 
C3" 70(8) 151(13) 87(9) -27(8) -23(6) -48(9) 
------------------------------------------------------------------------------------------------------------
The anisotropic displacement exponent takes the form: 
-2x2(h2a•2u11 + ... + 2hka*b*U12) 
TABLE 15 






































































































































































CL 1-CU 1-N1-C6 
CL 1-CU1-N1-C2 
CL1A CU1-N1-C6 



























































































































Figure 33: Projection view of 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl}-pyridine • NOa • H20(III) I.H 
TA~LE 17 
CRYSTAL DATA FOR 
2,6-Dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)pyridine • N03 • H20 (Ill) 
134 
------------------------------------------------------------------------------------------------------------
Formula C1sH15N301 o 
M.W. 397.3 g mole·1 
a 8.8130(1 o) A 
.t2 9.5970(1 o) A 
k 12.805(2) A 
a 70.120(0) 0 
p 84.450(0) 0 
'Y 67.870(0) 0 
V 942.9(3) A3 
F(OOO) 412 
µMo Ka 11.28 cm·1 
A.Mo Ka o.71069 A 
Deale 1.399 g/cm3 
z 2-
Meas refl 3002 
Obs refl 1318 
R 5.00 o/o 
Rw 6.11 % 
G.0.F. 1.29 
Space Group P-1 
Octants meas -1 s h s 9, -9 s k s 9, -13 s I s 13 
135 
TABLE 18 
POSITIONAL PARAMETERS FOR 
2,6-Dimethyl-3,5-dicarboxylate-4-{3-nitrophenyl)-pyridine • N03 • H20 {Ill) 
------------------------------------------------------------------------------------------------------------
ATOM X(SIG(X)) Y(SIG{Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 0.2679(5) 0.7168(4) 0.5523{3) 
C2 0.2494(6) 0.6386(5) 0.6613{4) 
C2' 0.2589{7) 0.4669{5) 0.6895(4) 
C3 0.2227{6) 0.7183(5) 0.7389{4) 
C3' 0.1893(9) 0.6343(6) 0.8575(5) 
03' 0.503{6) 0.6445{5) 0.8880(3) 
03" 0.3232{5) ·o.5486(4) 0.9229{3) 
C4 0.2149{6) 0.8788{5) 0.7039{4) 
cs 0.2311 (6) 0.9545{5) 0.5887(4) 
CS' 0.2310(7) 1.1258(6) 0.5471 (4) 
05' 0.3349(5) 1.1594(4) 0.5783(3) 
05" 0.1061 (5) 0.12274(4) 0.4755(3) 
cs 0.2578(6). 0.8737(6) 0.5117(4) 
CS' 0.2799(7) 0.9420(6) 0.3882(4) 
C7 0.1833(6) 0.9670(5) 0.7869(4) 
CB 0.0483(7) 1.1132(6) 0.7700(4) 
C9 0.163(8) 1.1934(6) 0.8470(5) 
C10 0.1186(9) 1.1334(7) 0.9421 (5) 
C11 0.2512(8) 0.9899(7) 0.9579(4) 
C12 0.2869(7) 0.9063(6) 0.8820{4) 
N2 0.3609(9) 0.9208(8) 1.0592(4) 
N3 0.2996(7) 0.4818(6) 0.3743(4) 
01 0.3282(8) 0.9913(7) 1.1268(4) 
02 0.4763(9) 0.8000(8) 1.0727(5) 
03 0.3692(6) 0.3788(5) 0.3271 (3) 
04 0.3753(6) 0.5549(5) 0.3962(4) 
05 0.1510(6) 0.5088(4) 0.4032(3) 
06 0.2618(6) 0.3899(5) 1.1216(3) 
H1A 0.2869 0.6719 0.4808 
H2'A 0.2792 0.4385 0.6231 
H2'B 0.3467 0.3964 0.7432 
H2'C 0.1574 0.4584 0.7193 
H2'D* 0.2242 0.4492 0.7699 
H2'E* 0.3739 0.3916 0.6383 
H2'F* 0.1987 0.4320 0.6352 
H3"8 0.2895 0.4731 1.0162 





















































*Disorder of methyl hydrogens on C2' and C6' 
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TABLE 19 
ANISOTROPIC THERMAL PARAMETERS FOR 
2,6-Dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-pyridine • N03 • H20 (Ill) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U23 U13 U12 
------------------------------------------------------------------------------------------------------------
N1 54(3) 46(3) 47(3) -16(2) -4(2) -18(2) 
C2 48(4) 47(3) 53(4) -13(3) -4(3) -18(3) 
C2' 94(5) 49(3) . 68(4) -33(3) 9(3) -29(3) 
C3 44(3) 41 (3) 44(3) -10(3) 0(3) -16(3) 
C3' 77(5) · 41 (3) 54(4) -20(3) -5(4) -18(3) 
03' 84(4) 109(4) 73(3) -44(3) 20(3) -24(2) 
03" 93(3) 69(3) 61 (3) -28(2) -11 (2) 0(2) 
C4 45(3) 39(3) 46(3) -11 (3) -3(3) -14(3) 
cs 41(3) 37(3) 52(3) -13(2) -4(3) -14(3) 
CS' -50(4) 47(3) 51(3) -14(3) -2(3) -11 (3) 
05' 80(3) 60(2) 88(3) -36(2) -31 (2) -10(2) 
05" 68(3) 43(2) 101 (3) -18(2) -29(2) -1(2) 
C6 43(4) 50(3) 50(3) -15(3) -5(3) -18(3) 
C6' 68(4). . 67(4) 43(3) -26(3) 0(3) -18(3) 
C7 58(4) 40(3) 51(3) -18(3) 3(3) -18(3) 
C8 69(4) 45(3) 68(4) -14(3) 0(3) -26(3) 
C9 85(5) 58(4) 75(4) -21 (3) 10(4) -37(3) 
C10 105(5) 64(4) 64(4) -44(4) 22(4) -37(3) 
C11 89(5) 65(4) 45(3) -38(4) -1(3) -22(3) 
C12 66(4) 50(3) 51 (3) -20(3) -7(3) -11 (3) 
N2 133(6) 103(5) 50(4) -54(4) -12(4) -23(4) 
N3 68(4) 56(3) 63(3) -21 (3) -1 (3) -22(3) 
01 203(7) 173(5) 72(3) -65(5) -18(4) -65(4) 
02 213(7) 130(5) 109(4). 17(5) -97(5) -40(4) 
03 110(4) 90(3) 86(3) -32(3) 4(3) -56(3) 
04 108(4) . 110(4) 125(4) -62(3) 25(3) -76(3) 
05 67(3) 53(2) 104(3) -15(2) -3(3) -11 (2) 
06 149(4) 134(4) 48(2) -95(4) -7(2) -7(2) 
------------------------------------------------------------------------------------------------------------
The anisotropic displacement exponent takes the form: 
-2x2(h2a•2u11 + ... + 2hka*b*U12) 
TABLE 20 
BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 
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TORSION ANGLES (0 ) FOR 






























































































Figure 34: Projection view of Methyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-pyridine(IV) -~ 
TABLE 22 
CRYSTAL DATA FOR 
141 
Dimethyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate (IV) 
Formula C11H1sN20s 
M.W. 344.3 g mole-1 
a 11.598(1) A 
.b 14.526(1) A 
' 10.s12(1) A a 90.0° 
f3 111.500(10) 0 
'Y 90.0 ° 
V 1663.4(2) A3 
F(OOO) 720 
µMo Ka 11.28 cm-1 
)i.MoKa 0.11059 A 
Deale 1.375 g/cm3 
z 4 
Meas refl 2068 
Obs refl 1173 
R 4.71 % 
Rw 6.48% 
G.0.F. 1.53 
Space Group P21/c 




POSITIONAL PARAMETERS FOR 
Dimethyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate (IV) 
------------------------------------------------------------------------------------------------------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 0.0313(3) 0.3562(3) -0.1119(4) 
C2 0.0916(4) 0.3135(3) 0.0056(5) 
C2' 0.0462(4) 0.2193(3) 0.0210(5) 
C3 0.1916(4) 0.3545(3)· 0.1072(4) 
C3' 0.2482(4) 0.3098(3) 0.2434(5) 
C3" 0.3750(5) . 0.1882(4) 0.3673(5) 
03' 0.2351 (3) 0.3364(3) 0.3431 (4) 
03" 0.3165(3) 0.2368(2) 0.2403(3) 
C4 0.2343(4) 0.4406(3) 0.0850(5) 
cs 0.1737(4) 0.4823(3) -0.0402(5) 
CS' 0.2280(5) 0.5664(3) -0.0759(4) 
CS" 0.1944(5) . 0.7212(3) -0.1478(5) 
05' 0.3291(3) 0.5691 (2) -0.0811 (3) 
05" 0.1515(3) 0.6378(2) -0.1037(3) 
C6 0.0697(4) 0.4390(3) -0.1358(4) 
C6' -0.0011 (4) 0.4811 (3) -0.2698(5) 
C7 0.3431 (4) 0.4843(3) 0.1893(4) 
CB 0.3354(4) 0.5711 (3) 0.2391(5) 
C9 0.4366(5) 0.6113(4) 0.3342(5) 
C10 0.5496(5) 0.5670(4) 0.3815(5) 
C11 0.5555(4) 0.4811 (4) 0.3320(5) 
C12 0.4559(4) 0.4384(3) 0.2378(5) 
N2 0.6741 (5) 0.4315(5) 0.3812(5) 
01 0.7693(4) 0.4763(4) 0.4279(5) 
02 0.6703(4) 0.3476(4) 0.3695(5) 
H2'A -0.0233 0.2030 -0.0587 
H2'B 0.1123 0.1761 0.0339 
H2'C 0.0220 0.2179 0.0983 
H3"A 0.4222 0.1374 0.3539 
H3"8 0.4290 0.2292 0.4339 
H3"C 0.3122 0.1655 0.3982 
H5"A 0.1341 0.7695 -0.1643 
H5"8 0.2707 0.7404 -0.0789 
H5"C 0.2083 0.7081 -0.2298 
H6'A -0.0676 0.4410 -0.3208 


























ANISOTROPIC THERMAL PARAMETERS FOR 
Dimethyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate (IV) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U12 U13 U23 
------------------------------------------------------------------------------------------------------------
N1 53(2) 52(3) 55(3) -7(2) 16(2) -3(2) 
C2 52(3) 49(3) 55(3) -4(3) 21 (3) -2(3) 
C2' 76(3) 71 (4) 77(4) -16(3) 26(3) 5(3) 
C3 52(3) 47(3) 43(3) 4(3) 16(3) 6(3) 
C3' 57(3) 43(3) 56(4) -3(3) 27(3) -3(3) 
C3" 117(4) 70(4) 68(4) 20(3) 40(3) 19(3) 
03' 100(3) 85(3) 53(2) 19(2) 37(2) 1 (2) 
03" 93(2) 62(2) 54(2) 20(2) 32(2) 12(2) 
C4 42(3) 42(3) 50(3) 5(2) 18(3) -3(3) 
C5 42(3) 44(3) 46(3) 4(2) 15(3) -2(3) 
C5' 47(3) 46(3) 43(3) 6(3) 12(2) 1 (2) 
C5" 113(4) 51 (3) 81 (4) 2(3) 40(4) 9(3) 
05' 58(2) 80(3) 94(3) 9(2) 33(2) 27(2) 
05" 66(2) 49(2) 83(3) 5(2) 29(2) 9(2) 
C6 48(3) 55(3) 48(3) 6(3) 17(3) -2(3) 
C6' 58(3) 71 (4) 53(3) 1 (3) 5(3) -2(3) 
C7 48(3) 44(3) 43(3) -2(3) 19(3) 1(2) 
CB 49(3) . 57(3) 55(3) -2(3) 15(3) -7(3) 
C9 70(4) · 72(4) 67(4) -16(3) 24(3) -20(3) 
C10 62(4) 96(5) 50(3) -23(4) 17(3) -12(3) 
C11 46(4) 91 (4) 40(3) 4(3) 15(3) 10(3) 
C12 51 (3) 60(3) 42(3) 3(3) 14(3) 6(3) 
N2 64(4) 161 (6) 52(3) 21 (5) 14(3) 10(4) 
01 53(3) 241 (6) 111 (4) 2(3) -2(3) -38(4) 
02 101 (3) 149(4) 97(4) 59(4) 33(3) 45(4) 
------------------------------------------------------------------------------------------------------------
The anisotropic displacement exponent takes the form: 
-21t2(h2a•2u11 + ... + 2hka*b*U12) 
TABLE 25 
BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 

































































C3'-03"-C3" .. 116.4(4) 
C3-C4-C5 117.6(3) 


























TORSION ANGLES (0 ) FOR 
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Figure 35: Projection view of Ethyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-1,4-dihydropyridine(V) -:e; 
TABLE 27 
CRYSTAL DATA FOR 
148 
Diethyl 2,6-dimethyl-4-(3-nitrophenyl)-1 ,4-dihydropyridine3,5-dicarboxylate (V) 
------------------------------------------------------------------------------------------------------------
Formula C19H22N20a 
M.W. 374.4 g mole-1 
.a 14.328(4) A 
b 15.292(3) A 
' .8.673(2) A a 90.0° 
J3 90.0° 
'Y 90.0 ° 
V 1900.5(8) A3 
F(OOO) 792 
µMo Ka 11.28 cm·1 
A.Mo Ka o.71069 A 
Deale 1.308 Mglm3 
z 4 
Meas refl 3024 
Obs refl 1238 
R 4.82 o/o 
Rw 5.37 o/o 
G.0.F. 1.16 
Space Group Pna21 
Octants meas -1 S h S 18, -1 s k S1 9, -1 s I S 11 
149 
TABLE 28 
POSITIONAL PARAMETERS FOR 
Ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine3,5-dicarboxylate (V) 
----------------------------------·-------------------------------------------------------------------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 0.2054(3) 0.2890(3) 0.6351 (10) 
C2 0.1452(4) 0.2315(3) . 0.7052(10) 
C2' 0.1939(4) 0.1541(4) 0.7764(11) 
C3 0.0533(4) 0.2483(4) 0.7042(10) 
C3' -0.0203(4) 0.1948(3) 0.7732(10) 
C3" -0.0609(4) 0.0644(4) 0.9072(10) 
C3"' -0.0092(5) -0.0056(5) 0.9918(13) 
03' -0.1022(3) 0.2123(3) 0.7656(9) 
03" 0.0094(3) 0.1224(2) 0.8472(9) 
C4 0.0131 (3) 0.3279(3) 0.6182(?) 
cs 0.0899(4) 0.3945(3) 0.5828(10) 
CS' 0.0615(4) 0.4840(4) 0.5437(12) 
CS" -0.0678(6) 0.5800(4) 0.5274(15) 
CS"' -0.1642(6) 0.5832(5) 0.5566(17) 
05' 0.1102(3) 0.5418(3) 0.4970(12) 
05" -0.0301 (3) 0.4963(2) 0.5635(9) 
C6 0.1802(4) 0.3717(4) 0.5864(10) 
C6' 0.2612(4) 0.4276(4) 0.5359(11) 
C7 -0.0344(3) 0.3006(3) 0.4685(10) 
CB 0.0098(4) 0.2474(4) 0.3629(10) 
C9 -0.0327(4) 0.2266(4) 0.2253(11) 
C10 -0.1207(4) 0.2572(4) 0.1882(10) 
C11 -0.1637(4) 0.3099(4) 0.2939(10) 
C12 -0.1224(4) 0.3324(3) 0.4332(10) 
N2 -0.2567(4) 0.3435(4) 0.2612(11) 
01 -0.2986(3) 0.3143(4) 0.1489(10) 
02 -0.2914(4) 0.3974(3) 0.3482(11) 
H1A 0.2707 0.2721 0.6635 
H2'A 0.1483 0.1169 0.8243 
H2'B 0.2259 0.1222 0.6971 
H2'C 0.2380 0.1734 0.8524 
H3"A -0.0969 0.0397 0.8246 
H3"B -0.1020 0.0952 0.9757 
H3"C -0.0523 -0.0470 0.10349 
H3"D 0.0319 -0.0351 0.9214 
H3"E 0.0267 0.0205 0.10730 
H4A -0.0327 0.3548 0.6836 


















































ANISOTROPIC THERMAL PARAMETERS FOR 
Diethyl 2,6-di methyl-4-(3-nitrophenyl)-1 ,4-di hydropyridine3,5-dicarboxylate {V) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U12 U13 U23 
------------------------------------------------------------------------------------------------------------
N1 27(2) 54(3) 64(4) -2(2) 2(3) -1 (3) 
C2 34(3) 44(3) 42(4) -5(3) -5(3) 3(3) 
C2' 39(3) 59(4) 60(4) 5(3) -10(3) 4(4) 
C3 36(3) 37(3) 40(3) -7(3) -3(3) -1 (3) 
C3' 37(3) 39{3) 38(4) 5(3) -10(3) -5(3) 
C3" 50(4) 50(4) 51 (4) -8(3) 10(3) 5(4) 
C3"' 80(5) 64{4) 101 (7) 6(4) -6(5) 30(5) 
03' 35(2) · 51 (2) 75(3) 2(2) 1 (2) 17(3) 
03" 35(2) 43(2) 63(3) 2(2) 0(2) 13(2) 
C4 39(3) 28(3) 41 (4) 3(3) 0(3) -1 (3) 
cs 44(3) 36(3) 49(4) -6(3) -5(3) 1(4) 
CS' 56(4) 48(4) 75(5) -14(4) -6(4) 6(4) 
CS" 99(6) 44(4) 137(9) 5(4) -10(7) 22(5) 
CS"' 114(7} 73(5) 177(12) 37(5) 16(8) 17(7) 
05' 82(3) 55(3) 213(8) -11 (3) 24(5) 41 (5) 
05" 65(3) 34(2) 89(4) 3(2) -9(3) 3(3) 
C6 42(3) 51 (4) 41 (4) -14(3) -4(3) -3(4) 
C6' 43(3) 78(4) 83(6) -29(3) -9(4) 17(5) 
C7 41(3) 34(3) 34(3) -16(3) -2(3) 4(3) 
cs 42(3) 51 (3) 55(4) 1(3) -5(4) -7(4) 
C9 52(4) 64(4) 48(4) 9(3) -4(4) -15(4) 
C10 58(4) 59(4) 42(4) -5(4) -4(4) -4(4) 
C11 33(3) 40(3) 52(4) -3(3) -7(3) 9(3) 
C12 32(3) 40(3) 44(4) -5(3) -1 (3) 3(3) 
N2 44(3) 75(4) 68(4) -1 (3) -16(4) 22(4) 
01 55(3) 128(5) 82(4) 2(3) -29(3) 13(4) 
02 72(3) 95(4) 102(5) 40(3) -17(4) -20(4) 
------------------------------------------------------------------------------------------------------------
The anisotropic displacement exponent takes the form: 
-21t2(h2a•2u11 + ... + 2hka*b*U12) 
152 
TABLE 30 
BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 









































































































































TORSION ANGLES (0 ) FOR 
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Figure 36: Projection view of Ethyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-pyridine(VI) -~ 
TABLE 32 
CRYSTAL DATA FOR 
155 
Diethyl 2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate (YI) 
--------------------------------------------~-------------------------------------------------------------
Formula C19 H20 N2 Os 
M.W. 372.37 g mole·1 
.a 12.0180(1 O)A · 
b. 19.517(2) A 
' 8.6060(10) A a 90.00 ° 
13 109.920(10) 0 
'Y 90.00 ° 
V 1897.8(3)A3 
F(OOO) 784 
µMo Ka 11.28 cm-1 
lMoKa o.71069 A 
Deale 1.303 g/cm3 
z 4 
Meas refl 2402 




Space Group P21/c 




POSITIONAL PARAMETERS FOR 
Diethyl 2, 6-di methyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate (VI) 
------------------------------------------------------------------------------------------------------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
-------------------------------------------------------. ---------------------------------------------------
N1 0.8611 (6) 0.4858(3) 0.1636(8) 
H1A 0.8039(6) 0.5156(3) 0.1631 (8) 
C2 0.8301 (6) 0.4265(5) 0.0794(9) 
C2' 0.6999(5) 0.4178(4) -0.0093(8) 
H2'A 0.6577(5) 0.4567(4) 0.0104(8) 
H2'B 0.6855(5) 0.4136(4) -0.1257(8) 
H2'C 0.6734(5) 0.3771 (4) 0.0300(8) 
C3 0 .. 9168(6) 0.3799(4) 0.0775(8) 
C3' 0.8852(6) 0.3182(4) -0.0293(9) 
C3" 0.7720(6) 0.2170(4) -0.0896(10) 
H3"A 0.7411 (6) 0.2281 (4) -0.2051 (10) 
H3"B 0.8403(6) 0.1884(4) -0.0711 (10) 
C3'" 0.6838(7) 0.1807(4) -0.0432(10) 
H3'A 0.6624(7) 0.1397(4) -0.1079(10) 
H3'B 0.7150(7) 0.1690(4). 0.0720(10) 
H3'C 0.6150(7) 0.2091 (4) -0.0632(10) 
03' 0.9289(4) 0.3041(2) -0.1301 (6) 
03" 0.8055(4) 0.2795(2) 0.0063(5) 
C4 1.0358(6) 0.3953(4) 0.1657(8) 
cs 1.0624(6) 0.4570(4) 0.2519(8) 
CS' 1.1870(6) 0.4758(4) 0.3504(9) 
C5" 1.3485(6) 0.4491 (4) 0.5981 (10) 
H5"A 1.3624(6) 0.4976(4) 0.6078(10) 
H5"B 1.3557(6) 0.4314(4) 0.7051 (10) 
CS"' 1.4337(7) 0.4160(4) 0.5364(11) 
H5"C 1.5123(7) 0.4246(4) 0.6116(11) 
H5"D 1.4193(7) 0.3676(4) 0.5275(11) 
H5"E 1.4260(7) 0.4343(4) 0.4296(11) 
05" 1.2294(4) 0.4347(3) 0.4785(6) 
05' 1.2399(4) 0.5232(2) 0.3211(6) 
C6 0.9733(7) 0.5018(4) 0.2481(9) 
C6' 0.9968(6) 0.5685(3) 0.3428(9) 
H6'A 0.9241 (6) 0.5930(3) 0.3249(9) 
H6'B 1.0334(6) 0.5590(3) 0.4585(9) 
H6'C 1.0492(6) 0.5959(3) 0.3056(9) 
C7 1.1307(5) 0.3458(4) 0.1698(8) 































































ANISOTROPIC THERMAL PARAMETERS FOR 
Diethyl 2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate (VI) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U23 U13 U12 
------------------------------------------------------------------------------------------------------------
N1 38(3) 68(4) 78(4) -9(4) -4(3) -1(3) 
N1 60(5) 62(5) 86(5) 14(4) 48(4) 22(4) 
C2 51(5) 65(6) 60(5) 4(5) 29(4) -7(5) 
C2' 52(5) 82(6) 92(6) 18(5) 22(5) 10(4) 
C3 39(5) 49(5) 58(5) 12(4) 29(4) -1 (4) 
C3' 35(4) 69(6) 56(6) 1(5) 20(4) -12(4) 
C3" 79(6) . 92(7) 80(6) -14(6) 26(5) -34(5) 
C3"' 110(7) 86(7) 106(7) -22(6) 24(6) -24(6) 
03' 73(4) 83(4) 64(4) -5(3) 40(3) -15(3) 
03" 63(3) 63(3) 58(3) -8(3) 23(3) -22(3) 
C4 45(5) 51 (5) 40(4) 8(4) 26(4) -5(4) 
cs 38(5) 57(5) 49(5) 5(5) 13(4) -4(4) 
CS' 60(6) 50(5) 41(5) 5(5) 22(5) 6(5) 
CS" 63(6) 131 (8) 102(7) 6(6) 31(6) 9(6) 
CS"' 111 (7) 102(7) 129(8) 23(7) 13(7) -38(6) 
05" 45(3) 93(4) 69(4) 15(4) 6(3) -13(3) 
05' 69(3) 63(4) 100(5) 13(3) 22(3) -22(3) 
C6 41(5) 72(6) 59(5) 18(5) 23(5) 9(5) 
C6' 85(5) 51(5) 90(6) -10(5) 53(5) 4(4) 
C7 30(4) 53(5) 52(5) -6(4) 15(4) 1 (4) 
ca 55(5) 67(6) 63(6) 8(5) 20(4) -9(5) 
C9 85(6) 48(5) 98(7) 11 (5) 15(6) 10(6) 
C10 52(6) 77(8) 88(7) 1 (5) 26(5) 18(5) 
C11 37(5) 71 (6) · 71(6) -6(5) 23(4) -4(5) 
C12 46(4) . 45(5) 50(5) 0(4) 13(4) 7(4) 
N2 54(5) 98(6) 95(6) -6(5) 24(4) 21(5) 
01 99(5) . 126(6) 276(10) 63(7) 127(6) 25(5) 
02 65(4) 146(6) 159(6) -27(5) 58(4) 8(4) 
------------------------------------------------------------------------------------------------------------
The anisotropic displacement exponent takes the form: 
-2x2(h2a•2u11 + ... + 2hka*b*U12) 
TABLE 35 
BOND DIS~ANCES (A) AND BOND ANGLES (0 ) FOR 


































































































































































































































































M.W. 402.4 g mole-1 
a 9.452(1) A 
b. 10.718(1) A 
~ 12.081(2) A 
a 103.36(1) 0 
J3 96.10(1) 0 
'Y 104.53(1) 0 
V 1054.6(2) A3 
F(OOO) 428 
µMo Ka 11.28 cm-1 
A.Mo Ka 0.11059 A 
Deale 1.267 g/cm3 
z 2 
Meas refl 4398 




Space Group P-1 
Octants meas -1 Sh S11 , -12 S ks 11, -14 S I S 14 
------------------------------------------------------------------------------------------------------------
TABLE 38 
POSITIONAL PARAMETERS FOR 
163 
Dipropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (VII) 
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
-------------------------------------------------~--------------------------------------------------------
N1 0.3377(6) -0.3553(5) 0.2676(5) 
C2 0.3041 (7) -0.2822(6) 0.1978(5) 
C2' 0.1508(7) -0.3739(6) 0.1061 (5) 
C3 0.4029(6) -0.1429(5) 0.2183(4) 
C3' 0.3615(8) -0.0593(6) 0.1494(5) 
03' 0.2415(6) -0.1015(5) 0.0773(4) 
03" 0.4790(4) 0.0744(4) 0.1781 (3) 
C4 0.5582(6) -0.0663(5) 0.3077(4) 
cs 0.5567(6) -0.1490(6) 0.3968(4) 
CS' 0.6791 (7) -0.0758(6) 0.5056(5) 
05' 0.6900(6) -0.1210(5) 0.5872(4) 
05" 0.7866(5) 0.0531 (4) 0.5065(3) 
CG 0.4499(7) -0.2875(6) 0.3711 (5) 
CG' 0.4425(8) -0.3855(7) 0.4435(6) 
C7 0.6989(6) -0.0452(5) 0.2496(4) 
ca 0.7232(7) -0.1605(6) 0.1918(4) 
C9 0.8483(7) -0.1431 (6) 0.1384(4) 
C10 0.9556(7) -0.0068(6) 0.1413(5) 
C11 0.9326(6) 0.1069(6) 0.1972(5) 
C12 0.8072(6) 0.0905(5) 0.2523(4) 
C13 0.4554(9) 0.1703(7) 0.1200(6) 
C14 0.5932(9) 0.3120(7) 0.1649(7) 
C15 0.5777(11) 0.4210(8) 0.1147(8) 
C16 0.9218(9) 0.1284(8) 0.6043(6) 
N2 0.10433(7) 0.2523(6) 0.2017(5) 
02 0.11482(6) 0.2684(5) 0.1497(5) 
01 0.10258(7) 0.3535(5) 0.2546(5) 
C17 0.10452(14) 0.2556(11) 0.5725(10) 
C18 0.10125(15) 0.3521 (10) 0.5723(11) 
H1A 0.2838 -0.4521 0.2437 
H2'A 0.1324 -0.3171 0.0608 
H2'B 0.1597 -0.4527 0.0559 
H2'C 0.0631 -0.4106 0.1425 
H4A 0.5710 0.0270 0.3492 
H6'A 0.5238 -0.3321 0.5145 
H6'B 0.3394 -0.4212 0.4618 














































































ANISOTROPIC THERMAL PARAMETERS FOR 
Dipropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (VII) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U12 U13 U23 
---------------------------------------------------~------------------------------------------------------
N1 54(3) 43(3) 97(4) 3(3) -4(3) 31(3) 
C2 42(4) 58(4) 70(4) 13(3) 2(3) 25(3) 
C2' 60(4) 57(4) 85(4) -1 (3) -11 (4) 17(3) 
C3 32(3) 45(3) 60(4) 17(3) 13(3) 24(3) 
C3' . 48(4) 56(4) 69(4) 27(3) 13(3) 24(3) 
03' 63(3) 90(3) 100(3) 32(2) -16(3) 42(3) 
03" 52(3) 61 (3) 97(3) 23(2) 12(2) 49(2) 
C4 32(3) 39(3) 51(3) 10(2) 7(3) 18(3) 
cs 43(3) 54(4) 48(3) 15(3) 7(3) 26(3) 
CS' 47(4) 75(4) 63(4) 26(3) 23(3) 35(4) 
05' 108(4) 106(4) 71 (3) · 28(3) 5(3) 52(3) 
05" . 62(3) 73(3) 52(2) 10(2) -5(2) 16(2) 
C6 50(4) · 62(4) 78(5) 16(3) 8(4) 43(3) 
C6' 84(5) 92(5) 123(6) 15(4) 1(5) 78(5) 
C7 34(3) . 37(3) . 39(3) 13(3) 2(2) 15(2) 
ca 50(4) 43(3) 56(4) 21(3) 10(3) 18(3) 
C9 61(4) 56(4) 51(4) 30(3) 15(3) 15(3) 
C10 49(4) 72(4) 57(4) 33(4) 15(3) 29(3) 
C11 32(3) 43(3) 56(4) 7(3). 11 (3) 17(3) 
C12 46(4) 38(3) 55(4) 11 (3) 8(3) 17(3) 
C13 103(6) 97(6) 132(6) 62(5) 21(5) 79(5) 
C14 102(6) 73(5) 167(8) 25(5) 13(6) 81(5) 
C15 145(8) 85(5) 181 (8) 46(6) . 31(7) 68(6) 
C16 80(6) 89(5) 81(5) -1 (5) -21 (5) 16(4) 
N2 68(4) 61 (4) 98(5) 12(3) 36(3) 33(4) 
02 79(3) 85(3) 156(5) 23(3) 74(4) 55(3) 
01 121 (5) 40(3) 202(6) 8(3) 89(4) 27(3) 
C17A 185(12) 98(8) 159(10) 30(9) ~115(9) -24(8) 
C18A 215(15) 98(9.) 203(13) 21(9) -7(11) -12(9) 
------------------------------------------------------------------------------------------------------------
The anisotropic displacement exponent takes the form: 
-2x2(h2a•2u11 + ... + 2hka*b*U12) 
166 
TABLE 40 
BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 


















































































































































TORSION ANGLES (0 ) FOR 
Dipropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (VII) 
------------------------------------------------------------------------------------------------------------
C6-N 1-C2-C2' -165.3(0.6) 
C6-N1-C2-C3 13.1(1.0) 
C2-N 1-C6-C5 -14.8( 1.1 ) 
C2-N1-C6-C6' 168.2(0.6) 



















C3-C4-C7-C8 -67 .6(0. 7) 
C3-C4-C7-C12 112.2(0.5) 
C5-C4-C7-C8 55.7(0.6) 






C4-C5-C6-C6' 17 4.2(0. 7) 
C5'-C5-C6-N1 -178.8(0.6) 
C5'-C5-C6-C6' -2.1 (1.2) 
C5-C5'-05"-C16 -173.7(0.6) 
05'-C5'-05"-C16 5.3(1.0) 






C1O-C11-C12-C7 -1.1 (0.9) 
N2-C11-C12-C7 179.5(0.5) 
C1 O-C11-N2-02 4.3(0.9) 
C8-C9-C10-C 11 -0.3(0.9) 
C7-C8-C9-C10 0.1 (0.9) 








Figure 37: Projection view of Propyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-1,4-dihydropyridine(VII) -~ 
TABLE 42 





M.W. 402.4 g mote-1 
.a 7.612(2) A 
11 11.441 (2) A 
' 12.938(2) A a 75.8.3(1) 0 
J3 89.61 (1) 0 
'Y 73.18(2) 0 
V 1043.3(4) A3 
F(OOO) 428 
µMo Ka 11.28 cm.;1 
l.MoKa o.11os9 A 
Deale 1.281 g/cm3 
z 2 
Meas refl 4521 




Space Group P-1 
Octants meas -1 s h s 8, -12 s kS 13,-15 s I s 15 
TABLE 43 




ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
----------------------------------------.-------------------------------------------------------------------
N1 0.5182(6) f:0668(4) 0.3075(3) 
C2 0.4243(7) 0.9790(5) 0.3322(3) 
C2' 0.5495(7) 0.8480(5) 0.3832(4) 
C3 0.2405(7) 1.0170(4) 0.3092(3) 
C3' 0.1198(8) 0.9375(5) 0.3407(4) 
03' -0.0454(5) 0.9753(3) 0.3172(3) 
03" 0.2043(4) 0.8202(3) 0.3992(3) 
C4 0.1463(6) 1.1482(4) 0.2403(3) 
cs 0.2505(7) 1.2392(5) 0.2502(4) 
CS' 0.1516(9) 1.3760(5) 0.2222(4) 
05' 0.2126(6} 1.4589(4} 0.2295(3} 
05" -0.213(5} 1.3950(3) 0.1857(3} 
C6 0.4310(8}. 1.1974(5} 0.2798(4} 
C6' 0.5594(8) 1.2728(5) 0.2873(4) 
C7 0.1229(7) 1.1461(4) 0.1237(3) 
ca 0.2714(7) 1.1208(4) 0.0621(4) 
C9 0.2513(7) 1.1177(5) -0.0425(4} 
C10 0.0791 (8) · 1.1423(4) -0.0895(4) 
C11 -0.0684(7) 1.1688(4) -0.0300(4) 
C12 -0.0512(7) 1.1706(4) 0.0764(4) 
C13 0.0997(7) 0.7312(5) 0.4238(4) 
C14 0.2387(9) 0.6036(5) 0.4342(5) 
C15 0.0071 (7) 0.7414(5) 0.5249(4) 
C16 -0.1352(8) 1.5256(5) 0.1469(5) 
C17 -0.2642(9) 1.5239(5) 0.0609(5) 
C18 -0.2344(9) 1.5701 (5) 0.2373(4) 
N2 -0.2540(7) 1.1962(4) -0.0791 (4) 
01 -0.2720(6) 1.2001 (4) -0.1726(3) 
02 -0.3810(6) 1.2094(4) -0.0216(3) 
H1A 0.6418 1.0389 0.3092 
H2'A 0.4773 0.7903 0.3990 
H2'B 0.6406 0.8219 0.3352 
H2'C 0.6092 0.8486 0.4481 
H4A 0.0264 1.1775 0.2652 
H6'A 0.4920 1.3609 0.2675 
H6'B 0.6121 1.2502 0.3593 
------------------------------------------------------------------------------------------------------------
171 













































































































ATOM U11 U22 U33 U23 U13 U12 
------------------------------------------------------------------------------------------------------------
N1 38(3) 63(3) 64(3) -19(3) 7(2) -15(3) 
C2 42(4) 45(4) 37(3) -17(3) 6(3) -12(3) 
C2' 38(4) 68(4) 84(4) -7(3) -6(3) 0(3) 
C3 29(3) 41 (3) 35(3) -8(3) -1(2) -8(2) 
C3' 44(4) 42(3) 31 (3) -13(3) 1(3) -13(2) 
03' 32(2) 49(2) 59(2) -10(2) -4(2) -4(2) 
03" 41 (2) · 43(2) 53(2) -10(2) -2(2) 1 (2) 
C4 27(3) 40(3) 42(3) -7(3) 4(2) -14(2) 
cs 35(3) 54(4) 41(3) -16(3) 5(3) -17(3) 
CS' 64(4) 49(4) 54(4) -22(4) 8(3) -18(3) 
05' 101 (4) 54(3) 111(4) -37(3) 0(3) -30(2) 
05" 55(3) 33(2) 71 (3) -5(2) 8(2) -11 (2) 
C6 66(4) 55(4) 37(3) -30(3) 10(3) -18(3) 
C6' 62(4) 82(5) 80(4) -40(4) 8(3) -28(3) 
C7 40(3) 26(3) 36(3) -6(2) 1(3) -7(2) 
cs 35(3) 48(3) 42(3) -7(3) 2(3) -6(3) 
C9 37(4) 61 (4) 48(4) -3(3) 9(3) -18(3) 
C10 63(4) 44(3) 37(3) -18(3) -1(3) -10(3) 
C11 32(3) 37(3) · 46(3) -8(2) 0(3) -8(3) 
C12 36(3) 40(3) 42(3) -9(3) 3(3) -8(2) 
C13 56(4) 54(4) 46(3) -25(3) 0(3) -5(3) 
C14 111 (6) 55(4) 94(5) -22(4) 11 (4) -19(3) 
C15 65(4) 82(5) 48(4) -31 (4) 4(3) -4(3) 
C16 68(5) 32(4) 77(4) -5(3) 17(4) -7(3) 
C17 110(6) 54(4) 71 (4) 10(4) -5(4) 2(3) 
C18 105(5) 46(4) 84(4) 3(4) 16(4) -16(3) 
N2 50(4) . 66(3) 70(4) -17(3) -3(3) -22(3) 
01 83(3) 125(4) 58(3) -14(3) -24(2) -33(3) 
02 39(3) 141(4) 86(3) -24(3) -7(3) -33(3) 
------------------------------------------------------------------------------------------------------------
The anisotropic displacement exponent takes the form: 
-21t2(h2a•2u11 + ... + 2hka*b*U12) 
173 
TABLE 45 
BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 
·Di-isopropyl 2,6-dimethyl:.4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
(VIII) 


































































































































































C2'-C2-C3-C4 -169.1 (0.5) 
C2-C3-C3'-03' -179.2(0.5) 



















C4-C5-C5'-05' 177.1 (0.5) 
C4-C5-C5'-05" . -3.3(0.6) 
C6-C5-C5'-05' ~5.5(0.8) 






































Figure 39: Projection view of Butyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-1.4-dihydropyridine(VIV) -...:a a,. 
TABLE 47 
CRYSTAL DATA FOR 
177 
Dibutyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-Dihydropyridine-3,5-dicarboxylate (VIV) 
------------------------------------------------------------------------------------------------------------
Formula C23H30N20s 
M.W. 430.5 g mole-1 
a 11.358(4) A 
12 16.352(6) A 
k 12.999(5) A 
a 90.0 ° 
J3 101.56(1) 0 
'Y 90.0 ° 
V 2364.9(15) A3 
F(OOO) 920 
µMo Ka 11.28 cm-1 
A.Mo Ka o.71069 A 
Deale 1.209 g/cm3 
z 4 
Meas refl 5197 




Space Group P21/c 
Octants meas -1 S h S1 3, -1 S k S 19, -15 S I S 15 
178 
TABLE48 
POSITIONAL PARAMETERS FOR 
Dibutyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-Dihydropyridine-3,5-dicarboxylate (IX) 
----------------------------------------------------------------------------------------------.-------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 0.8738(4) 0.1670(3) 0.3466(3) 
N2 1.0175(5) 0.0910(4) -0.1728(4) 
01 0.9788(4) 0.0460(3) -0.2493(4) 
02 1.1108(5) 0.1320(3) -0.1632(3) 
C2 0.8040(4) 0.2257(4) 0.2851 (4) 
C2' 0.6925(4) 0.2491(3) 0.3277(4) 
C3 0.8420(4) 0.2573(3) 0.2001 (4) 
C3' 0.7863(4) 0.3253(3) 0.1353(4) 
03' 0.8149(3) 0.3487(2) 0.0536(3) 
03" 0.6984(3) 0.3675(2) 0.1724(3) 
C4 0.9526(4) 0.2196(3) 0.1650(4) 
cs 1.0376(4) 0.1813(3) 0.2584(4) 
CS' 1.1678(6) 0.1713(4) 0.2552(5) 
05' 1.2451 (4) 0.1392(3) 0.3204(4) 
05" 1.1933(3) 0.2067(3) 0.1678(3) 
C6 0.9943(5) 0.1510(3) 0.3422(4) 
cs· 1.0610(5) 0.1039(4) 0.4347(4) 
C7 0.9177(4) 0.1577(3) 0.0747(3) 
ca 0.9775(4) 0.1547(3) -0.0105(4) 
C9 0.9469(5) 0.0949(4) -0.0870(4) 
C10 0.8570(5) 0.0368(4) -0.0860(4) 
C11 0.7992(5) . 0.0403(4) -0.008(5) 
C12 0;8293(5) 0.0991 (4) 0.0781 (4) 
C13 0.6497(5) 0.4405(4) 0.1144(5) 
C14 0.5579(6) · 0.4803(5) 0.1673(6) 
C15 0.4467(7) 0.4379(5) 0.1638(7) 
C16 0.3473(7) 0.4826(5) 0.2065(8) 
\ 
C17 1.3171 (5) 0.2006(5) 0.1532(6) 
C18 1.3232(9) 0.2269(11) 0.0427(9) 
C18A 1.3411 (28) 0.1750(36) 0.0783(28) 
C19 1.4455(10) 0.2184(10) 0.0134(11) 
C19A 1.4621 (27) 0.1693(28) 0.0615(25) 
C20 1.4820(9) 0.1439(8) -0.0166(10) 
H1A 0.8389 0.1370 0.3903 
H2'A 0.6486 0.2905 0.2836 
H2'8 0.6430 0.2014 0.3267 
H2'C 0.7149 0.2693 0.3982 
------------------------------------------------------------------------------------------------------------
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ANISOTROPIC THERMAL PARAMETERS FOR 
Dibutyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-Dihydropyridine-3,5-dicarboxylate (IX) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U23 U13 U12 
---------------------------------------------------------------------------------------~-----------------
N1 61(3) 67(3) 55(3) -7(3) 27(2) 4(3) 
N2 91(4) 79(4) 50(3) 31(4) 22(3) -3(3) 
01 133(4) 129(4) 64(3) 23(3) 26(3) -27(3) 
02 108(3) ·. 100(4) 82(3) 5(3) 58(3) -12(3) 
C2 56(3) 59(4) 40(3) -2(3) 16(3) -3(3) 
C2' 53(3) 91 (5) 62(3) 2(3) 30(3) -1 (3) 
C3 51(3) 50(4) 41(3) 1(3) 20(2) -6(3) 
C3' 56(3) 61(4) 43(3) 1 (3) 22(3) -13(3) 
03' 89(3) 87(3) 48(2) 19(2) 32(2) 11 (2) 
03" 68(2) 76(3) 67(2) 13(2) 32(2) 6(2) 
C4 55(3) 53(4) 48(3) 0(3) 25(3) -9(3) 
C5 52(3) 52(4) 47(3) -2(3) 14(3) -9(3) 
C5' 59(4) 61 (4) 80(4) -3(4) 21(4) -6(4) 
05' 64(3) 140(5) 106(4) 16(3) 19(3) 28(3) 
05" 52(2) 121 (4) 78(3) -3(2) 29(2) 1(3) 
C6 54(4) 58(4) 51 (3) -1 (3) 15(3) -9(3) 
C6' 84(4) 70(4) 68(4) 11 (4) 18(4) 6(4) 
C7 59(3) 43(4) 42(3) 6(3) 17(3) -2(3) 
ca 60(3) . 64(4) . 45(3) 6(3) 22(3) -2(3) 
C9 67(4) 72(4) 36(3) 20(4) 14(3) -3(4) 
C10 75(4) 64(5) 57(4) 6(4) 3(3) -10(4) 
C11 73(4) 81 (5) 79(4) -7(4) 26(4) 8(4) 
C12 68(4) 67(4) 47(3) -2(4) 22(3) -7(4) 
C13 70(4) 91 (5) 85(4) 15(4) 23(4) 14(4) 
C14 80(5) 107(6) 120(6) 23(5) 19(4) 1(5) 
C15 128(7) 117(7) 143(7) -1 (6) 50(6) 2(6) 
C16 101 (6) 182(9) 208(10) 55(6) 74(7) 45(8) 
C17 57(4) 163(8) 119(6) -6(5) 34(4) 8(6) 
C18 62(5) 145(13) 86(8) -9(8) 31(5) 19(9) 
C18A 62(5) 145(13) 86(8) -9(8) 31 (5) 19(9) 
C19 79(6) 157(14) 80(9) 5(8) 40(7) 9(8) 
C19A 79(6) 157(14) 80(9) 5(8) 40(7) 9(8) 
C20 125(8) 344(20) 282(16) -33(11) 134(10) -76(14) . 
-------------------------------------------------------------------------~----------------------------------
The anisotropic displacement exponent takes the form: 
-21t2(h2a*2U11 + ... + 2hka*b*U12) 
181 
TABLE 50 
BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 





























































































































































C20-C19A-C1 SA 121.0(28) 
182 
TABLE 51 
TORSION ANGLES (0 ) FOR 
183 






















































































































Figure 40: Projection view of lsobutyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-1,4-dihydropyridine(X) -~ 
TABLE 52 






M.W. 430.49 g mole·1 
a 9. 7150(10) A 
b 1 o.9320(1 O) A 
' 12.5010(10) A 
(X 99.290(10) 0 
~ 97.270(10) 0 
'Y 116.350(10) 0 
V 1144.2(2) A3 
F(OOO) 460 
µMo Ka 11.28 cm-1 
A.Mo Ka o.71069 A 
Deale 1.249 g/cm3 
z 2 
Meas refl 2623 




Space Group P-1 
Octants meas -1S h S 9, -10 S k S 9, -12 SIS 12 
TABLE 53 




ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 0.1571 (4) 1.3679(3) 0.7555(3) 
C2 0.0591(4) 1.3042(4) 0.6512(3) 
C2' 0.0753(5) 1.4042(4) 0.5777(4) 
C3 -0.0388(4) 1.1638(4) 0.6240(3) 
C3' -0.1340(5) 1.0906(5) 0.5124(4) 
C3" -0.3525(6) 0.8808(5) 0.4012(4) 
03' -0.1169(4) 1.1333(4) 0.4300(3) 
03" -0.2489(3) 0.9624(3) 0.5082(2) 
C4 -0.0529(4) 1.0797(4) 0.7123(3) 
cs 0.0995(4) 1.1536(4) 0.8032(3) 
CS' 0.1406(5) 1.0687(4) 0.8656(3) 
C5" 0.0532(5) 0.8416(4) 0.9004(4) 
05' 0.2639(4) 1.1076(3) 0.9309(3) 
05" 0.0256(3) 0.9368(3) 0.8438(2) 
C6 0.1930(4) 1.2933(4) 0.8231(3) 
C6' 0.3382(5) 1.3819(4) 0.9120(4) 
C7 -0.1957(4) 1.0546(4) 0.7612(3) 
cs -0.2262(5) 1.1634(4) 0.8022(3) 
C9 -0.3535(5) 1.1411(4) 0.8491 (3) 
C10 -0.4573(5) 1.0072(5) 0.8554(3) 
C11 -0.4266(4) 0.9001 (4) 0.8146(3) 
C12 -0~2981(4) 0.9218(4) 0.7678(3) 
C13 -0.4830(6) 0.7517(5) 0.4119(4) 
C14 -0.5874(6) 0.7760(6) 0.4794(5) 
C15 -0.4303(9) 0.6617(8) 0.4486(7) 
C16 -0.0779(6) 0.6970(4) 0.8513(4) 
C17 -0.0544(7) 0.5961(5) 0.9142(4) 0 
C18 -0.0631 (29) 0.6610(36) 0.7342(35) 
C18A -0.1395(29) 0.6372(34) 0.7297(32) 
01 -0.6409(5) 0.7386(4) 0.8662(4) 
02 -0.5118(5) 0.6613(4) 0.7774(4) 
N2 -0.5339(5) 0.7577(5) 0.8197(4) 
H1A 0.2307(4) 1.4611 (3) 0.7608(3) 
H2'A 0.0048(5) 1.3544(4) 0.5062(4) 
H2'B 0.0507(5) 1.4746(4) 0.6125(4) 
H2'C 0.1819(5) 1.4484(4) 0.5687(4) 
------------------------------------------------------------------------------------------------------------
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ATOM U11 U22 U33 U23 U13 U12 
------------------------------------------------------------------------------------------------------------
N1 53(2) 30(2) 66(2) 17(2) 6(2) 5(2) 
C2 47(2) 44(3) 54{3) 22(2) 14(2) 17(2) 
C2' 77(3) 54(3) 81 (3) 36(2) 15(3) 23(2) 
C3 39(2) 39(2) 49(3) 15(2) 10(2) 13(2) 
C3' 49(3) 63(3) 51 (3) 24(2) 14(2) 20(3) 
C3" 68(3) 83(3) 58(3) -8(3) 7(3) 13(3) 
03' 97(3) 98(2) 55(2) 33(2) 9(2) 10(2) 
03" 57(2) . 54(2) 47(2) 55(13) 38(14) 7(2) 
C4 39(2) 35(2) 51(2) 15(2) 9(2) 15(2) 
cs 34(2) 39(2) 49(2) 15(2) 6(2) 11 (2) 
CS' 36(3) 55(3) 57(3) 17(2) 0(2) 18(2) 
CS" 76(3) 59(3) 90(3) 35(3) 6(3) 35(3) 
05' 66(2) 71 (2) 112(3) 39(2) -12(2) 21 (2) 
05" 51 (2) 42(2) 78(2) 288(14) 39(14) 18(2) 
C6 38(2) 43(3) 53(2) 12(2) 2(2) 8(2) 
C6' 63(3) 55(3) 80(3) 16(2) -6(3) 6(2) 
C7 34(2) 32(2) 40(2) 11 (2) 3(2) 11 (2) 
cs 44(3) 42(2) 61 (3) 17(2) 9(2) 14(2) 
C9 61 (3) 53(3) 69(3) 17(2) 17(2) 29(2) 
C10 55(3) 73(3) 63(3) 31 (2) 21 (2) 34(3) 
C11 39(3) 43(3) . 59(3) 25(2) 11 (2) 7(2) 
C12 40(2) 35(2) 56(2) 15(2) 9(2) 11 (2) 
C13 75(4) 62(3) 85(4) -14(3) 1(3) 19(3) 
C14 69(4) 112(4) 116(5) 11 (4) 19(3) 28(3) 
C16 93(4) 051 (3) 71 (3) 27(2) 14(3) 31(3) 
C17 124(5) 54(3) 110(4) 38(3) 14(4) 39(3) 
C18 159(27) 66(15) 104(17) 35(12) 66(24) 52(21) 
C18A 119(19) . 49(10) 85(12) 10(8) 16(15) 33(13) 
N2 52(3) 68(3) 114(3) 45(3) 31 (2) 17(2) 
01 81 (3) 98(3) 201 (4) 81 (3) 83(3) 32(2) · 
02 117(3) 47(2) 174(4) 36(2) 81 (3) 14(2) 
C15 109(5) 119(5) 177(7) 13(5) 22(5) 43(5) 
------------------------------------------------------------------------------------------------------------
The anisotropic displacement exponent takes the form: 
-21t2(h2a•2u11 + ... + 2hka*b*U12) 
189 
TABLE 55 































































































































































































































































































Figure 41: Projection view of lsobutyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-pyridine(XI) -~ 
TABLE 57 
CRYSTAL DATA FOR 
193 
Di-isobutyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate (XI) 
Formula C23H34N20s 
M. W. 434.52 g mole-1 
.a 20.059(9) A 
b 6.340(3) A 
k 21.122(1 o) A 
a 90.00° 
~ 115.91 (1 )0 
'Y 90.00° 
V 2484.8(20) A3 
F(OOO) 936 
µMo Ka 11.28 cm-1 
1..MoKa o.71069 A 
Deale 1.162 g/cm3 
z 4 
Meas refl 5608 
Obs refl 896 
R 11.79% 
Rw 21.54% 
G. 0. F. 1.009 
Space Group P21/c 




POSITIONAL PARAMETERS FOR 
Di-isobutyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate (XI) 
------------------------------------------------------------------------------------------------------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 0.5318(5) 0.0171 (19) 0.8990(5) 
C2 0.5854(7) -0.1245(23) 0.9401(6) 
C2' 0.5561 (6) -0.2643(21) 0.9789(6) 
H2'A 0.5041 (6) -0.2407(21) 0.9644(6) 
H2'B 0.5640(6) -0.4082(21) 0.9701 (6) 
H2'C 0.5825(6) -0.2360(21) 1.0270(6) 
C3 0.6569(6) -0.1169(21) 0.9466(5) 
C3' 0'.7161 (9) -0.2756(24) 0.9980(7) 
03' 0.7064(5) -0.4570(15) 0.9979(4) 
03" o.n47(5) -0.1547(13) 1.0388(4) 
C4 0.6745(6) 0.0168(21) 0.9058(5) 
cs 0.6220(6) 0.1638(20) 0.8612(5) 
CS' 0.6367(7) 0.3162(29) 0.8150(7) 
05' 0.6390(6) 0.5062(16) 0.8208(4) 
05" 0.6480(4) . 0.2078(13) 0.7676(4) 
C6 0.5502(7) 0.1581(21) 0.8624(6) 
CS' 0.4896(6) 0.3097(17) 0.8152(5) 
H6'A 0.4459(6) 0.2882(17) 0.8221(5) 
H6'B 0.5064(6) 0.4525(17) 0.8268(5) 
H6'C 0.4783(6) 0.2836(17) 0.7682(5) 
C7 0.7529(7) 0.0229(22) 0.9091 (5) 
CB 0.8007(7) 0.2005(21) 0.9405(5) 
H8A 0.7807(7) 0.3164(21) 0.9555(5) 
C9' 0.8713(9) 0.2146(37) 0.9442(9) 
C10 0.8980(8) 0.0476(40) 0.9204(9) 
H10A 0.9451 (8) 0.0620(40) 0.9193(9) 
C11 0.8507(8) -0.1270(34) 0.8877(7). 
C12 0.7784(6) -0.1402(23) 0.8841 (6) 
H12A 0.7461(6) -0.2561 (23) 0.8617(6) 
C13 0.8373(8) -0.2788(23) 1.0879(7) 
H13A 0.8475(8) -0.4000(23) 1.0670(7) 
H13B 0.8274(8) -0.3219(23) 1.1255(7) 
C14 0.9019(10) -0.1501 (35) 1.1205(9) 
H14A 0.9146(10) -0.1091 (35) 1.0844(9) 
C15 0.8994(10) 0.0679(31) 1.1408(9) 
H15A 0.8624(10) 0.1557(31) 1.0975(9) 






































































































ANISOTROPIC THERMAL PARAMETERS FOR 
Di-isobutyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate (XI) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U23 U13 U12 
------------------------------------------------------------------------------------------------------------
N1 60(7) 91(8) 71 (6) 3(6) 31(6) -8(7) 
C2 61(8) 116(12) 66(7) 0(8) 42(7) -13(9) 
C2' 84(9) 186(15) 98(9) 7(10) 55(8) 6(10) 
C3 75(9) 93(11) 54(7) -10(8) 39(7) -18(8) 
C3' 111(12) 68(10) 66(9) 3(9) 66(9) 0(11) 
03' 98(6) 70(6) 112(7) 7(6) 33(5) -7(7) 
03" 78(5) 71(6) 77(5) 6(5) 3(4) 3(6) 
C4 40(7) 87(10) 59(7) -5(8) 20(6) 2(7) 
C5 64(8) 75(10) 50(7) -19(8) 11 (6) 3(8) 
C5' 72(8) 130(15) . 48(8) 15(11) 20(7) -7(11) 
05' 143(8) 79(7) 94(6) -15(6) 50(6) -19(8) 
05" 99(6) 99(7) 72(5) 8(5) 50(5) -9(5) 
C6 66(9) 70(10) 58(7) · -16(8) 5(7) 12(9) 
C6' 79(8) 80(10) 106(9) 11 (8) 31(7) 5(8) 
C7 77(9) 65(10) 58(7) -15(7) 29(7) -5(9) 
CB 70(9) 76(10) 80(8) 2(8) 21(7) 15(8) 
C9' 50(11) 154(20) 122(13) 51 (13) 24(9) 14(13) 
C10 45(10) 178(21) 140(14) 48(14) 28(10) -5(14) 
C11 65(10) . 160(18) 85(10) 22(11) 34(9) 28(14) 
C12 55(8) 102(12) 95(9) 2(9) 27(7) -13(9) 
C13 97(10) 128(14) 92(9) 15(11) 26(8) 5(12) 
C14 121 (15) 159(19) 127(14) 15(16) -33(12) 0(18) 
C15' 132(15) 166(19) 214(20) 44(18) · -47(14) -50(17) 
C16 125(13) 243(23) 171 (15) 35(16) -30(12) 13(16) 
C17 75(9) 143(14) 104(10) 33(12) 40(8) 9(9) 
C18 143(15) 143(17) 111(12) 14(13) 81(11) -6(12) 
C19 216(17) 172(17) 104(10) 16(11) 110(11) -10(14) 
C20 332(28) 294(28) 203(20) 135(20) 212(21) 186(26) 
N2 45(19) 162(41) 173(31) 2(28) 71 (20) -23(22) 
N3 45(25) 128(44) 168(29) 16(29) 2(17) -34(22) 
01 75(19) 142(28) 193(21) -21 (18) 74(17) 4(18) 
02 179(25) 152(21) 386(34) -86(21) 176(22) -28(18) 
03 51 (18) 244(33) 227(28) -1 (23) 67(17) -54(19) 
04 126(23) 147(41) 171(22) 4(23) 48(18) -37(25) 
------------------------------------------------------------------------·-----------------------------------
The anisotropic displacement exponent takes the form: 
-2x2(h2a•2u11 + ... + 2hka*b*U12) 
TABLE 60 
BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 















































































































































































TORSION ANGLES (0 ) FOR 
199 






























































































































Figure 42: Projection view of Tertia,y-butyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-1,4-dihydropyridine(XII) 8 
TABLE 62 




Formula C23 H30 N2 06 
M.W. 430.49 g mole-1 
a 11.1420(1 o) A 
b 16.803(2) A 
k 13.3840(1 o) A 
a 90.00 ° 
J3 109.900(10) 0 
'Y 90.00 ° 
V 2356.1 (4) A3 
F(OOO) 920 
µMo Ka 11.28 cm-1 
A.Mo Ka o.71069 A 
Deale 1.214 g/cm3 
z 4 
Meas refl 2898 
Obs refl , 1383 
A 5.42% 
Aw 12.09% 
. G. 0. F. 1.123 
Space Group P21/n 
Octants meas -1 s h s 1 0, -1 s kS 16, -12 s I s 12 
TABLE 63 




ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 0.2005(3) 0.2790(2) · 0.2687(3) 
C2 0.1253(5) 0.3456(3) 0.2626(4) 
C2' 0.1766(5) 0.4011 (3) 0.3560(4) 
C3 0.0222(4) 0.3576(3) 0.1770(3) 
C3' -0.0543(4) 0.4308(3) 0.1659(4) 
C3" -0.2107(5) 0.5140(3) 0.0333(4) 
03' -0.0569(3) 0.4730(2) 0.2389(3) 
03" -0.1237(3) 0.4454(2) 0.0645(3) 
C4 . -0.0235(4) 0.2945(3) 0.0902(3) 
cs 0.0825(4) 0.2369(3) 0.0938(3) 
CS' 0.0597(5) 0.1938(3) -0.0061 (4) 
CS" 0.1547(5) 0.1038(3) -0.1047(4) 
05' -0.0373(3) 0.2026(2) -0.0818(3) 
05" 0.1557(3) 0.1459(2) -0.0080(2) 
C6 0.1864(4) 0.2291 (3) 0.1830(4) 
C6' 0.2957(4) 0.1705(3) 0.2042(4) 
C7 -0.1419(4) 0.2523(3) 0.0980(3) 
ca -0.1328(5) 0.1909(3) 0.1701(4) 
C9 -0.2408(6) 0.1568(3) 0.1795(5) 
C10 -0.3596(5) 0.1851 (4) 0.1233(5) 
C11 -0.3679(5) 0.2456(3) 0.0524(4) 
C12 -0.2622(5) 0.2790(3) 0.0382(4) 
C13 -0.2619(6) 0.5080(4) -0.0860(4) 
C14 -0.3173(5) 0.5039(3) 0.0776(5) 
C15 -0.1387(5) 0.5911 (3) 0.0685(5) 
C16 0.1405(6) 0.1618(4) -0.1936(4) 
C17 0.0516(6) 0.0426(4) -0.1351 (5) 
C18 0.2851 (5) 0.0652(3) -0.0693(5) 
N2 -0.4927(5) 0.2780(3) -0.0067(5) 
01 -0.5837(4) 0.2592(3) 0.0187(4) 
02 -0.5019(4) 0.3253(3) -0.0779(4) 
H1A 0.2948(3) 0.2802(2) 0.3243(3) 
H2'A 0.1214(5) 0.4463(3) 0.3480(4) 
H2'B 0.1823(5) 0.3730(3) 0.4199(4) 
H2'C 0.2600(5) 0.4187(3) 0.3600(4) 
H2'D. 0.1001 0.3956 0.4012 
------------------------------------------------------------------------------------------------------------
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ATOM U11 U22 U33 U23 U13 U12 
------------------------------------------------------------------------------------------------------------
N1 42(2) 63(3) 39(3) -3(2) 0(2) 3(2) 
C2 53(3) 46(3) 46(3) 0(3) 16(3) 4(3) 
C2' 67(4) 57(3) 59(3) -18(3) 12(3) 0(3) 
C3 42(3) 35(3) 43(3) 7(3) 13(3) 4(3) 
C3' 49(3) 61(4) 47(4) 5(3) 14(3) -2(3) 
C3" 58(3) 50(4) · 71(4) 11 (3) 26(3) 11 (3) 
03' 97(3) 75(3) 59(2) -14(2) 22(2) 25(2) 
03" 51(2) 48(2) 55(2) 5(2) 17(2) 15(2) 
C4 34(3) 50(3) · 33(3) -2(2) · 7(2) 3(3) 
cs 38(3) 42(3) 39(3) 1(2) 10(3) 0(2) 
CS' 44(3) 49(3) 45(3) 2(3) 16(3) 2(3) 
CS" 73(4) 55(3) 45(3) -8(3) 19(3) 11 (3) 
05' 49(2) 82(3) 43(2) -13(2) -5(2) 13(2) 
05" 57(2) 67(2) 44(2) -5(2) 15(2) 18(2) 
C6 45(3) 48(3) 42(3) 1(3) 12(3) -1 (3) 
C6' 55(3) 78(4) 49(3) -4(3) 0(3) 22(3) 
C7 38(3) 42(3) 39(3) -6(3) 10(3) 5(3) 
ca 60(4) · 58(4) 58(3) 9(3) 19(3) 4(3) 
C9 77(4) 62(4) 93(4) 13(3) 45(4) -4(4) 
C10 55(4) 72(4) 93(4) -17(4) 37(4) -9(3) 
C11 39(4) 54(4) 67(4) -10(3) 18(3) 1(3) 
C12 46(3) 45(3) 48(3) -9(2) 14(3) -2(3) 
C13 112(5) 98(5) 79(5) 26(4) 26(4) 49(4) 
C14 59(3) 62(4) 119(5) -4(4) 27(4) 13(3) 
C15 86(4) 51(4) 122(5) 20(4) 45(4) 8(4) 
C16 142(6) 101 (5) 69(4) 15(4) 59(4) 42(5) 
C17 114(5) 87(5) 116(5) -38(4) 53(4) 0(5) 
C18 107(5) 78(4) 83(4) -2(4) 48(4) 26(4) 
N2 48(4)' 84(4) 106(5) -11 (3) 19(4) 1(3) 
01 49(3) 147(5) 203(6) 33(4) 43(3) 0(3) 
02 62(3) 128(4) 102(3) 6(3) 4(3) 23(3) 
------------------------------------------------------------------------------------------------------------























































































































































































































































-5. 78(0. 76) 












































Figure 43: Projection view of Pentyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-1,4-dihydropyridine(XIII) 00 
TABLE67 





M.W. 458.54 g mole-1 
il 12.626(2) A 
12 14.079(3) A 




V 2684.2(8) A3 
F(OOO) 980 
µMo Ka 11.28 cm-1 
lMoKa o.71069 A 
Deale 1.152 g/cm3 
z 4 
Meas refl 5878 
Obs refl 1393 
R 9.76% 
Aw 10.38 % 
G.0. F. 1.75 
Space Group P21/c 
Octants meas -1 Sh:S:15,-1 SkS16,-19SIS18 
210 
TABLE 68 
POSITIONAL PARAMETERS FOR 
Dipentyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (XIII) 
------------------------------------------------------------------------------------------------------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 -0.3721 (7) 0.3346(8) · 0.2570(7) 
C2 -0.3458(11) 0.4283(9) 0.2756(8) 
C2' -0.4483(10) 0.4912(9) 0.2628(9) 
C3 -0.2393(11) 0~4550(7) 0.3000(8) 
C3' -0.2091 (12) 0.5523(10) 0.3247(9) 
03' -0.2666(9) 0.6196(6) . 0.3292(8) 
03" -0.0964(8) 0.5640(5) 0.3516(6) 
C4 -0.1463(8) 0~3875(7) 0.3000(7) 
cs -0.1840(9) 0.2854(7) 0.3070(7) 
CS' -0.0982(11) · 0.2113(9) 0.3381 (8) 
05' -0.1119(6) 0.1287(5) 0.3498(6) 
05" 0.0068(6) 0.2473(5) 0.3570(5) 
C6 -0.2925(1 O) 0.2627(8) 0.2812(8) 
C6' -0.3448(9) 0.1659(8) 0.2766(8) 
C7 -0.1111(10) 0.3998(6) 0.2191 (8) 
cs -0.1923(10) 0.4016(7) 0.1348(8) 
C9 -0.1616(10) 0.4083(7) 0.0610(8) 
C10 -0.0509(12) 0.4164(8) 0.0683(9) 
C11 0.0256(10) 0.4148(7)· 0.1514(10) 
C12 0.0016(9) 0.4089(7) 0.2290(8) 
C13 -0.0461 (22) 0.6640(20) 0.3672(41) 
C13A -0.0506(26) 0.6548(22) 0.4109(46) 
C14 0.0681 (27) 0.6441 (21) . 0.4470(28) 
C14A 0.0730(29) 0.6578(22) 0.3807(28) 
C15 0.1429(34) 0.6155(28) 0.4002(26) 
C15A 0.418(28) 0.5806(23) 0:4548(21) 
C16 0.2768(31) 0.6050(25) 0.4594(21) 
C17 0.3130(31) 0.5378(28) 0.4608(23) 
C18 0.0975(9) 0.1812(8) 0.3869(9) 
C19 0.2057(10) 0.2339(10) 0.4018(10) 
C20 0.3075(11) . 0.1700(11) 0.4337(11) 
C21 0.4138(13) 0.2154(15) 0.4501 (13) 
C22 0.5097(13) 0.1536(16) 0.4813(13) 
N2 0.1498(10) 0.4230(7) 0.1653(8) 
01 0.2181 (7) 0.4238(7) 0.2404(7) 
02 0.1744(7) 0.4231(6) 0.0991 (6) 










































































































ANISOTROPIC THERMAL PARAMETERS FOR 
Dipentyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (XIII) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U12 U13 U23 
------------------------------------------------------------------------------------------------------------
N1 40(7) 67(7) 122(10) -1 (7) 31(6) -6(7) 
C2 58(10) . 53(9) 101 (11) 12(8) 29(8) 1(8) 
C2' 62(9) 83(10) 184(16) 20(9) 40(10) 11 (11) 
C3 63(9) 20(6) 85(10) -2(7) 31 (7) 1(6) 
C3' 59(10) 77(11) 83(10) -10(9) 27(8) -16(9) 
03' 125(10) 65(6) 203(12) 25(6) 56(8) -35(7) 
03" 98(7) 38(5) 133(9) -18(5) 41(7) -32(5) 
C4 42(7) 38(7) 51(8) 7(6) 5(6) 5(6) 
cs 42(8) 39(7) 73(9) -12(7) 29(7) -5(7) 
CS' 65(9) 45(7) ... 57(9) 7(8) 35(7) 19(7) 
05' 57(6) 44(5) 130(8) · 8(5) 29(5) 29(6) 
05" 42(5) 56(5) 99(7) 9(4) 16(5) 24(5) 
C6 44(8) 47(8) 72(9) 8(7) 22(7) 8(7) 
C6' 40(8) 67(9) 148(14) 3(7) . 22(8) 24(9) 
C7 66(9) . 22(6) 55(9) 13(6) 25(7) 14(6) 
ca 63(8) 48(7) 53(9) -2(7)· 19(8) 21(7) 
C9 57(9) 56(8) 57(10) -17(7) -3(7) 6(7) 
C10 83(10) 45(8) 59(10) -22(8) 14(9) 6(7) 
C11 39(8) 24(6) 107(12) -6(6) 41(9) -9(8) 
C12 38(8) 38(7) 81 (11) -4(6) 21 (7) -14(7) 
C18 54(8) 66(9) 126(12) 22(8) 16(8) 44(9) 
C19 48(9) 105(12) 161(15) 25(9) 25(10) 47(11) 
C20 51(9) 153(16) 172(17) -11(12) 24(10) 43(13) 
C21 73(12) 260(28) 234(25) 31 (17) 15(15) 69(20) 
C22 94(15) 433(42) 199(23) 41 (23) 10(15) 16(24) 
N2 98(10) 49(6) 59(8) 18(7) 59(8) 15(7) 
01 75(7) 121 (8) 82(7) 13(6) 32(6) 18(7) 
02 89(7) 102(7) 92(7) 10(5) 58(6) 4(6) 
03 45(5) 91 (7) 279(13) 1(5) 57(7) 33(8) 
------------------------------------------------------------------------------------------------------------










































































































































































































































































































































M.W. 345.33 g mole-1 
il 10.744(1) A 
.b. 10.887(1) A 
~ 12.223(1) A 
a 103.07(1) 0 
~ 97.39(1) 0 
'Y 109.51(1) 0 
V 1279.9(2) A3 
F(OOO) 492 
µMo Ka 11.28 cm·1 
11.MoKa o.71069 A 
Deale 1.190 g/cm3 
z 2 
Meas refl 5249 
Obs refl N/A(refinement on F2) 
R 5.8% 
Rw 12.42 % 
G.O.F. 0.796 
Space Group P-1 
Octants meas -1 Sh S1 2, -12 S k S11, -14 S I S 14 
TABLE 73 




ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
-••••••••••---•--••••••••••••--••••••••••••••••••••r--•--••••••••••--•••--•••••••••••••----••••••••••••••••• 
N1 0.3382(4) -0.0013(3) 0.1233(3) 
H1A 0.3415(4) -o.on4(3) 0.0781 (3) 
C2 0.2131 (4) 0.0012(3) 0.1326(3) 
C2' 0.0996(4) -0.1378(3) 0.0914(4) 
H2'A 0.0154(4) -0.1288(3) 0.1005(4) 
H2'8 0.0938(4) . -0.1786(3) 0.0117(4) 
H2'C 0.1181(4) -0.1942(3) 0.1362(4) 
H2'D* 0.0365 -0.1050 0.0079 
H2'E* 0.1591 -0.2055 0.0731 
H2'F* 0.0808 -0.1554 0.1633 
C3 0.2015(4) 0.1211 (3) 0.1737(3) 
C3' 0.0725(4) 0.1280(4) 0.1960(3) 
03' -0.0363(3) 0.0371 (3) 0.1731 (3) 
03" 0.0892(2) 0.2574(2) 0.2489(2) 
C4 0.3223(3) 0.2527(3) 0.1976(3) 
H4A 0.3176(3) 0.3150(3) 0.2650(3) 
cs 0.4532(4). 0.2303(3) 0.2240(3) 
CS' 0.5738(5) 0.3436(4) 0.2981 (4) 
05' 0.6635(69) 0.3248(64) 0.3362(52) 
OS'A 0.6922(48) 0.3512(44) 0.3222(27) 
05" 0.5450(3) 0.4552(3) 0.3331 (2) 
C6 0.4596(4) 0.1067(4) 0.1796(3) 
C6' 0.5787(4) 0.0680(4) 0.1874(4) 
H6'A 0.6584(4) 0.1471 (4) 0.2271 (4) 
H6'8 0.5668(4) 0.0018(4) 0.2293(4) 
H6'C 0.5886(4) 0.0300(4) 0.1116(4) 
H6'D* 0.6284 0.1042 0.2805 
H6'E* 0.5125 -0.0673 0.1275 
H6'F* 0.6444 0.1192 0.1440 
C7 0.3197(3) 0.3164(3) 0.0998(3) 
cs 0.2917(4) 0.2407(4) -0.0145(3) 
HSA 0.2754(4) 0.1456(4) -0.0305(3) 
C9 0.2885(4) 0.2993(4) -0.1030(4) 
H9A 0.2682(4) 0.2430(4) -0.1808(4) 
C10 0.3103(4) 0.4359(4) -0.0814(4) 
H10A 0.3107(4) 0.4780(4) -0.1425(4) 
------------------------------------------------------------------------------------------------------------
219 
TABLE 73 (Continued) 
------------------------------------------------------------~---------------------------------------------
C11 0.3361(4) 0.5090(4) 0.0316(4) 
C12 0.3420(4) 0.4541(3) 0.1220(3) 
H12A 0.3614(4) 0.5104(3) 0.1997(3) 
C13 · -0.0281 (4) 0.2799(4) 0.2778(4) 
H13A -0.0720(4) 0.2171 (4) o.31n(4) 
H13B -0.0908(4) 0.2674(4) 0.2090(4) 
C14 0.0191 (4) 0.4251(4) 0.3498(4) 
H14A 0.0782(4) 0.4340(4) 0.4195(4) 
H14B -0.0564(4) 0.4459(4) 0.3701(4) 
C15 0.0980(5) 0.5304(4) 0.2988(5) 
H15A 0.1797(5) 0.5159(4) 0.2887(5) 
C16 0.0236(6) 0.5164(5) 0.1810(5) 
H16A 0.0767(6) 0.5827(5) 0.1483(5) 
H16B 0;0027(6) 0.4267(5) 0.1314(5) 
H16C -0.0589(6) 0.5300(5) 0.1890(5) 
C17 0.1364(6) 0.6712(5) .. 0.3747(5) 
H17A 0.1846(6) 0.7380(5) 0.3400(5) 
H17B 0.0562(6) 0.6856(5) 0.3903(5) 
H17C 0.1932(6) 0.6794(5) 0.4454(5) 
C18 0.6528(4) 0.5755(4) 0.4104(4) 
H18A 0.7335(4) ·. 0.5970(4) 0.3808(4) 
H18B 0.6721(4) 0.5613(4) 0.4844(4) 
C19 0.6014(5) 0.6887(4) 0.4201(4) 
H19A 0.5167(5) 0.6609(4) 0.4433(4) 
H19B 0.5850(5) 0.7022(4) 0.3454(4) 
C20 0.6922(6) 0.8192(5) 0.5049(4) 
H20A 0.7103(6) 0.8013(5) 0.5774(4) 
C21 0.6249(7) o ..9199(5) 0.5227(5) 
H21A 0.6805(7) 1.0067(5) 0.5763(5) 
H21B 0.5977(7) 0.9320(5) 0.4492(5) 
H21C 0.5460(7) 0.8792(5) 0.5505(5) 
C22 0.8233(7) 0.8795(6) 0.4806(6) 
H22A 0.8655(7) 0.8139(6) 0.4750(6) 
H22B 0.8075(7) 0.8965(6) 0.4073(6) 
H22C 0.8816(7) 0.9627(6) 0.5375(6) 
N2 0.3571(4) 0.6553(4) 0.0594(5r 
01 0.3452(4) 0.7036(3) -0.0192(3) 
02 0.3850(4) 0.7207(3) 0.1593(4) 
------------------------------------------------------------------------------------------------------------
*Disorder of methyl hydrogens on C2' and C6' 
220 
TABLE 74 




ATOM U11 U22 U33 U23 U13 U12 
------------------------------------------------------------------------------------------------------------
N1 71(2) 43(2) 86(2) 8(2) . 23(2) 22(2) 
C2 63(3) 43(2) 6.4(3) 15(2) ·12(2) 14(2) 
C2' 89(3) 41(2) 99(3) 14(2) 11 (3) 11 (2) 
C3 54(2) 37(2) .· 60(2) 14(2) 10(2) 9(2) 
C3' 60(3) 52(3). 72(3) 13(2) 18(2) 15(2) 
03' 61(2) 61(2) 134(3). 3(2) 29(2) 1(2) 
03" 51(2) 57(2) 108(2) 7(2) 27(2) 19(1) 
C4 50(2) 41(2) 54(2) 9(2) 12(2) 16(2) 
cs 48(2) 46(2) 56(2) 13(2) 8(2) 12(2) 
CS' 60(3) 61(3) 75(3) 17(2) 13(3) 24(3) 
05' 24(15) 56(16) 109(25) -24(16) -2(11) -9(14) 
05'A 43(10) 89(9) 170(10) 7(9) 0(7) 21 (8) 
05" 56(2) 53(2) 97(2) 1(2) -2(2) 8(1) 
C6 60(3) 53(2) 81(3) 24(2) 26(2) 22(2) 
C6' 71(3) 68(3) 111 (4) 23(2) 25(3) 32(2) 
C7 44(2) 38(2) 67(3) 11 (2) 16(2) 14(2) 
cs 65(3) 47(2) 68(3) 12(2) 14(2) 20(2) 
C9 88(3) 69(3) 69(3) 20(2) 17(3) 25(3) 
C10 65(3) 83(3) 88(3) 44(3) 27(3) 28(2) 
C11 58(3) 50(2) 93(3) 30(2) 26(2) 25(2) 
C12 · 53(2) 43(2) 73(3) 11 (2) . 20(2). 15(2) 
C13 60(3) 76(3) 115(4) 22(3) 35(3) 24(2) 
C14 70(3)· 93(3) 106(4) 17(3) 37(3) 38(3) 
C15 84(4) 74(3) 119(4) 13(3) 26(3) 37(3) 
C16 161(6) 105(4) 192(7) 59(5) 29(6) 48(4) 
C17 182(7) 84(4)" 177(6) -8(4) 55(5) 19(4) 
C18 67(3) · 74(3) 88(3) -3(3) 0(3) 5(3) 
C19 87(4) 64(3) 87(3) 2(2) 6(3) 8(3) 
C20 147(5) 63(3) 98(4) 5(3) 14(4) 7(4) 
C21 207(8) 82(4) 139(5) 6(4) 25(5) 25(5) 
C22 173(7) 96(5) 225(8) -24(5) 67(6) -:46(5) 
N2 86(3) 58(3) 129(4) 45(3) 41(3) 33(2) 
01 133(3) 88(2) 162(3) 78(2) 41 (3) 50(2) 
02 182(4) 53(2) 145(3) 28(2) 51(3) 51(2) 
------------------------------------------------------------------------------------------------------------














































































































































































































































































































Figure 45: Projection view of lsopentyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-pyridine(XV) 
~ 
TABLEn 





M.W. 456.53 g mole-1 
.a 13:329(2) A 
b 13.331(3) A 
C 14.493(4) A 
a 90.00 ° 
13. 90.00 ° 
y 90.00 ° 
V 2575.2(10) A3 
F(OOO) 976 
µMo Ka 11.28 cm-1 
)..Mo Ka o.71069 A 
Deale 1.18 g/cm3 
z 4 
Meas refl 3293 
Obs refl 1469 
R 6.95% 
Rw 13.38 % 
G.O.F. 0.947 
Space Group P212121 
Octants meas -1 s; h S:15 , -1 s; k S:15 , -17 s; I s; 1 
226 
TABLE 78 
POSITIONAL PARAMETERS FOR 
Di-isopentyl 2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate (XV) 
------------------------------------------------------------------------------------------------------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 0.8728(4) 0.3768(4) 0.8749(4) 
C2 0.8553(5) 0.2894(6) 0.8321 (4) 
C2' 0.7555(5) 0.2760(6) 0.7876(6) 
H2'A 0.7167(5) 0.3361 (6) 0.7950(6) 
H2'B 0.7210(5) 0.2208(6) 0.8161 (6) 
H2'C . 0.7645(5) 0.2623(6) 0.7231 (6) 
C3 0.9276(5) 0.2138(5) 0.8332(4) 
C3' 0.9041 (5) 0.1162(6) 0.7883(5) 
03' 0.8884(6) 0.1037(5) 0.7075(3) 
03" 0.9029(4) 0.0410(3) 0.8480(3) 
C4 1.0199(5) 0.2294(5) 0.8754(4) 
cs 1.0361 (5) 0.32.16(5) 0.9178(4) 
cs· 1.1335(6) 0.3440(5) 0.9624(5) 
05' 1.1456(4) 0.3609(6) 1.0427(3) 
05" 1.2081 (3) 0.3459(4) 0.9025(3) 
cs 0.9599(5) 0.3944(5) 0.9167(4) 
C6' 0.9726(6) 0.4947(5) 0.9623(6) 
H6'A 0.9117(6) 0.5327(5) 0.9562(6) 
H6'B 1.0267(6) 0.5304(5) 0.9334(6) 
H6'C 0.9874(6) 0.4853(5) 1.0265(6) 
C7 1.0982(5) 0.1496(5) 0.8763(5) 
CB 1.1463(6) 0.1212(8) 0.7968(6) 
H8A 1.1257(6) 0.1506(8) 0.7418(6) 
C9 1.2203(9) 0.0546(12) 0.7932(12) 
C10 1.2426(10) 0.0056(11) 0.8738(18) 
H10A 1.2936(10) -0.0420(11) 0.8733(18) 
C11 1.1887(11) 0.0253(8) 0.9628(11) 
C12 1.1234(8) 0.1018(6) 0.9573(7) .. 
H12A 1.0934(8) 0.1239(6) 1.0115(7) 
C13 0.8847(8) -0.0579(6) 0.8134(5) 
H13A 0.9457(8) -0.0858(6) 0.7875(5) 
H13B 0.8339(8) -0.0562(6) 0.7656(5) 
C14 0.8494(11) -0.1205(8) 0.8942(7) 
H14A 0.8317(11) -0.1862(8) 0.8704(7) 
H14B 0.7881 (11) -0.0904(8) 0.9172(7) 
C15 0.9154(10) -0.1355(7) 0.9721 (7) 
H15A 0.9371 (10) -0.0691 (7) 0.9933(7) 
------------------------------------------------------------------------------------------------------------
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ANISOTROPIC THERMAL PARAMETERS FOR 
Di-isopentyl 2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate (XV) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U23 U13 U12 
------------------------------------------------------------------------------------------------------------
N1 59(3) 75(4) 79(3) 6(3) 3(3) 0(3) 
C2 59(4) 79(4) 54(3) 10(4) 6(3) -7(4) 
C2' 70(4) 90(5) 97(5) 6(5) -16(4) 1 (4) 
C3 62(4) . 70(4) 48(3) 3(3) 5(3) -1(4) 
C3' 80(5) 92(5) 53(4) -10(4) 6(4) -4(4) 
03' 195(6) 109(4) 59(3) -10(3) -19(4) -14(5) 
03" 126(4) 68(3) 52(2) 0(2) -19(3) -16(3) 
C4 70(4) 83(4) 41(3) -2(3) 0(3) 6(4) 
C5 66(4) 76(4) 46(3) 6(3) 4(3) 3(4) 
C5' 83(5) 88(5) 55(4) -2(4) -7(4) 4(5) 
05' 99(4) 199(6) 59(3) -18(4) -6(3) -18(5) 
05" 63(3) 132(4) 56(3) -18(3) -2(2) -12(3) 
C6 74(4) 67(4) 57(4) 12(3) 14(4) 0(4) 
C6' 83(5) 81 (5) 98(6) -18(4) 8(4) 3(4) 
C7 68(4) 73(4) 88(4) -21 (4) -19(4) 22(4) 
CB 83(5) 150(8) 113(6) -74(6) -10(5) 31(6) 
C9 107(8) 251 (16) 238(16) -64(14) -91 (10) 102(10) 
C10 139(10) 167(12) 402(25) -182(15) -172(15) 111 (9) 
C11 192(13) 92(7) 219(15) -59(9) -134(12) 59(8) 
C12 139(7) 80(5) · 112(6) -14(5) -71 (6) 25(6) 
C13 171 (9) 89(6) 69(5) -23(4) -18(6) -35(6) 
C14 275(15) 92(6) 111 (7) 11(6) -49(10) -52(9) 
C15 214(12) 72(5) 95(6) -6(5) -33(7) 9(7) 
C16 245(17) 161(11) 208(15) -28(12) -9(15) 11 (13) 
C17 411 (26) . 156(10) 107(8) 41(8), -20(13) -77(15) 
C18 75(5) 184(9) 69(4) -16(6) -12(4) -21(6) 
C19 76(5) 260(14) 136(~) -40(10) -3(6) -31 (8) 
C20 71(5) 210(11) 081(5) -40(7) -4(5) 9(7) 
C21 149(1.1) 256(18) 215(16) 13(15) -31 (12) 34(12) 
C22 149(10) 384(24) 137(10) 23(15) 37(9) -62(15) 
02 111 (12) 118(12) 150(20) -38(16) 12(16) 40(10) 
01 92(9) 110(11) 061(8) 31 (10) 2(8) 30(8) 
N2 70(8) 105(10) 114(12) -29(10) 15(9) 33(8) 
N2A 66(7) 57(7) 97(11) 6(8) -21 (8) 11 (6) 
01A 91 (11) 112(13) 71 (10) 19(9) 24(10) 14(10) 
02A 131 (13) 131(13) 82(11) 0(13) -22(12) -11(12) 
------------------------------------------------------------------------------------------------------------
The anisotropic displacement exponent takes the form:-2x2(h2a•2u11 + ... + 
2hka*b*U12) 
TABLE 80 
BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 
























































































































































































TORSION ANGLES FOR (0 ) 
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Figure 46: Projection view of Neopentyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-pyridine(XVI) N w 
N 
TABLE 82 
CRYSTAL DATA FOR 
233 
Dineopentyl 2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate (XVI) 
------------------------------------------------------------------------------------------------------------
Formula C25H32N20s 
M.W. 456.50 g mole-1 
a 17.736(3) A 
.t2 6.139(1) A 
' 24.756(4) A a 90.0 ° 
13 108.460(0) 0 
"I 90.0 ° 
V 2556.38(9) Aa 
F(OOO) 976 
µMo Ka 11.28 cm-1 
A.Mo Ka o.71069 A 
Deale 1.186 g/cm3 
z 4 
Meas refl 5973 
Obs refl 1495 
R 5.86% 
Rw 6.67% 
G.0. F. 1.29 
Space Group P21/c 
Octants meas -1 sh s 21, -1 s ks 7, -29 s Is 28 
234 
TABLE83 
POSITIONAL PARAMETERS FOR 
Dineopentyl 2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate (XVI) 
------------------------------------------------------------------------------------------------------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 -0.4538(3) -0.7465(10) -0.0410(2) 
C2 -0.4123(4) -0.6527(13) 0.0085(3) 
C2' -0.4280(4) -0. 7 496(12) 0.0606(2) 
C3 -0.3556(3) -0.4933(12) 0.0126(2) 
C3' -0.3080(4) -0.4039(12) 0.0695(2) 
03' -0.3347(3) -0.3027(11) 0.1000(2) 
03" -0.2318(2) -0.4534(8) 0.0816(2) 
C4 -0.3413(3) -0.4193(12) -0.0376(2) 
cs -0.3865(3) -0.5164(12) -0.0886(2) 
CS' -0.3776(4) -0.4328(15) -0.1436(3) 
05' -0.4000(3) -0.2602(10) -0.1633(2) 
05" -0.3409(2) -0.5788(8) -0.1658(2) 
C6 -0.4412(3) -0.6751 (13) -0.0889(2) 
C6' -0.4923(3) -0. 7860(12) -0.1428(2) 
C7 -0.2803(3) -0.2548(13) -0.0354(2) 
cs -0.2791 (4) -0.0551 (14) -0.0097(3) 
C9 -0.2209(4) 0.0976(14) -0.0072(3) 
C10 -0.1619(4) 0.0540(14) -0.0309(3) 
C11 -0.1651 (4) -0.1434(15) -0.057 4(3) · 
C12 -0.2208(4) -0.3004(12) -0.0600(2) 
C13 -0.1794(3) -0.3571 (13) 0.1334(3) 
C14 -0.0952(4) -0.4319(16) 0.1419(3) 
C15 -0;0709(4) -0.3628(16) 0.0907(3) 
C16 -0.0086(4) -0.6705(16) 0.1479(3) 
C17 -0.0427(4) -0.3180(16) 0.1950(3) 
C18 -0.3221 (4) -0.5040(13) , -0.2165(3) 
C19 -0.2935(4) -0.6969(15) -0.2421 (3) 
C20 -0.3604(5) -0.8531 (16) -0.2662(3) 
C21 -0.2261 (5) -0.8108(16) -0.2000(3) 
C22 -0.2661 (5) -0.6024(14) -0.2908(3) 
N2 -0.021 (5) -0.1910(18) -0.0836(4) 
01 -0.0500(4) -0.0654(13) -0.0779(3) 
02 -0.1134(4) -0.3444(16) -0.1145(4) 
H2'A -0.4690 -0.8577 0.0483 
H2'B -0.3805 -0.8158 0.0851 
H2'C -0.4451 -0.6366 0.0809 
H2'D* -0.4997 -0.7354 0.0506 
------------------------------------------------------------------------------------------------------------
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ANISOTROPIC THERMAL PARAMETERS FOR 
Dineopentyl 2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate (XVI) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U23 U13 U12 
--------------------------------------------------------------------------------------~-------------------
N1 36(3) 81 (5) 41(3) -3(3) 9(3) -1 (3) 
C2 32(3) 75(6) 42(4) 8(4) 13(3) -1 (4) 
C2' 64(4) 90(7) 46(4) 4(5) 23(3) 11(4) 
C3 34(4) 71 (6) 37(4) 10(4) 9(3) -1 (4) 
C3' 45(4) 77(6) 36(4) 9(4) 15(3) -9(4) 
03' 60(3) 164(6) 52(3) 23(4) 15(2) -36(3) 
03" 37(2) 88(4) 41(2) 13(3) 0(2) -16(3) 
C4 38(4) 60(6) 46(4) -3(4) 17(3) -1 (4) 
cs 37(4) 62(6) · 30(4) 0(4) 7(3) -2(4) 
CS' 52(4) 65(6) 43(4) 12(5) 9(3) 0(5) 
05' 116(5) 87(5) 66(3) 30(4) 40(3) 24(4) 
05" 73(3) 74(4) 40(2) 15(3) 31(2) 7(3) 
C6 36(4) 74(6) 38(4) 4(4) 4(3) 2(4) 
C6' 58(4) 91(7) 45(4) -18(5) 12(3) -16(4) 
C7 43(4) 52(6) 35(3) 4(4) 9(3) 1(4) 
CB 54(4) 64(6) 53(4) 9(5) 15(3) 1(4) 
C9 76(5) 58(7) 64(5) -1(5) · 18(4) ·-7(4) 
C10 53(5) 65(7) 74(5) -8(5) 14(4) 2(5) 
C11 50(4) 68(7) 64(5) -6(5) 26(4) -8(5) 
C12 49(4) 62(6) 50(4) 2(5) 19(3) -6(4) 
C13 57(5) 73(6) 56(4) 1 (5) -6(4) -17(4) 
C14 58(5) 74(7) 60(5) -2(5) -7(4) 5(5) 
C15 44(5) 175(12) 130(7) -3(6) 3(5) 39(8) 
C16 63(5) 110(9) 78(5) 17(6) 4(4) 10(6) 
C17 89(6) 122(9) 124(7) -3(7) -45(5) -20(7) 
C18 88(5) 78(7) 49(4) 10(5) 37(4) 14(4) 
C19 76(5) 78(7) 42(4) 1(5) 23(4) 1(4) 
C20 152(9) 129(9) 75(5) -14(8) 64(6) -15(6) 
C21 124(7) 161(10) 81 (5) 64(8) 49(6) 23(6) 
C22 126(7) 145(10) 65(5) 6(7) 58(5) -1 (6) 
N2 83(6) 126(9) 159(8) -36(6) 78(6) -42(6) 
01 117(5) 164(8) 231(8) -69(6) 120(6) -54(6) 
02 126(6) 185(9) 240(9) -48(6) 133(6) -97(7) 
------------------------------------------------------------------------------------------------------------
The anisotropic displacement exponent takes the form: 
-21t2(h2a•2u11 + ... + 2hka*b*U12) 
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TABLE 85 
BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 















































































































































































TORSION ANGLES (0 ) FOR 
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Figure 47: Projection view of Hexyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-1,4-dihydropyridine(XVII) 
~ 
TABLE 87 
CRYSTAL DATA FOR 
241 
Dihexyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (XVII) 
Formula C27H39N20s 
M.W. 487.6 g mole-1 
a 13.782(5) A 
b 16.259(6) A 
" 13.027(5) A a 90.0 ° 
p 104.48(1) 0 
'Y 90.0 ° 
V 2826(2) A3 
F(OOO) 1052 
µMo Ka 11.28 cm-1. · 
1'.MoKa o.71069A 
Deale 1.146 g/cm3 
z 4 
Meas refl 6130 
Obs refl 1656 
A 6.81 % 
Aw 7.88% 
G.0.F. 1.59 
Space Group P21/c 




POSITIONAL PARAMETERS FOR 
Dihexyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (XVII) 
------------------------------------------------------------------------------------------------------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 0.3912(4) 0.3320(3) 0.3390(4) 
N2 0.5137(6) 0.4095(5) -0.172Q(6) 
01 0.4821(5) 0.4535(4) -0.2494(5) 
02 0.5923(5) 0.3688(4) -0.1555(5) 
C2 0.4908(5) 0.3471(4) 0.3401(5) 
C2' 0.5464(5) · 0.3941(4) 0.4362(6) 
C3 0.5277(5) 0.3183(4) 0.2594(5) 
C3' 0.6368(6) 0.3261 (5) 0.2635(8) 
03' 0.7006(4) 0.3586(4) 0.3333(5) 
03" 0;6584(3) 0.2921 (3) 0.1773(4) 
C4 0.4571(5) 0.2788(4) 0.1607(5) 
cs 0.3646(4) 0.2416(4) 0.1899(5) 
CS' 0.3180(5) 0.1726(4) 0.1226(6) 
05' 0.3418(3) 0.1506(3) 0.0426(4) 
05" 0.2464(3) 0.1313(3) 0.1583(3) 
C6 0.3335(5) 0.2732(4) 0. 2734(5) 
C6' 0.2390(5) 0.2514(4) 0.3097(5) 
C7 0.4286(5) 0.3426(4) 0.0705(5) 
cs 0.3536(5) 0.4017(4) 0.0675(6) 
C9 0.3305(5) 0.4612(4) -0.0125(6) 
C10 0.3807(6) 0.4631 (5) -0.0923(6) 
C11 0.4557(6) 0.4058(5) -0.0878(6) 
C12 0.4809(5) 0.3449(4) -0.0100(5) 
C13 0.7645(10) 0.3028(13) 0.1769(13) 
C13A 0.7491 (35) 0.2494(44) 0.1592(47) 
C14 o.n99(6) 0.2905(7) 0.0769(8) 
C15 0.8894(7) 0.2912(7) 0.0663(9) 
C16 0.9135(9) 0.3150(14) -0.0167(12) 
C17 1.0185(15) . 0.2800(11) -0.0405(16) 
C17A 1.0253(43) 0.3847(38) -0.0053(44) 
C18 1.0763(12) 0.3381(40) -0.0067(23) 
C18A 1.2709(358) 0.3344(821) 0.0877(722) 
C19 0.2051(5) 0.0569(5) 0.0968(6) 
C20 0.1331(6) 0.0156(5) 0.1520(7) 
C21 0.0406(6) 0.0597(5) 0.1508(7) 
C22 -0.0355(7) 0.0113(5) 0.1982(8) 
C23 -0.1332(8) 0.0551(6) 0.1890(9) 
------------------------------------------------------------------------------------------------------------
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TABLE 88 (Continued) 
------------------------------------------------------------------------------------------------------------
C24 -0.2085(7) 0.0126(6) 0.2298(10) 
H1A 0.3595 0.3447 0.3988 
H2'A 0.6144 0.4023 0.4325 
H2'B 0.5148 0.4466 0.4380 
H2'C 0.5456 0.3637 0.4991 
H2'D" 0.5781 0.4441 0.4030 
H2'E" 0.5004 0.4057 0.4913 
H4A 0.4936 0.2255 0.1309 
H6'A 0.2015 0.2111 0.2621 
H6'B 0.2583 0.2290 0.3801 
H6'C 0.1983 0.2994 0.3095 
H6'D0 0.2604 0.2013 0.3286 
H6'E" 0.1776 0.2600 0.2399 
H6'F" 0.2149 0.2831 0.3794 
H8A 0.3187 0.4008 0.1226 
H9A 0.2790 0.5010 -0.0127 
H10A 0.3651 0.5022 -0.1494 
H12A 0.5320 0.3051 -0.0112 
H13A 0.7999 0.2584 0.2185 
H13B 0.7936 0.3538 0.2070 
H13C 0.7812 0.2041 0.2016 
H13D o.n39 0.3010 0.1908 
H14A 0.7473 0.3366 0.0365 
H14B 0.7469 0.2412 0.0459 
H15A 0.9243 0.2484 0.1115 
H15B 0.9211 0.3426 0.0910 
H16A 0.8585 0.3431 -0.0633 
H16B 0.9036 0.2572 -0.0307 
H17A 0.10123 0.2908 -0.1143 
H17B 0.10392 0.2239 -0.0261 
H17C 0.10334 0.4232 -0.0584 
H17D 0.10316 0.3312 -0.0341 
H18A 0.11837 0.3143 -0.0007 
H18B 0.10979 0.3801 -0.0225 
H18C 0.11229 0.3306 0.0841 
H18D 0.11135 0.3248 -0.0006 
H18E 0.10077 0.3518 -0.0685 
H18F 0.10314 0.3541 0.0556 
H19A 0.2588 0.0203 0.0930 
H19B 0.1696 0.0719 0.0261 
H20A 0.1678 0.0088 0.2252 
H20B 0.1151 -0.0381 0.1227 
H21A 0.0078 0.0713 0.0782 
H21B 0.0564 0.1109 0.1880 
H22A -0.0049 0.0029 0.2722 
------------------------------------------------------------------------------------------------------------
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TABLE 88 (Continued) 
H22B -0.0478 -0.0414 0.1642 
H23A -0.1626 0.0638 0.1148 
H23B -0.1199 0.1079 0.2226 
H24A -0.2698 0.0430 0.2205 
H24B -0.2222 -0.0399 0.1955 
H24C -0.1791 0.0046 0.3041 
*Disorder of methyl hydrogens on C2' and CG' 
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TABLE 89 
ANISOTROPIC THERMAL PARAMETERS FOR 
Dihexyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (XVII) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U23 U13 U12 
---------------------------------------·--------------------------------------------------------------------
N1 61(4) 61(4) 63(4) -4(3) 36(3) -2(3) 
N2 98(6) 85(6) 74(6) -43(5) 25(5) 5(5) 
01 153(6) 146(6) 76(4) -37(5) 33(4) 39(4) 
02 127(5) 101 (5) 90(4) -16(4) 64(4) 7(4) 
C2 65(5) 45(4) 61(5) 2(4) 17(4) -1 (4) 
C2' 86(5) 75(5) 85(6) -8(4) 45(5) -1 (5) 
C3 54(5) 47(4). 64(5) 6(4) 28(4) 15(4) 
C3' 67(6) 69(6) 91(7) 6(5) 36(5) 14(5) 
03') 64(4) 152(6) 133(6) -15(4) 31(4) -34(5) 
03" 59(3) 135(5) 96(4) 16(3) 42(3) 7(4) 
C4 68(5) 49(4) 61(5) 3(4) 37(4) 2(4) 
cs 52(4) 52(4) 44(4) 1(4) 20(4) -1 (4) 
CS' 58(5) 66(5) 54(5) 6(4) 25(4) 6(4) 
05' 100(4) · 84(4) 65(3) -10(3) 48(3) -7(3) 
05" 66(3) 73(3) 73{3) -13(3) 32(3) -14(3) 
C6 55(4) 54(5) 52(5) -3(4) 17(4) 4(4) 
C6' 63(5) 85(6) n(5) 7(4) 40(4) -1(4) 
C7 55(4) 57(5) 54(5) -3(4) 22(4) -5(4) 
ca 73(5) 64(5) 69(5) 4(4) 33(4) 7(5) 
C9 75(5) 61(5) 77(6) 7(4) 18(5) 3(5) 
C10 81(6) 61 (5) 66(6) -11 (5) 5(5) 19(4) 
C11 . 76(5) 66(6) 63(5) -26(5) 28(5) -5(5) 
C12 68(5) 46(4) · 62(5) -7(4) 23(4) 0(4) 
C13 65(8) 105(13) 144(11) -3(9) 43(7) -24(11) 
C13A 65(8) . 105(13) 144(11) -3(9) 43(7) -24(11) 
C14 86(7) 186{10) 156(10) 9(7) 76(7) 38(8) 
C15 123(9) 165(9) 170(11) 13(7) 92(8) 44(8) 
C16 98(10) 880(59) 332(24) 68(20) 87(14) 333(32) 
C17 114(15) 204(15) 173(15) -18(12) 51 (12) 58(15) 
C17A 114(15) 204(15) 173(15) -18(12) 51 (12) 58(15) 
C18 72(12) 767(63) 398(29) 9(27) 47(15) -100(36) 
C18A 72(12) 767(63) 398(29) 9(27) 47(15) -100(36) 
C19 79(5) 84(6) 84(6) -17(5) 25(5) -30(5) 
C20 81(6) 91 (6) 122(7) -21 (5) 26(5) -26(6) 
C21 105(7) 92(6) 135(8) -14(6) 47(6) -12(6) 
C22 112(7) 116(8) 137(8) -37(7) 50(6) -18(7) 
------------------------------------------------------------------------------------------------------------
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TABLE 89 (Continued) 
C23 
C24 
113(7) 119(8) 186(10) -31 (7) 73(8) -26(8) 
. 133(8) · 153(1 O) 286(15) -37(8) 126(10) -37(10) 




BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 






























































































































































































TORSION ANGLES (0 ) FOR 
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Figure 48: Projedion view of Hexyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-pyridine(XVIII) ~ 
TABLE 92 
CRYSTAL DATA FOR 
251 
Dihexyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate (XVIII) 
Formula C27H3sN20s 
M. W. 484.58 g mole-1 
.a 8.089(2) A 
.t2 11.495(2) A 
k 15.707(5) A 
a. 69.29(2) 0 
J3 88.12(2) 0 
'Y 87~03(2) 0 
V 1364.2(6) A3 
F(OOO) 520 
µMo Ka. 11.28 cm-1 
>..Mo Ka. o.71069 A 
Deale 1.18 g/cm3 
z 2 
Meas refl 9318 
Obs refl 769 
R 6.05% 
Rw 13.12 % 
G. 0. F. 0.537 
Space Group P-1 




POSITIONAL PARAMETERS FOR 
·-
Dihexyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate (XVIII) 
------------------------------------------------------------------------------------------------------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 0.7484(12) 0.5015(13) 0.5650(7) 
H1A 0.7463(12) 0.5115(13) . 0.6168(7) 
C2 0.6967(14) 0.5977(12) 0;4903(10) 
C2' 0.6446(14) 0.7115(9) 0.5105(8) 
H2'A 0.6470(14) . 0.6933(9) ·o.5750(8) 
H2'B 0.5343(14) 0.7381(9) 0.4891(8) 
H2'C 0.7190(14) o.n65{9) 0.4804{8) 
C3 0.7104(11) 0.5848(10) 0.4088(8) 
C3' 0.6557(17) 0.6938(11) 0.3270(10) 
03' 0.5320(12) 0.7562{8) 0.3242{7) 
03" 0.7690(10) 0.7202(6) 0.2606{5) 
C4 0.7652(11) 0.4739(10) 0.3972(7) 
C5 0.8111 (11) 0.3737(9) 0.4788(8) 
CS' 0.8696(16) . 0.2503(1 t) 0.4752(8) 
05' 0.9887(11) 0.1929(7) 0.5131 (6) 
05" 0.7643(9) o.2on(6) 0.4308(4) 
C6 0.8025(14) 0.3920(12) 0.5608(8) 
C6' 0.8506(14) 0.2916(11) 0.6490(6) 
H6'A 0.8351 (14) 0.3231 (11) 0.6979(6) -
H6'B 0.9648(14) 0.2661 (11) 0.6456(6) 
H6'C 0.7827(14) 0.2216(11) 0.6599(6) 
C7 o.n67(19) 0.4586(8) 0.3088(8) 
cs 0.6391(19) 0.4625(9) 0.2622(10) 
HSA 0.5389(19) 0.4744(9) 0.2893(10) 
C9 0.6314(26) 0.4499(13) 0.1725(13) 
C10 0. 7980(36) . 0.4398(14) 0.1446(12) 
H10A 0.8088(36) 0.4359(14) , 0.0865(12) 
C11 0.9473(23) 0.4346(12) 0.1857(13) 
C12 0.9303(18) 0.4446(8) 0.2693(9) 
H12A 1.0255(18) 0.4419(8) 0.3018(9) 
C13 0.7245(19) 0.8214(11) 0.1768(9) 
H13A 0.7428(19) 0.9011 (11) 0.1824(9) 
H138 0.6087(19) 0.8189(11) 0.1636(9) 
C14 0.8328(28) 0.8038(15) 0.1024(10) 
H14A 0.8056(28) 0.7257(15) -- 0.0968(10) 
H14B 0.8015(28) 0.8693(15) 0.0459(10) 
C15 1.0117(27) 0.8028(16) 0.1091(12) 
------------------------------------------------------------------------------------------------------------
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ANISOTROPIC THERMAL PARAMETERS FOR 
Dihexyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate (XVIII) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U23 U13 U12 
------------------------------------------------------------------------------------------------------------
N1 95(8) 148(10) 92(8) -79(8) 28(7) -53(8) 
C2 87(9) 85(10) 95(10) .-49(8) 18(9) -20(8) 
C2' 117(10) 88(9) 186(12) -85(9) 46(9) -26(8) 
C3 53(7) 64(8) 78(8) -20(7) 7(6) -4(6) 
C3' 71 (1 O) 62(8) 139(12) -16(9) 18(10) 6(7) 
03' 118(8) 92(7) 255(11) 13(6) 37(8) 40(6) 
03" 98(7) 72(5) 97(6) -1(5) -8(5) 10(5) 
C4 43(6) 72(7) 64(7) -25(6) -7(6) -1 (6) 
cs 59(7) 56(7) 71(8) -19(6) -4(6) -6(6) 
CS' 50(8) 72(9) 100(10 -3(7) 2(7) -3(7) 
05' 94(7) 92(6) 230(10) -32(6) -55(7) 23(5) 
05" 81(6) 62(5) 101 (6) -32(4) -7(4) 20(4) 
C6 68(8) 87(9) 86(10) -33(8) -8(7) -19(7) 
C6' 129(12) 141(11) 77(8) 5(8) -12(8) -31(9) 
C7 124(11) 52(6) 57(8) -15(6) 4(9) 20(7) 
ca 175(15) 71 (8) 83(10) -16(7) -59(10) 0(8) 
C9 143(21) 81 (9) 156(15) 1(9) -85(14) -10(13) 
C10 208(29) . 73(10) 118(13) -12(8) -52(17) -24(17) 
C11 154(18) 86(9) 122(13) -40(9) 72(13) -24(11) 
C12 143(14) 68(8) 89(9) -22(6) 46(9) 0(8) 
C13 178(15) 104(9) 90(9) 23(9) -12(11) 28(9) 
C14 232(23) 153(14) 85(11) 39(10) -38(15) -17(15) 
C15 179(20) 182(16) 111(14) 16(11) -33(16) -20(15) 
C16 204(23) 170(14) 95(12) 22(10) -3(16) -39(16) 
C17 218(25) 256(22) 129(17 -29(15) 10(19) -51 (21) 
C18 220(24) 348(29) 196(19) -52(19) 79(18) -59(20) 
C19 112(11) 68(8) 131(10) -36(7) 14(9) 24(7) 
C20 156(15) 79(8) 104(1 O) -45(7) 15(11) 8(9) 
C21 . 132(13) 104(10) 134(12) -71 (8) 31 (11) -15(9) 
C22 173(16) 90(9) 113(11) -54(8) 24(11) -20(10) 
C23 136(15) 140(12) 143(13) -75(10) 39(12) -25(10) 
C24 170(16) 256(19) 157(13) -103(13) -40(12) -23(13) 
------------------------------------------------------------------------------------------------------------
The anisotropic displacement exponent takes the form: 
-21e2(h2a•2u11 + ... + 2hka*b*U12) 
255 
TABLE 95 
BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 






























































































































































































Dihexyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate (XVIII) 
C6-N1-C2-C3 



































































































C1 O-C11-N2A-01 A 
C12-C11-N2A-02A 
C10-C11-N2A-02A 































Figure 49: Projection view of [Heptyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-1.4-dihydropyridine} 











M.W. 555.7 g mole-1 
.a 9.632(2) A 
.t2 12.361(1)A 
k 15.127(2) A 
a 105.96(1) 0 
13 99.75(1) 0 
'Y 103.07(1) 0 
V 1634~3(4) A3 
F(OOO) 600 
µMo Ka 11.28 em-1 
lMoKa o.71069 A 
Deale Mg!m3 
z 2 
Meas refl 5642 
Obs refl 1347 
R 7.41 % 
Rw 8.65% 
G.0.F. 1.84 
Space Group P-1 
Octants meas -1S.,h S 11,-13 S k S13, -17S I S17 
260 
TABLE98 
POSITIONAL PARAMETERS FOR 
Diheptyl 2,6-Dimethyl-4-(3-nitrophenyl)-1 ,4-dihydropyridine-3,5-dicarboxylate 
(XIX) 
------------------------- ------------------------------------------------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 0.3482(10) 0.7545(9) 0.1059(5) 
C2 0.4595(13) o.asn(11) 0.1514(9) 
C2' 0.4805(12) 0.9388(9) 0.938(7) 
C3 0.5311 (11) 0.8797(8) 0.2406(7) 
C3' 0.6408(12) 0.9930(10) . 0.2982(9) 
03' 0.6869(9) 1,0736(7) 0.2704(5) 
03" 0.6909(8) 0.9951(6) 0.3849(6) 
C4 0.5062(10) 0~7854(7) 0.2892(6) 
cs 0.3570(10) 0.6931(7) 0.2390(6) 
CS' 0.2951 (12) 0.6238(9) 0.2954(7) 
05' 0.1784(8) · 0.5479(6) 0.2684(4) 
05" 0.3799(6) 0.6559(5) 0.3822(5) 
C6 0.2902(11) . •. 0.6800(9) 0.1503(8) 
C6' 0.488(10) 0.5905(8) 0.0921(6) 
C7 0.6296(11) 0.7298(9) 0.2930(9) 
cs 0.6721 (14) 0.6802(10) 0.2111 (9) 
C9 0.7831 (16) 0:6261 (11) 0.2138(9) 
C10 0.8565(12) 0.6203(10) 0.2973(12) 
C11 0.8142(13) 0.6680(10) 0.3762(9) 
C12 0.7056(12) 0.7217(8) 0.3766(7) 
C13 0.7941(16) 1.0995(11) 0.4499(10) 
C14 0.8549(19) 1.0567(16) 0.5547(19) 
C15 0.7671(23) 1.0654(23) 0.5711 (15) 
C16 0.8157(39) 1.0159(25) 0.6770(21) 
C17 0.9040(35) 1.0561 (23) 0.7396(18) 
C18 0.9501(33) 1.0506(29) 0.8372(17) 
C19 1.0336(33) 1.0594(30) 0.8946(17) 
C20 0.3317(11) 0.6007(9) 0.4485(7) 
C21 0.4488(12) 0.6629(10) 0.5406(8) 
C22 0.4184(13) · 0.6219(11) 0.6167(10) 
C23 0.5364(16) 0.6863(12) 0.7088(9) 
C24 0.5258(18) 0.6429(15) 0.7864(12) 
C25 0.6359(23) . 0.6907(17} 0.8695(11) 
C26 0.6164(20) 0.6411(14) 0.9418(11) 
N2 0.8853(11) 0.6586(10) 0.4672(8) 


























ATOM U11 U22 U33 U23 U13 U12 
------------------------------------------------------------------------------------------------------------
N1 75(7) 102(8) 55(6) 7(6) -11 (6) 34(6) 
C2 69(9) 90(10) 95(10) 24(8) 11 (7) 48(9) 
C2' 125(11) 109(10) 116(10) 13(9) -7(9) 67(9) 
C3 72(8) 66(7) 72(8) 5(6) 18(7) 41(7) 
C3' 64(8) · 68(8) 107(11) ·5(7) 13(8) 43(8) 
03' 150(8) 89(6) 117(7) -22(6) -3(6) 62(6) 
03" 78(6) 66(5) 91 (6) -17(5) -12(5) 24(5) 
C4 46(7) 49(7) 51(7) 23(6) 6(5) 9(6) 
cs 49(7) 49(6) 40(6) -7(6) 6(5) 9(5) 
CS' 43(7) 67(8) 59(8) 9(6) 6(6) 25(6) 
05' 66(5) 89(5) 80(5) -16(5) -5(4) 26(4) 
05" 51(4) 86(5) 60(5) 8(4) 5(4) 37(4) 
cs 55(8) 71 (8) 67(8) 8(6) 7(7) 24(7) 
CS' 75(9) 104(9) 72(8) 3(7) -11 (6) 29(7) 
C7 47(8) 51 (7) 67(8) 1 (6) 16(7) 21(7) 
ca 66(10) 75(9) 92(12) 17(7) 19(8) 34(8) 
C9 88(11) 112(11) 64(10) 35(9) 35(8) 16(8) 
C10 56(9) 75(9) 116(12 12(7) 17(10) 29(10) 
C11 47(8) 54(8) 79(10) 13(6) 11 (7) 33(7) 
C12 42(7) 48(7) 66(9) 3(6) 6(6) 16(6) 
C13 85(11) 68(9} 166(15) -2(9) -18(10) 21 (11) 
C14 58(15) 115(15) 460(53) -3(11) 6(20) -109(20) 
C15 137(22) 591 (59) 169(24) 132(28) -54(18) -289(35) 
C16 709(94) 312(39) 309(49) -151 (45) 430(61) -190(37) 
C17 371 (39) 251 (34) 177(31) -23(30) 156(32) -91 (27) 
C18 388(45) . 480(45) 134(24) 232(40) 114(33) 63(30) 
C19 646(98) 901(98) 284(52) 215(80) 111(51) 334(63) 
C20 69(8) 113(9) 81 (9) 30(7) 28(8) 62(8) 
C21 73(9) 154(12) 106(10) 2(8) 8(8) 100(10) 
C22 88(11) 149(13) 142(13) 37(10) 37(10) 67(12) 
C23 158(15) 147(14) 84(12) 35(12) 15(12) 21 (11) 
C24 175(18) 223(20) 116(15) 33(16) 18(15) 21 (16) 
C25 282(26) 259(23) 71 (13) 46(20) 42(16) 51 (15) 
C26 264(23) 241 (22) 153(18) 106(19) 52(17) -2(17) 
••••••••••n••••••••-••••••••••••••••••••·•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
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TABLE 99 (Continued) 
------------------------------------------------------------------
N2 46(8) 92(9) 100(10) 10(6) -6(8) 47(8) 
N3 156(10) 214(11) 76(7) 65(9) -10(7) 56(7) 
01 83(7) 155(9) 167(9) 48(6) 11 (6) 86(7) 
02 103(7) 142(8) 83(7) 45(6) -1(6) 49(6) 
C92 110(10) 99(9) 103(10) 12(8) 15(8) 52(8) 
C91 105(10) 109(9) 68(8) 12(8) -6(7) 47(7) 























































































































































































































































































































































Figure 50: Projection view of Octyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-1,4-dihydropyridine(XX) ~ 
TABLE 102 
CRYSTAL DATA FOR 
268 
Dioctyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (XX) 
Formula C31H45N20& 
- M.W. 542.7 g mole-1 
a 15.983(2) A 
12 15.916(2) A 
' 12.856(3) A a 90.0 ° 
p 106.32(1) 0 
'Y 90.0 ° 
V 3139.1(9) Aa 
F(OOO) 1176 
µMo Ka 11.28 cm-1 
A.Mo Ka o.71069 A 
Deale 1.13 g/cm3 
z 4 
Meas refl 6810 
-Obs refl 1027 
R 7.53 o/o 
Aw 7.85 o/o 
G. 0. F. 1.50 
Space Group P21/c 




POSITIONAL PARAMETERS FOR 
Dioctyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (XX) 
------------------------------------------------------------------------------------------------------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 0.967(8) 0.3309(8) 0.1690(9) 
C2 0.91 (11) 0.3445(10) 0.1637(11) 
C2' -0.0365(8) 0.3958(8) 0.0662(11) 
C3 -0.0201 (8) 0.3178(8) 0.2438(13) 
C3' -0.1160(10) 0.3256(11) 0.2339(15) 
03' -0.1700(7) 0.3569(8) 0.1621(10) 
03" -0.1342(6) 0.2885(8) 0.3166(9) 
C4 0.0391 (8) 0.2774(9) - 0.3444(12) 
cs 0.1163(9) 0.2387(8) 0.3171 (10) 
CS' 0.1582(10) 0.1718(8) 0.3866(11) 
05' 0.1406(6) 0.1489(6) 0.4678(7) 
05" 0.2190(7) 0.1287(7) 0.3532(7) 
cs 0.1462(9) 0.2703(9) 0.2370(12) 
C6' 0.2262(7) 0.2491 (8) 0.2019(10) 
C7 0.0615(10) 0.3413(10) 0.4363(12) 
ca 0.1277(9) 0.3993(10) 0.4422(12) 
C9 0.1450(10) 0.4607(10) 0.5200(13) 
C10 0.1021 (11) 0.4630(9) 0.5991 (12) 
C11 0.0360(9) 0.4063(10) 0.5921 (11) 
C12 0.0179(8) 0.3460(8) 0.5140(11) 
C13 -0.2227(10) 0.2919(15) 0.3170(15) 
C14 -0.2407(11) 0.2.811 (14) 0.4104(16) 
C15 -0.3332(17) 0.2816(17) 0.4168(21) 
C16 -0.3596(18) 0.3020(24) 0.4854(24) 
C17 -0.4573(31) 0.3045(33) 0.4970(33) 
C18 -0.4886(37) 0.2755(30) 0.5404(42) 
C19 -0.5744(26) · 0.2916(34) 0.5478(41) 
C20 -0.6248(25) 0.3167(25) 0.5313(26) 
C21 0.2549(10) 0.0563(11) 0.4160(13) 
C22 0.3128(12) 0.0103(11) 0.3606(15) 
C23 0.3912(12) 0.0542(10) 0.3625(13) 
C24 0.4531 (12) 0.0038(12) 0.3105(14) 
C25 0.5371(14) 0.0431 (12) 0.3148(16) 
C26 0.5972(13) -0.0022(16) 0.2661 (21) 
C27 0.6820(19) 0.0459(16) 0.2835(20) 


















ANISOTROPIC THERMAL PARAMETERS FOR 
Dioctyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (XX) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U23 U13 U12 
---------------------------------------------------------------~--------------------------------------------
N1 61(9) 65(10) 64(9) -27(8) 44(8) 0(8) 
C2 83(14) 65(13) 38(11) -36(11) 19(11) 0(10) 
C2' 93(12) 68(12) 81 (13) -4(10) 54(11) -14(11) 
C3 53(10) 17(9) 63(10) 11 (8) 32(10) .. -7(9) 
C3' 62(13) 75(15) · 60(14) 14(11) 23(12) 10(12) 
03' 67(9) 137(12) 119(12) 21(8) 22(8) 37(10) 
03" 54(8) 134(11) 83(9) -19(8) 34(7) -25,.,;\ 
C4 42(10) 59(11) 51 (11) 7(10) 25(10) 8(11) 
cs 61 (10) 45(11) 51(9) -5(8) 40(9) -1(9) 
cs· 72(13) 35(11) 38(10) 6(9) 1 (10) -4(9) 
05' 101 (9) 75(8) 31(6) 3(7) 27(6) 8(6) 
05" 70(8) 73(9) 68(8) 30(6) 29(7) 21(7) 
cs 51 (11) 30(10) 51 (11) -7(9) 7(10) 5(9) 
CS' 54(9) 72(12) 84(12) -3(9) 46(9) 8(9) 
C7 49(11) 51 (11) .· 50'(11) -3(9) 17(10) -22(10) 
cs 55(12) 64(12) 56(12) 22(10) 15(10) -23(11) 
C9 85(13) 62(14) . 62(12) 3(10) 28(11) -6(11) 
C10 86(14) 37(12) 43(11) 8(10) 1 (11) -20(9) 
C11 53(11) . 31 (9) 43(10) 25(9) -1 (9) -18(9) 
C12 61(10) 33(10) 48(10) 32(9) 29(9) 6(9) 
C13 62(15) 248(28) 177(26) -26(18) 70(16) 25(21) 
C14 84(17) 216(24) 188(26) -9(18) 98(19) 5(20) 
C15 175(29) 207(27) 209(34) 3(23) 119(25) -45(23) 
C16 152(30) 560(63) 301(50) -22(37) 77(31) -278(47) 
C17 248(55) 711(109 274(46) -74(65) 168(45) -1 (54) 
C18 257(73) 214(43) 957(179 33(44) 50(99) -89(70) 
C19 127(61) 939(154 559(90) -36(60) 16(48) -557(110) 
C20 108(42) 890(127 239(38) -53(51) 90(34) -97(54) 
C21 58(13) 97(16) 86(14) 32(11) 15(11) 10(13) 
C22 79(14) 87(17) 133(18) -25(14) 11 {14) 8(15) 
C23 109(18) 75(16) 102(16) 20(14) 23(15) 9(12) 
------------------------------------------------------------------------------------------------------------
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BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 



























































































































































































------------------------------------------------- ,- .. ---------------------------------------------------
TABLE 106 
TORSION ANGLES (0 ) FOR 
275 






































































































































CRYSTAL DATA FOR 
Di-(2-methoxyethyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxylate (XXI) 
----------------------------------·· -- - -----------------------------
Formula C21H2sN20s 
M.W. 434~2g mole·1 
a 15.3210(10) A 
.b 51.520(4) A 
.c 10.8740(10) A 
a 90.0 ° 
f3 90.0 ° 
'Y 90.0 ° 
V 8582.9(12) A3 
F(OOO) 3680 
µMo Ka 11.28 cm·1 
lMoKa 0.11069 A 
.Deale 1.345 g/cm3 
z 20 
Meas refl 2036 




Space Group Fdd2 
Octants meas -1 S hS 17, -1 S k S 49, -1 SIS 12 
278 
TABLE 108 




ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 -0.1031 (3) 0.2489(1) · 0.8578(8) 0.049(2) 
C2 -0.0904(4) -0.2302(1) 0.9489(8) 0.039(2) 
C2' -0.1132(4) 0~2397(1) o.1on4(9) 0.053(3) 
C3 -0.0655(4) 0.2060(1) 0.9158(8) 0.039(2) 
C3' -0;0539(4) 0.1856(1) 0.10097(9) 0.042(3) 
03' -0.0570(4) 0.1884(1) 0.11204(8) 0.077(2) 
03" -0.0341(3) .0.1625(1) 0.9604(7) 0.052(2) 
C4 -0.0399(4) 0.1996(1) 0.7832(?) 0.039(2) 
cs -0.0746(4) 0.2196(1) 0.6933(8) 0.037(2) 
CS' -0;0755(4) 0.2140(1) 0.5642(9) 0.043(2) 
05' -0.1035(4) 0.2275(1) 0.4816(8) 0.088(2) 
05" -0.0385(3) 0.1910(1) 0.5400(7) 0.049(2) 
C6 -0.1002(4) 0.2436(1) 0.7358(9) 0.042(3) 
C6' -0.1298(5) 0.2663(1) 0.6596(9) 0.062(3) 
C7 0.0592(4) 0.1963(1) o.n70(9) 0.037(2) 
ca 0.1149(4) 0.2157(1) 0.8148(9) 0.047(2) 
C9 0.2046(4) 0.2124(1) 0.8106(9) 0.056(3) 
C10 0.2406(5) 0.1895(2) o.n13(10) 0.067(3) 
C11 0.1841 (5) 0.1703(1) 0.7349(9) 0.054(3) 
C12 0.0946(4) 0.1729(1) 0.7360(8) 0.050(3) 
C13 -0.0137(5) 0.1415(1) 0.10431 (9) 0.055(3) 
C14 0.0245(5). 0.1201(1) .0.9685(10) 0.064(3) 
015 -0.0424(4) 0.1081(1) 0.9011 (9) 0.077(2) 
C16 -0.0126(6) 0.0892(2) 0.8188(12) 0.099(4) 
C17 -0.0221 (4) 0.1837(1) 0.4123(9) 0.053(3) 
C18 0.0706(4) 0.1750(1) 0.3982(9) 0.048(2) 
019 0.1259(3) 0.1967(1) 0.4241(8) 0.059(2) 
C20 0.2151 (4) 0.1903(2) 0.4163(11) 0.080(3) 
01 0.1729(6) 0.1287(1) 0.6539(12) 0.183(6) 
02 0.2938(5) 0.'1414(1) 0.7000(14) 0.223(7) 
N2 0.2194(6) 0.1451(1) 0.6933(10) 0.91 (4) 
H1A -0.1119 0.2655 0.8808 0.080 
H2'A -0.1043 0.2259 1.1351 0.080 
H2'B -0.0756 0.2540 1.0979 0.080 
H2'C -0.1729 0.2453 1.0806 0.080 
H4A -0.0691 0.1780 0.7518 0.050 
------------------------------------------------------------------------------------------------------------
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ATOM U11 U22 U33 U12 U13 U23 
------------------------------------------------------------------------------------------------------------
N1 38(3) 68{4) 78(4) -9(4) -4(3) -1 (3) 
N1 54(4) 43(3) 51(4) -4(3) 14(3) -3(3) 
C2 39(4) 45(4) 33(4) -4(3) 8(3) 2(3) 
C2' 64(5) 36(4) 61(5) -2(3) -3(4) -13(4) 
C3 28(3) 43(4) 46(4) 5(3) 9(3) -1 (3) 
C3' 41(4) 52(5) 34(4) -8(3) 8(3) -11 (4) 
03' 131 (5) · 59(4) 40(3) 13(3) 7(3) -4(3) 
03" 78(3) 40(2) 38(3) 7(2) 6(3) 4(2) 
C4 38(4) 38(4) 42(4) 1 (3) 9(3) -3(3) 
cs 30(4) 39(4) 43(4) 1 (3) -1(3) 3(3) 
CS' 50(4) . 40(4) 41(4) -4(3) -7(4) -1 (4) 
05' 160(6) 61 (3) 44(3) 38(4) -26(4) -5(3) 
05" 55(3) 50(3) 43(3) 13(2) 0(2) -1 (2) 
C6 34(4) 41 (4) 50(5) -1 (3) -1 (3) 0(3) 
C6' 73(5) 52(4) 61 (5) 8(4) 7(4) 5(4) 
C7 33(4) 44(4) 34(4) 7(3) 2(3) 11 (3) 
cs 38(4) 56(4) 47(4) 3(3) 2(4) 1(4) 
C9 46(4) 63(5) 60(5) -8(4) -3(4) 21(4) 
C10 43(4) 74(5) 83(6) 8(4) 4(5) 39(5) 
C11 58(5) 53(5) 51(5) 22(4) 7(4) 21(4) 
C12 50(5) 56(4) 44(4) -1 (4) 11 (4) 8(4) 
C13 84(5) 36(4) 44(5) 4(3) -2(4) 7(4) 
C14 75(6) 38(4) 79(6) 10(4) 2(5) 17(5) 
015 77(4) 73(4) 79(4) 9(3) 3(4) -17(3) 
C16 141 (8) 78(5) 79(7) 7(6) 4(7) -37(6) 
C17 58(5) 61 (5) 41(4) -10(4) -1 (4) -13(4) 
C18 60(4) 36(4) 47(4) 9(4) .· 3(4) 3(3) 
019 43(3) 54(3) 81(4) -2(2) 0(3) 0(3) 
C20 52(5) 108(7) 80(6) 5(4) -7(5) 0(6) 
01 146(7) 87(5) 315(15) 33(5) -15(9) -94(8) 
02 96(6) 101 (5) 471(20) 47(4) 102(10) 37(9) 
N2 84(6) . 69(5) 118(7) 39(5) 50(6) 20(5) 
------------------------------------------------------------------------------------------------------------


































































































































































































































































































CRYSTAL DATA FOR 
285 
(Dibenzyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate) • 
0.5 CH3CN (XXII) 
Formula C31H29N20s 
M. W. 519.0 g mole-1 
.a 9.499(1) A 
12 10.804(1) A 
' 13.174(2) A a 80.48(1) 0 
b 88.53(1) 0 
g 82.19(1) 0 
V . 1320.2(3) A3 
F(OOO) 544.5 
µMo Ka 11.28 cm·1 
A.Mo Ka o.71069 A 
Deale 1.306 Mg/m3 
z 2 
Meas refl 4209 
Obs refl 2241 
R 5.19 % 
Rw 6.06 % 
G. 0. F. 1.26 
Space Group P-1 
Octants meas -1 S hS10, -11 S k S 11 , -14 S I S 14 
------------------------------------------------------------------------------------------------------------
TABLE 113 
POSITIONAL PARAMETERS FOR 
286 
(Dibenzyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate) • 
0.5 CH3CN {XXII) 
-------~-------------------------------------------------------------------------------------------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) 
------------------------------------------------------------------------------------------------------------
N1 0.1177(3) 0.4354(3) 0.1929(2) 
N2 0.1450(4) -0.2248(3) 0.1232(4) 
N3 0.5476 0.6769 0.0000 
01 0.1060(4) -0.2744(3) 0.2072(3) 
02 0.1821(4) -0.2848(3) 0.0549(3) 
C2 0.2110(4) 0.3557(3) 0.2606(3) 
C2' 0.3344(4) 0.4164(3) · 0.2889(3) 
C3 0.1832(3) 0.2359(3) 0.2936(3) 
C3' 0.2744(4) 0.1507(3) 0.3706(3) 
C3" 0.3221 (4) -0.0594(3) 0.4601 (3) 
03' 0.3757(3) 0.1739(2) 0.4131 (2) 
03" 0.2333(2) 0.337(2) 0.3889(2) 
C4 0.0583(3) 0.1870(3) 0.2506(3) 
cs -0.0555(4) 0.2973(3) 0.2111 (2) 
cs· -0.2031 (4) 0.2757(3) 0.2091 (3) 
CS" -0.3641 (4) 0.1242(3) 0.2369(3) 
05' -0.3063(3) 0.3558(2) 0.1920(2) 
05" -0.2186(2) 0.1507(2) 0.2307(2) 
C6 -0.199(4) 0.4131(3) 0.1783(3) 
C6' -0.1118(5) 0.5282(3) 0.1231 (3) 
C7 0.1066(3) 0.1095(3) 0.1662(3) 
ca 0.1036(3) -0.0205(3) 0.1821 (3) 
C9 0.1485(4) . -0.0871 (3) 0.1045(3) 
C10 0.1960(4) -0.0320(3) 0.0113(3) 
C11 0.2003(4) 0.0963(4) -0.0039(3) 
C12 0.1563(4) 0.1651 (3) 0.0730(3) 
C13 -0.3662(4) -0.0155(4) 0.2476(3) 
C14 -0.4796(4) -0.0586(4) 0.2092(4) 
C15 -0.4887(5) -0.1854(5) 0.2207(5) 
C16 -0.3857(6) -0.2716(5) 0.2697(4) 
C17 -0.2718(6) -0.2305(4) .0.3065(3) 
C18 -0.2618(4) -0.1035(4) 0.2963(3) 
C19 0.2573(4) -0.1792(3) 0.4804(3) 
C20 0.1130(5) -0.1821 (4) 0.4814(3) 
C21 0.0584(5) -0.2962(4) 0.5060(3) 






























ANISOTROPIC THERMAL PARAMETERS FOR 
(Dibenzyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate) • 
0.5 CH3CN (XXII) 
------------------------------------------------------------------------------------------------------------
ATOM U11 U22 U33 U23 U13 U12 
------------------------------------------------------------------------------------------------------------
N1 70(2) 28(2) 83(2) -6(2) 20(2) 3(2) 
N2 68(3) 39(2) 109(3) -2(2) -15(2) -28(2) 
01 176(4) 41 (2) 116(3) -.30(2) -3(3) -3(2) 
02 124(3) 60(2) 157(3) -3(2) 22(2) -62(2) 
C2 52(2) 35(2) 61(2) -5(2) -8(2) -9(2) 
C2' 76(3) 41(2) 90(3) -15(2) -18(2) -3(2) 
C3 45(2) 30(2) 48(2) -2(2) -4(2) -7(2) 
C3' 46(2) 41 (2) 51(2) -9(2) -6(2) -5(2) 
C3" 68(3) 47(2) 61(2) -2(2) -29(2} 10(2) 
03' 68(2) 57(2) 85(2) -21 (1) -35(2) 6(1) 
03" 54(2) 38(1) 61(2) -5(1) -22(1) 3(1) 
C4 41(2) 31 (2) 48(2) -4(2) -7(2) -2(2) 
cs 48(2) 31 (2) 46(2) 5(2) -10(2) -5(2) 
CS' 49(3) 46(2) 56(2) · 6(2) -9(2) -7(2) 
CS" 37(2) 69(3) 76(3) -5(2) 1(2) -7(2) 
05' 50(2) 61 (2) 113(2) 17(1) -12(2) 3(2) 
05" 39(2) .50(2) 70(2) -3(1) -1 (1) -10(1) 
C6 55(3) 35(2) 66(3) 6(2) -14(2) -6(2) 
C6' 77(3) 40(2) 113(4) 5(2) -27(3) 1(2) 
C7 36(2) 30(2) 49(2) -1 (2) -10(2) -3(2) 
CB 46(2) 32(2) 55(2) -2(2) -12(2) -3(2) 
C9 48(2) 32(2) 68(3) -2(2) -14(2) -14(2) 
C10 65(3) 53(3) 68(3) 1 (2) -4(2) · -22(2) 
C11 86(3) 54(2) 53(2) -9(2) 10(2) -8(2) 
C12 67(3) 35(2) 54(2) -5(2) 2(2) 0(2) 
C13 36(2) 73(3) 61 (3),, -7(2) 4(2) -9(2) 
C14 51(3) 82(3) 121 (4) · -3(3) -20(3) -13(3) 
C15 66(4) 96(4) 166(5) -28(3) -22(4) -33(4) 
C16 88(4) 74(3) 119(4) -32(3) 12(3) -12(3) 
C17 91(4) 68(3) 92(4) -14(3) -14(3) 6(3) 
C18 60(3) 70(3) 73(3) -14(2) -11 (2) 1 (2) 
C19 59(3) 43(2) 45(2) -7(2) -12(2) 1(2) 
C20 65(3) 56(3) 64(3) -2(2) -2(2) -6(2) 





























BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 
(Dibenzyl 2,6-dimethyl-4-(3-nitrophenyl)-1.4-dihydropyridine-3,5-dicarboxylate) • 

















































































































































































































TORSION ANGLES (0 ) FOR 
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(Dibenzyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate) • 






















































































































































Figure 53: Projection view of [Methyl ethyl 2,6-dimethyl-3,5-dicarboxylate-4-(3-nitrophenyl)-pyridine] • N03 (XXIII) ~ 
l.u 
TABLE 117 
CRYSTAL DATA FOR 
294 
Ethyl methyl 2,kfimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate • N03 
(XXIII) 
Formula C11H11N20s 
M.W. 345.33 g mole-1 
.a 9.034(1) A 
b 10.228(1) A 
~ 12.392(2) A 
a 78.71 (1) 0 
J3 71.05(1) 0 
'Y 69.40(1) 0 
V 1009.4(2) A3 
F(OOO) . 362 
µMo Ka 11.28 cm-1 
lMoKa 0.11069 A 
Deale 1.136 g/cm3 
z 2 
Meas refl 4289 
Obs refl Refined on F2 
R 6.6% 
Aw 16.47 % 
G.O.F. 0.914 
Space Group P-1 




POSITIONAL PARAMETERS FOR 
Ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate • N03 
(XXIII) 
------------------------------------------------------------------------------------------------------------
ATOM X(SIG(X)) Y(SIG(Y)) Z(SIG(Z)) . 
------------------------------------------------------------------------------------------------------------
N1 0.1657(5) 0.1143(5) 0.0479(3) 
C2 0.1314(6) 0.1959(5) 0.1302(4) 
C2' 0.0295(7) 0.3465(6) 0.1135(4) 
C3 0.1957(6) 0.1393(5) 0.2227(4) 
C3' 0.1615(8) 0.2338(5) 0.3133(4) 
C3" -0.0328(11) 0.3571 (8) 0.4616(7) 
C3'" -0.2006(22) 0.4151(14) 0.4934(10) 
03' 0.2637(5) 0.2740(4) 0.3253(4) 
03" 0.0067(5) 0.2638(4) 0.3756(3) 
C4 0.2971 (6) 0.0010(5) 0.2274(4) 
cs 0.3330(6) -0.0795(5) 0.1381 (4) 
CS' 0.4437(8) -0.2275(6) 0.1329(5) 
CS" 0.4904(14) -0.4641 (8) 0.2156(8) 
05' 0.5687(6) .;0.2626(5) 0.0581 (4) 
05" 0.3850(5) -0.3110(4) 0.2181 (3) 
C6 0.2647(7) -0.0212(6) 0.0469(4) 
C6' 0.2920(8) -0.0979(7) -0.0531 (5) 
C7 0.3623(6) -0.0605(5) 0.3301 (4) 
cs 0.5291 (6) -0.1316(5) 0.3155(4) 
C9 0.5896(7) -0.1870(6) 0.4103(5) 
C10 0.4825(7) -0.1737(5) 0.5195(5) 
C11 0.3175(7) -0.1024(5) 0.5315(4) 
C12 0.2543(6) -0.0444(5) 0.4386(4) 
N2 0.2030(8) -0.0838(6) 0.6458(4) 
N3 -0.0051 (9) 0.3072(7) 0.8267(5) 
01 0.2439(6) -0.1623(6) 0.7259(3) 
02 0.0712(7) 0.0101 (6) 0.6566(3) 
03 0.0936(17) 0.2047(15) 0.8494(10) 
04 -0.1377(11) 0.3603(9) 0.9046(9) 
05 0.0014(27) 0.3695(19) 0.7311(13) 
06 0.1292(22) 0.3174(27) 0.8269(18) 
07 -0.0129(159) 0.2016(76) 0.8934(56) 
07' -0.0749(96) 0.2650(119) 0.9072(52) 
08 -0.0550(62) 0.3663(59) 0.7592(37) 
296 
TABLE 119 
ANISOTROPIC THERMAL PARAMETERS FOR 
Ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate • N03 
(XXIII) 
------------~-----· ---------------------------------------------------------------------------------------
ATOM U11 U22 U33 U23 U13 U12 
------------------------------------------------------------------------------------------------------------
N1 70(3) 72(3) 50(2) 3(2) -24(2) -29(2) 
C2 63(3) 63(3) 52(3) 3(2) -24(2) -25(3) 
C2' 98(4) . 71 (4) 73(3) 11(3) -47(3) -7(3) 
C3 63(3) 60(3) 47(2) 4(2) -27(2) -25(2) 
C3' 79(4) 56(3) 62(3) 3(2) -41 (3) -18(3) 
C3" 114(6) 117(6) 104(5) -66(4) -35(5) 0(5) 
C3"' 228(16) 203(11) 182(9) -80(8) . 5(11) -112(12) 
03' 111 (3) 75(2) 113(3) 1(2) -77(3) -39(2) 
03" 87(3) 72(2) 70(2) -26(2) -28(2) -17(2) 
C4 54(3) 59(3) 49(2) 4(2) -21 (2) -22(2) 
cs 62(3) 62(3) 46(3) 0(2) -12(2) -26(2) 
CS' 82(4) 71(3) 63(3) -11 (3) -16(3) -23(3) 
CS" 211(10) 62(5) 153(7) 2(4) -6(7) -21 (6) 
05' 94(3) 97(3) 98(3) -24(3) 7(3) -8(3) 
05" 110(3) 59(2) 90(3) 2(2) -18(2) -19(2) 
C6 73(3) 80(4) 45(3) -1 (2) -17(2) -39(3) 
C6' 120(5) 105(4) 56(3) -15(3) -29(3) -44(4) 
C7 63(3) 55(3) 54(3) 4(2) -27(2) -22(2) 
CB 63(3) 62(3) 77(3) 7(2) -38(3) -16(3) 
C9 70(3) 76(3) 85(4) 5(3) -37(3) -21 (3) 
C10 89(4) 66(3) 88(4) 16(3) -59(3) -35(3) 
C11 76(4) 67(3) 54(3) 5(2) -34(3) -33(3) 
C12 67(3) 64(3). 47(3) 3(2) -25(2) -32(2) 
N2 102(4) . 108(4) 53(3) -2(3) -33(3) -57(3) 
N3 97(5) . 98(4) 68(4) 4(3) -41 (4) -34(5) 
01 158(4) 164(4) 55(2) 22(3) -54(3) -80(3) 
02 101 (3) 120(4) 71(3) -22(2) -15(2) -47(3) 
03 121 (8) 109(9) 62(7) -4(6) -45(6) 17(9) 
04 86(5) 122(7) 98(6) -26(5) -29(5) -11(5) 
05 158(14) 126(9) 52(6) 26(5) -26(7) -39(8) 
06 86(11) 148(17) 151(16) -55(14) -18(10) -25(11) 
07 405(156) 106(51) 71 (34) 83(31) -134(62) -180(79) 
07' 279(55) 711(126) 90(40) 54(57) -15(38) -433(76) 
08 242(35) 275(38) 185(39) 107(29) -184(34) -98(26) 
------------------------------------------------------------------------------------------------------------




BOND DISTANCES (A) AND BOND ANGLES (0 ) FOR 


































































































































































































TORSION ANGLES (0 ) FOR 
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